https://aml-hub.com daily 1 2026-04-12T07:38:23.173Z https://aml-hub.com/types weekly 0.8 2025-03-27T09:52:00.000Z https://aml-hub.com/types/aml-related-mutations weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/types/chromosomal-aberrations weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/types/risk weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/types/disease-type weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/types/treatment-naive-aml weekly 0.7 2025-03-27T10:02:00.000Z https://aml-hub.com/types/tp53-mutant-aml weekly 0.7 2025-03-27T10:02:00.000Z https://aml-hub.com/types/midh1 weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/therapeutics weekly 0.8 2025-03-27T09:52:00.000Z https://aml-hub.com/therapeutics/cellular-therapy weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/therapeutics/bh3-agonistsbcl-2-inhibitors weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/therapeutics/chemotherapy weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/therapeutics/idh1-inhibitors weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/therapeutics/flt3-inhibitors weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/therapeutics/hypomethylating-agents weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/therapeutics/granulocyte-colony-stimulating-factor weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/therapeutics/mtor-inhibitors weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/therapeutics/idh2-inhibitors weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/therapeutics/menin-inhibitors weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/therapeutics/conjugated-antibodies weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/therapeutics/cytidine-deaminase-inhibitors weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/therapeutics/immune-modulators weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/therapeutics/car-t-cell-therapy weekly 0.7 2025-03-27T10:02:00.000Z https://aml-hub.com/therapeutics/mth1-inhibitor weekly 0.7 2025-08-28T10:07:00.000Z https://aml-hub.com/therapeutics/axl weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/therapeutics/nuclear-receptor-agonists weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/therapeutics/kat2a2b-degrader weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/therapeutics/anti-fungals weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/therapeutics/checkpoint-inhibitors weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/therapeutics/cell-cycle-inhibitors weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/therapeutics/e-selectin-antagonist weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/therapeutics/dendritic-cell-vaccines weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/therapeutics/proteasome-inhibitors weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/therapeutics/tp53-activators weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/therapeutics/sphingosine-1-phosphate-receptor-modulators weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/therapeutics/gcn2-activator weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/therapeutics/rara-agonists weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/therapeutics/hdac-inhibitors weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/therapeutics/kinase-inhibitors weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/therapeutics/t-cell-engagers weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/therapeutics/btk-inhibitor weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/therapeutics/bp-1001 weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/therapeutics/bp-1002 weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/therapeutics/natural-killer-cell-engager weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/therapeutics/other-events-1 weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/therapeutics/sl-172154 weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/therapeutics/natural-killer-cell-therapy weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/therapeutics/hedgehog-pathway-inhibitors weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/therapeutics/nedd8-activating-enzyme-inhibitors weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/therapeutics/n-myristoyltransferase-inhibitors weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/therapeutics/microbiota-therapy weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/therapeutics/farnesyltransferase-inhibitors weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/therapeutics/jak2-inhibitors weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/therapeutics/antibody-therapy weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/therapeutics/pi3k-inhibitors weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/therapeutics/nuclear-export-inhibitors weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/therapeutics/splicing-inhibitors weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/therapeutics/micro-rnas weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/therapeutics/aurora-kinase-inhibitors weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/therapeutics/protein-translation-inhibitors weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/therapeutics/stem-cell-mobilizers weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/therapeutics/pan-idh-inhibitors weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/congresses weekly 0.8 2025-03-27T09:52:00.000Z https://aml-hub.com/congresses/ash weekly 0.7 2026-01-12T16:24:00.000Z https://aml-hub.com/congresses/iach weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/congresses/asco weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/congresses/ebmt weekly 0.7 2025-03-27T10:02:00.000Z https://aml-hub.com/congresses/car-t-meetings weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/congresses/soho weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/congresses/ncri weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/congresses/costem-2022 weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/congresses/llmc weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/congresses/eha weekly 0.7 2025-07-03T10:05:00.000Z https://aml-hub.com/congresses/other-events weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/congresses/nccn weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/congresses/tct-meetings weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/congresses/aacr weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/congresses/isal weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/congresses/esh weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials weekly 0.8 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/2102-hem-101 weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/quantum-first weekly 0.7 2025-10-07T13:32:00.000Z https://aml-hub.com/trials/viale-c weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/m14-387 weekly 0.7 2026-03-20T14:18:00.000Z https://aml-hub.com/trials/cltr0310-301 weekly 0.7 2026-01-30T17:26:00.000Z https://aml-hub.com/trials/pethema weekly 0.7 2025-12-19T10:15:00.000Z https://aml-hub.com/trials/filo weekly 0.7 2026-03-04T09:26:00.000Z https://aml-hub.com/trials/dataml weekly 0.7 2026-03-04T09:26:00.000Z https://aml-hub.com/trials/aml1310 weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/amlsg-21-13 weekly 0.7 2026-02-10T08:56:00.000Z https://aml-hub.com/trials/ratify weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/quantum-r weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/morpho weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/admiral weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/lacewing weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/hovon weekly 0.7 2025-12-19T10:14:00.000Z https://aml-hub.com/trials/cibmtr weekly 0.7 2025-12-19T10:14:00.000Z https://aml-hub.com/trials/amlsg weekly 0.7 2025-12-19T10:14:00.000Z https://aml-hub.com/trials/cetlam-aml-12 weekly 0.7 2025-12-19T10:14:00.000Z https://aml-hub.com/trials/hovon-sakk weekly 0.7 2025-12-19T10:14:00.000Z https://aml-hub.com/trials/goelams weekly 0.7 2025-12-19T10:15:00.000Z https://aml-hub.com/trials/komet-007 weekly 0.7 2026-01-07T10:15:00.000Z https://aml-hub.com/trials/komet-017 weekly 0.7 2025-09-10T08:48:00.000Z https://aml-hub.com/trials/aml18 weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/crest-uk weekly 0.7 2025-12-03T18:11:00.000Z https://aml-hub.com/trials/v-rules weekly 0.7 2025-12-03T18:11:00.000Z https://aml-hub.com/trials/agile weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/aml-17 weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/aml19 weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/commodore weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/cosi weekly 0.7 2025-12-03T18:09:00.000Z https://aml-hub.com/trials/palg-aml12016 weekly 0.7 2025-12-03T18:10:00.000Z https://aml-hub.com/trials/viceroy weekly 0.7 2025-12-03T18:11:00.000Z https://aml-hub.com/trials/aml21 weekly 0.7 2025-12-04T11:22:00.000Z https://aml-hub.com/trials/paradigm weekly 0.7 2025-12-03T18:14:00.000Z https://aml-hub.com/trials/augment-101 weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/save weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/eviction weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/venaza-5s weekly 0.7 2025-12-04T11:21:00.000Z https://aml-hub.com/trials/cadenza weekly 0.7 2025-12-04T11:22:00.000Z https://aml-hub.com/trials/alidhe weekly 0.7 2025-12-04T11:21:00.000Z https://aml-hub.com/trials/thiotepa weekly 0.7 2025-12-03T18:12:00.000Z https://aml-hub.com/trials/revumenib weekly 0.7 2025-12-03T18:12:00.000Z https://aml-hub.com/trials/pethema-aml weekly 0.7 2025-11-26T15:30:00.000Z https://aml-hub.com/trials/beat-aml weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/komet-001 weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/quiwi weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/quantum-wild weekly 0.7 2025-03-27T10:02:00.000Z https://aml-hub.com/trials/optimise-flt3 weekly 0.7 2025-10-22T12:56:00.000Z https://aml-hub.com/trials/rev5aza weekly 0.7 2025-10-14T16:08:00.000Z https://aml-hub.com/trials/precision-t weekly 0.7 2025-04-28T16:13:00.000Z https://aml-hub.com/trials/intercept weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/augment-102 weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/camelot-1 weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/ale1002 weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/evolve-2 weekly 0.7 2025-08-08T09:17:00.000Z https://aml-hub.com/trials/camelot-2 weekly 0.7 2025-09-10T08:47:00.000Z https://aml-hub.com/trials/komet-008 weekly 0.7 2025-09-10T08:47:00.000Z https://aml-hub.com/trials/gatla-8-lma-p07 weekly 0.7 2025-09-11T09:42:00.000Z https://aml-hub.com/trials/maateo weekly 0.7 2025-08-28T10:07:00.000Z https://aml-hub.com/trials/ascertain-v weekly 0.7 2025-08-01T08:07:00.000Z https://aml-hub.com/trials/vbp101 weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/mo-trans weekly 0.7 2025-03-27T10:02:00.000Z https://aml-hub.com/trials/enhance-2 weekly 0.7 2025-03-27T10:02:00.000Z https://aml-hub.com/trials/sormain weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/soraml weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/hovon-156-aml weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/alloha weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/vbp101-1 weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/precog-0905 weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/caveat weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/mc-fludt-14l weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/myechild-01 weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/viale-a weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/quazar-aml-001 weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/pethema-lamvyx weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/radius weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/hovon-155 weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/select-aml-1 weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/alice-mims-1 weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/verona weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/eortc-1301-aml21 weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/relaza2 weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/mb-106 weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/apollo weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/evi-2 weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/relax weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/river-52 weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/sierra weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/enhance weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/alfa-0701 weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/sl03-ohd-104 weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/idhentify weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/pre-measure weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/valdac weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/astral-2 weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/advance-ii weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/culminate weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/elpis weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/bergamo weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/astral-1 weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/ho132 weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/reset-02 weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/ascertain weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/figaro weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/bexmab weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/tocilam weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/frida weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/zn-d5-004c weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/takeaim-leukemia weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/aml12 weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/etal-1 weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/amlsg-09-09 weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/aml16 weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/amlsg-16-11 weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/amadeus weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/connect-myeloid-disease-registry weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/ecog-acrin weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/alfa1401 weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/azalena weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/bellini weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/epicovideha weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/calgb-10201-alliance weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/bright-1003 weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/flugaza weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/aaml1421 weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/nct02014558 weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/allg-amlm16 weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/cimon weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/armada-2000 weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/cp-mgd006-01 weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/aza-aml-001 weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/astral-3 weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/hovon-116 weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/gfm-apr-a19-11172 weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/samba weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/aml-15 weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/ksgct1702-ctdna weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/mavric weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/decider weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/alfa-0702 weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/alfa-1200 weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/li-1 weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/trial5f9005 weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/aaml0531 weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/e2906 weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/battle weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/vital weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/amv564-101 weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/sail weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/medalist weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/solidarity weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/qoless-aza-amle weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/hovon-97 weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/viola weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/think weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/epithink weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/valor weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/trials/ravva weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/expert-opinions weekly 0.8 2025-04-02T09:45:00.000Z https://aml-hub.com/drug-updates weekly 0.8 2025-04-02T09:45:00.000Z https://aml-hub.com/educational-resources weekly 0.8 2025-11-19T13:32:00.000Z https://aml-hub.com/educational-resources/aml-hub-symposiums weekly 0.7 2025-11-19T13:32:00.000Z https://aml-hub.com/educational-resources/spotlights weekly 0.7 2025-11-19T13:32:00.000Z https://aml-hub.com/educational-resources/editorial-themes-and-reviews weekly 0.7 2026-01-30T09:24:00.000Z https://aml-hub.com/educational-resources/steering-committee-meetings weekly 0.7 2025-11-19T13:32:00.000Z https://aml-hub.com/educational-resources/know-aml-webinar weekly 0.7 2025-08-05T15:34:00.000Z https://aml-hub.com/educational-resources/drug-approvals weekly 0.7 2025-11-19T13:32:00.000Z https://aml-hub.com/educational-resources/visual-abstracts weekly 0.7 2025-11-19T13:32:00.000Z https://aml-hub.com/educational-resources/diagnostic-and-treatment-guidelines-and-recommendations weekly 0.7 2025-03-27T09:52:00.000Z https://aml-hub.com/medical-information/a-modified-delphi-consensus-for-the-management-of-flt3-mutated-aml monthly 0.9 2026-04-10T14:00:00.000Z https://aml-hub.com/medical-information/outcomes-with-fewer-ic-ven-consolidation-cycles-in-nd-aml monthly 0.9 2026-04-07T09:00:00.000Z https://aml-hub.com/medical-information/allo-hsct-outcomes-in-aya-patients-with-acute-leukemia monthly 0.9 2026-04-02T08:40:00.000Z https://aml-hub.com/medical-information/olutasidenib-vs-ivosidenib-for-rr-idh1m-aml-matchingadjusted-indirect-comparison monthly 0.9 2026-04-01T15:00:00.000Z https://aml-hub.com/medical-information/pros-from-the-phase-iii-quantumfirst-trial-of-quizartinib-in-nd-flt3itd-aml monthly 0.9 2026-03-27T17:33:00.000Z https://aml-hub.com/medical-information/intermediate-dose-cytarabine-after-cpx351-induction-for-secondary-aml monthly 0.9 2026-03-25T16:00:00.000Z https://aml-hub.com/medical-information/risk-stratification-of-ldac-venetoclax-in-nd-aml-ineligible-for-ic monthly 0.9 2026-03-20T14:30:00.000Z https://aml-hub.com/medical-information/venetoclax-based-therapies-in-nd-non-cbf-therapy-related-aml monthly 0.9 2026-03-18T11:00:00.000Z https://aml-hub.com/medical-information/decitabine-priming-low-dose-chemotherapy-in-pediatric-rr-aml monthly 0.9 2026-03-13T10:00:00.000Z https://aml-hub.com/medical-information/prognostic-impact-of-mrg-mutations-in-flt3itd-aml-harmony-analysis monthly 0.9 2026-03-10T12:07:00.000Z https://aml-hub.com/medical-information/cltr0310-301-phase-iii-post-hoc-analysis-cpx351-vs-7-3-in-genetic-subgroups-of-aml monthly 0.9 2026-03-06T10:23:00.000Z https://aml-hub.com/medical-information/ic-midostaurin-in-adults-aged-60-years-with-nd-flt3-mutated-aml-a-real-world-study monthly 0.9 2026-03-04T10:00:00.000Z https://aml-hub.com/medical-information/refinement-of-the-eln2022-genetic-risk-classification-for-patients-with-aml-undergoing-allo-hsct monthly 0.9 2026-02-27T10:00:00.000Z https://aml-hub.com/medical-information/hma-ven-vs-ic-in-nd-aml-with-chromosome-5-andor-7-abnormalities monthly 0.9 2026-02-25T16:00:00.000Z https://aml-hub.com/medical-information/prognostic-value-of-prdm16-expression-in-npm1mut-aml monthly 0.9 2026-02-19T12:00:00.000Z https://aml-hub.com/medical-information/gimema-aml1310-sex-stratified-differences-in-de-novo-aml monthly 0.9 2026-02-17T10:00:00.000Z https://aml-hub.com/medical-information/amlsg-21-13-phase-iii-results-ic-dasatinib-for-cbf-aml monthly 0.9 2026-02-12T10:00:00.000Z https://aml-hub.com/medical-information/mrd-monitoring-in-aml-eln-2025-guideline-updates monthly 0.9 2026-02-10T10:00:00.000Z https://aml-hub.com/medical-information/outcomes-of-flumel-conditioning-tacsir-gvhd-prophylaxis-in-allo-hsct-in-aml monthly 0.9 2026-02-06T10:32:00.000Z https://aml-hub.com/medical-information/ash-2025-treatment-guidelines-nd-aml-in-older-patients monthly 0.9 2026-02-04T11:03:00.000Z https://aml-hub.com/medical-information/cpx-351-vs-7-3-in-nd-aml-a-post-hoc-analysis-of-cardiotoxicity monthly 0.9 2026-02-02T10:00:00.000Z https://aml-hub.com/medical-information/symposium-series-understanding-the-differences-between-flt3-itd-and-tkd-mutations-in-aml-implications-for-clinical-practice monthly 0.9 2026-01-30T10:00:00.000Z https://aml-hub.com/medical-information/komet-007-ziftomenib-venaza-for-nd-npm1-mutant-aml monthly 0.9 2026-01-28T09:31:00.000Z https://aml-hub.com/medical-information/ivosidenib-ic-in-nd-idh1mut-aml-updated-phase-i-results monthly 0.9 2026-01-26T16:00:00.000Z https://aml-hub.com/medical-information/symposium-understanding-the-differences-between-flt3-itd-and-tkd-mutations-in-aml-qa monthly 0.9 2026-02-12T07:42:00.000Z https://aml-hub.com/medical-information/symposium-implications-for-clinical-practice-managing-aml-with-flt3-itd-and-tkd-mutations monthly 0.9 2026-02-12T07:44:00.000Z https://aml-hub.com/medical-information/enzomenib-dsp-5336-monotherapy-in-rr-aml-preliminary-phase-i-results monthly 0.9 2026-01-20T14:00:00.000Z https://aml-hub.com/medical-information/gilteritinib-venaza-in-nd-flt3-mutated-aml-phase-ii-long-term-results monthly 0.9 2026-01-16T12:00:00.000Z https://aml-hub.com/medical-information/ncri-aml18-cpx-351-vs-dago2-in-older-patients-with-non-adverse-risk-aml monthly 0.9 2026-01-13T09:00:00.000Z https://aml-hub.com/medical-information/ash-2025-pivekimab-sunirine-ven-aza-in-unfit-patients-with-nd-cd123-aml-phase-ibii-efficacy-and-safety monthly 0.9 2026-01-13T17:56:00.000Z https://aml-hub.com/medical-information/komet-007-phase-iab-updated-results-ziftomenib-venaza-in-rr-npm1-m-or-kmt2a-r-aml monthly 0.9 2026-01-07T16:45:00.000Z https://aml-hub.com/medical-information/webinar-comparing-treatment-options-for-patients-with-flt3-itd-and-tkd-mutations monthly 0.9 2026-01-28T15:05:00.000Z https://aml-hub.com/medical-information/mrd-guided-interventions-for-patients-with-aml-undergoing-allo-hsct-ebmt-recommendations monthly 0.9 2025-12-30T12:00:00.000Z https://aml-hub.com/medical-information/webinar-flt3-mutations-in-aml-types-prevalence-and-clinical-significance monthly 0.9 2026-01-28T15:05:00.000Z https://aml-hub.com/medical-information/ash-2025-congress-coverage-real-world-and-retrospective-studies-in-aml monthly 0.9 2025-12-22T09:00:00.000Z https://aml-hub.com/medical-information/ash-2025-congress-coverage-phase-iii-clinical-trials-in-aml monthly 0.9 2025-12-18T12:00:00.000Z https://aml-hub.com/medical-information/ash-2025-paradigm-azacitidine-venetoclax-vs-conventional-induction-chemotherapy-in-fit-adults-with-nd-aml monthly 0.9 2025-12-18T13:54:00.000Z https://aml-hub.com/medical-information/2102-hem-101-phase-ii-final-5-year-results-of-olutasidenib-in-rr-midh1-aml monthly 0.9 2025-12-11T12:00:00.000Z https://aml-hub.com/medical-information/ash-2025-live-congress-coverage-from-the-aml-hub monthly 0.9 2025-12-16T15:09:00.000Z https://aml-hub.com/medical-information/ash-2025-top-abstracts-whats-hot-in-acute-myeloid-leukemia monthly 0.9 2025-12-03T19:40:00.000Z https://aml-hub.com/medical-information/transplant-outcomes-in-wt1-mutant-vs-wild-type-wt1-aml monthly 0.9 2025-12-01T15:50:00.000Z https://aml-hub.com/medical-information/pethema-aml-auto-hsct-vs-chemotherapy-consolidation-for-aml-in-first-remission monthly 0.9 2025-11-27T14:00:00.000Z https://aml-hub.com/medical-information/beat-aml-trial-impact-of-idh-mutations-in-older-patients-with-nd-aml-treated-with-hma-based-therapy monthly 0.9 2025-11-21T10:40:00.000Z https://aml-hub.com/medical-information/mechanisms-of-relapse-and-post-relapse-outcomes-following-flt3-inhibitor-therapy-in-flt3-mutated-aml monthly 0.9 2025-11-20T11:02:00.000Z https://aml-hub.com/medical-information/consensus-recommendations-for-diagnosis-and-management-of-pediatric-aml monthly 0.9 2025-11-14T17:32:00.000Z https://aml-hub.com/medical-information/ziftomenib-receives-fda-approval-for-adults-with-rr-npm1-mutated-aml monthly 0.9 2025-11-14T16:29:00.000Z https://aml-hub.com/medical-information/cpx-351-venetoclax-in-nd-high-risk-aml-phase-ibii-trial-outcomes monthly 0.9 2025-11-13T17:00:00.000Z https://aml-hub.com/medical-information/quiwi-trial-quizartinib-in-newly-diagnosed-flt3-itd-negative-aml monthly 0.9 2025-11-07T13:00:00.000Z https://aml-hub.com/medical-information/m2t-cd33-receives-fda-orphan-drug-designation-for-aml monthly 0.9 2025-11-07T10:30:00.000Z https://aml-hub.com/medical-information/ehaeln-guidance-on-blast-reporting-in-acute-leukemias monthly 0.9 2025-11-04T09:00:00.000Z https://aml-hub.com/medical-information/second-transplantation-outcomes-improve-for-relapsed-pediatric-aml monthly 0.9 2025-10-31T10:33:00.000Z https://aml-hub.com/medical-information/hma-venetoclax-flt3-inhibitor-in-flt3-mutated-aml-long-term-outcomes monthly 0.9 2025-10-29T15:43:00.000Z https://aml-hub.com/medical-information/revumenib-receives-fda-approval-for-adult-and-pediatric-patients-with-rr-npm1-mutated-aml monthly 0.9 2025-10-27T14:00:00.000Z https://aml-hub.com/medical-information/quantum-first-post-hoc-analysis-impact-of-quizartinib-on-mrd-in-flt3-itd-aml monthly 0.9 2025-11-06T14:38:00.000Z https://aml-hub.com/medical-information/aml19-trial-midotarg-substudy-gemtuzumab-ozogamicin-midostaurin-in-flt3-mutated-aml monthly 0.9 2025-10-23T07:48:00.000Z https://aml-hub.com/medical-information/clinical-research-round-up-current-and-emerging-treatments-for-idh1-mutated-aml monthly 0.9 2025-11-10T09:29:00.000Z https://aml-hub.com/medical-information/ven-hma-as-a-bridge-therapy-in-rr-aml-a-retrospective-study monthly 0.9 2025-10-16T15:35:00.000Z https://aml-hub.com/medical-information/association-between-molecular-profile-and-outcomes-in-secondary-or-adverse-cytogenetic-aml-a-filo-study monthly 0.9 2025-10-15T17:04:00.000Z https://aml-hub.com/medical-information/long-term-efficacy-and-safety-results-from-the-phase-iii-agile-trial monthly 0.9 2025-10-16T15:04:00.000Z https://aml-hub.com/medical-information/iach-2025-live-congress-coverage-from-the-aml-hub monthly 0.9 2025-10-14T08:44:00.000Z https://aml-hub.com/medical-information/augment-101-phase-ii-results-of-revumenib-in-npm1-mutated-rr-aml monthly 0.9 2025-10-08T13:58:00.000Z https://aml-hub.com/medical-information/biologics-license-application-for-orca-t-for-hematological-malignancies-granted-priority-review-by-fda monthly 0.9 2025-10-09T11:43:00.000Z https://aml-hub.com/medical-information/menin-inhibitors-in-aml-bridging-the-gap-between-trial-data-and-clinical-practice monthly 0.9 2025-10-24T14:12:00.000Z https://aml-hub.com/medical-information/low-intensity-therapy-lit-venetoclax-vs-lit-in-octa-nonagenarians-with-newly-diagnosed-aml monthly 0.9 2025-11-06T14:43:00.000Z https://aml-hub.com/medical-information/the-role-of-menin-in-the-pathogenesis-of-aml monthly 0.9 2025-10-01T14:51:00.000Z https://aml-hub.com/medical-information/revumenib-with-azacitidine-venetoclax-in-nd-npm1m-or-kmt2ar-aml monthly 0.9 2025-09-26T13:45:00.000Z https://aml-hub.com/medical-information/hma-venetoclax-idh-inhibitors-in-nd-idh-mutated-aml-a-pooled-analysis monthly 0.9 2025-09-25T17:03:00.000Z https://aml-hub.com/medical-information/prognostic-implications-of-npm1-co-mutation-in-flt3-tkd-mutated-aml-a-retrospective-study monthly 0.9 2025-09-19T12:27:00.000Z https://aml-hub.com/medical-information/ligufalimab-granted-orphan-drug-designation-by-the-fda-for-the-treatment-of-aml monthly 0.9 2025-09-17T16:59:00.000Z https://aml-hub.com/medical-information/mrd-as-surrogate-clinical-trial-endpoint-for-aml-perspectives-from-mpaact monthly 0.9 2025-09-16T12:21:00.000Z https://aml-hub.com/medical-information/gatla-8-lma-p07-2-cycle-consolidation-vs-standard-6-week-consolidation-chemotherapy-in-newly-diagnosed-pediatric-aml monthly 0.9 2025-09-11T11:53:00.000Z https://aml-hub.com/medical-information/targeting-the-menin-kmt2a-complex-in-aml-current-status-of-emerging-therapies monthly 0.9 2026-01-14T11:18:00.000Z https://aml-hub.com/medical-information/agile-long-term-results-of-ivosidenib-vs-placebo-in-idh1-mutated-newly-diagnosed-aml monthly 0.9 2025-09-04T14:33:00.000Z https://aml-hub.com/medical-information/soho-2025-live-congress-feed monthly 0.9 2025-09-10T11:16:00.000Z https://aml-hub.com/medical-information/addressing-uncertainty-in-patient-selection-for-transplant-in-aml monthly 0.9 2025-09-22T16:00:00.000Z https://aml-hub.com/medical-information/characteristics-and-outcomes-in-patients-with-newly-diagnosed-aml-with-kmt2ar-a-retrospective-study monthly 0.9 2025-08-29T09:05:00.000Z https://aml-hub.com/medical-information/karonudib-granted-orphan-drug-designation-by-the-ema-for-the-treatment-of-aml monthly 0.9 2025-08-28T10:56:00.000Z https://aml-hub.com/medical-information/morpho-post-hoc-analysis-impact-of-conditioning-regimen-intensity-mrd-and-npm1-mutations-in-flt3-itd-aml monthly 0.9 2025-08-22T08:44:00.000Z https://aml-hub.com/medical-information/prognostic-impact-of-co-mutations-in-patients-with-idh12-mutated-aml monthly 0.9 2025-08-15T08:17:00.000Z https://aml-hub.com/medical-information/integrating-menin-inhibitors-into-the-treatment-landscape-of-aml-future-directions monthly 0.9 2025-09-03T09:15:00.000Z https://aml-hub.com/medical-information/highlights-from-the-phase-ii-augment-101-trial monthly 0.9 2025-10-15T14:11:00.000Z https://aml-hub.com/medical-information/commodore-trial-long-term-follow-up-of-gilteritinib-vs-salvage-chemotherapy-in-rr-flt3-mutated-aml monthly 0.9 2025-08-06T10:16:00.000Z https://aml-hub.com/medical-information/ascertain-v-trial-all-oral-dec-c-venetoclax-regimen-in-newly-diagnosed-aml monthly 0.9 2025-08-01T08:38:00.000Z https://aml-hub.com/medical-information/ziftomenib-in-relapsedrefractory-npm1m-aml-komet-001-efficacy-and-safety-results monthly 0.9 2025-07-22T11:06:00.000Z https://aml-hub.com/medical-information/hematopoietic-cell-transplantation-frailty-scale-hct-fs-prognostic-utility-in-adult-candidates-for-allo-hsct monthly 0.9 2025-07-18T09:46:00.000Z https://aml-hub.com/medical-information/ziftomenib-in-combination-with-intensive-chemotherapy-in-newly-diagnosed-npm1m-or-kmt2ar-aml-updated-komet-007-results monthly 0.9 2025-07-11T08:20:00.000Z https://aml-hub.com/medical-information/eha-2025-real-world-studies-and-risk-stratification-of-acute-myeloid-leukemia monthly 0.9 2025-07-04T10:31:00.000Z https://aml-hub.com/medical-information/barriers-to-hsct-and-outcomes-post-hsct-in-responding-patients-with-tp53-mutated-aml monthly 0.9 2025-07-04T09:03:00.000Z https://aml-hub.com/medical-information/eha-2025-hsct-for-the-treatment-of-acute-myeloid-leukemia monthly 0.9 2025-06-30T17:56:00.000Z https://aml-hub.com/medical-information/clinical-and-genomic-classification-of-secondary-aml-implications-for-prognosis-and-treatment monthly 0.9 2025-06-29T05:49:00.000Z https://aml-hub.com/medical-information/eha2025-live-congress-coverage monthly 0.9 2025-06-27T13:11:00.000Z https://aml-hub.com/medical-information/supplemental-new-drug-application-for-revumenib-in-relapsedrefractory-npm1-mutated-aml-granted-priority-review-by-the-fda monthly 0.9 2025-06-25T13:28:00.000Z https://aml-hub.com/medical-information/flt3-inhibitor-phi-101-granted-orphan-drug-designation-by-the-ema monthly 0.9 2025-06-24T15:49:00.000Z https://aml-hub.com/medical-information/senti-202-granted-orphan-drug-designation-by-the-fda-for-hematologic-malignancies-including-relapsedrefractory-aml monthly 0.9 2025-06-19T14:46:00.000Z https://aml-hub.com/medical-information/prognostic-value-of-mrd-response-in-patients-with-aml-treated-with-ven-hma-validation-of-eln-2021-mrd-recommendations monthly 0.9 2025-06-18T10:48:00.000Z https://aml-hub.com/medical-information/know-aml-webinar-closing-remarks-and-qa monthly 0.9 2025-06-26T18:40:00.000Z https://aml-hub.com/medical-information/asco2025-live-congress-coverage-from-aml-hub monthly 0.9 2025-06-05T11:35:00.000Z https://aml-hub.com/medical-information/know-aml-webinar-how-can-physicians-and-patients-communicate-more-clearly-about-mutation-testing-in-aml-going-forward monthly 0.9 2025-06-19T17:09:00.000Z https://aml-hub.com/medical-information/know-aml-webinar-empowering-patients-to-ask-their-physician-the-right-questions-during-their-aml-journey monthly 0.9 2025-06-13T13:24:00.000Z https://aml-hub.com/medical-information/know-aml-webinar-what-are-mutations-and-why-do-they-matter-in-aml monthly 0.9 2025-06-09T14:09:00.000Z https://aml-hub.com/medical-information/validation-of-the-who-5-and-icc-guidelines-for-tp53-mutated-myeloid-neoplasm-in-an-independent-international-cohort monthly 0.9 2025-05-15T15:34:00.000Z https://aml-hub.com/medical-information/venetoclax-exposure-reduced-to-7-days-vs-standard-exposure-in-patients-with-newly-diagnosed-aml monthly 0.9 2025-05-14T14:34:00.000Z https://aml-hub.com/medical-information/impact-of-donor-age-and-type-on-outcomes-with-allo-hsct-for-aml-in-first-remission monthly 0.9 2025-05-08T13:59:00.000Z https://aml-hub.com/medical-information/quantum-first-a-post-hoc-analysis-of-the-impact-of-allo-hsct-and-quizartinib-in-newly-diagnosed-flt3-itd-positive-aml monthly 0.9 2025-04-29T05:48:00.000Z https://aml-hub.com/medical-information/precision-t-a-phase-iii-trial-of-orca-t-vs-soc-for-cgvhd-prophylaxis-in-advanced-hematologic-malignancies monthly 0.9 2025-04-29T05:10:00.000Z https://aml-hub.com/medical-information/aml-hub-spotlight-camelot-1-trial monthly 0.9 2025-08-14T09:22:00.000Z https://aml-hub.com/medical-information/ab8939-granted-orphan-drug-designation-by-the-ema-for-the-treatment-of-patients-with-aml monthly 0.9 2025-09-17T13:04:00.000Z https://aml-hub.com/medical-information/bemcentinib-in-older-patients-with-aml-ineligible-for-intensive-chemotherapy-a-phase-ibiia-trial monthly 0.9 2025-04-22T11:52:00.000Z https://aml-hub.com/medical-information/51st-annual-meeting-of-the-ebmt-congress-coverage-registry-based-studies-and-real-world-evidence monthly 0.9 2025-04-15T09:08:00.000Z https://aml-hub.com/medical-information/51st-annual-meeting-of-the-ebmt-congress-coverage-clinical-trials monthly 0.9 2025-04-15T08:55:00.000Z https://aml-hub.com/medical-information/how-i-treat-differentiation-syndrome-associated-with-differentiating-agent-therapy-in-aml monthly 0.9 2025-04-17T14:32:00.000Z https://aml-hub.com/medical-information/induction-with-idarubicin-cytarabine-and-cladribine-in-patients-with-nd-aml-results-from-a-phase-iii-trial monthly 0.9 2025-04-04T14:13:00.000Z https://aml-hub.com/medical-information/beat-aml-trial-updates-from-ash-2024 monthly 0.9 2025-04-04T16:42:00.000Z https://aml-hub.com/medical-information/induction-and-consolidation-with-flag-ida-venetoclax-in-nd-and-rr-aml-long-term-findings-from-a-phase-ii-trial monthly 0.9 2025-04-03T10:18:00.000Z https://aml-hub.com/medical-information/ehance-2-magrolimab-plus-azacitidine-vs-physicians-choice-for-untreared-tp53-mutated-aml monthly 0.9 2025-04-02T12:32:00.000Z https://aml-hub.com/medical-information/eln-recommendations-assessing-fitness-and-eligibility-for-treatment-in-aml monthly 0.9 2025-04-02T12:35:00.000Z https://aml-hub.com/medical-information/efficacy-and-safety-of-flt3-inhibitors-in-the-treatment-of-aml-a-review-of-clinical-data monthly 0.9 2025-04-29T05:40:00.000Z https://aml-hub.com/medical-information/prognostic-impact-of-mrd-clearance-timing-in-patients-with-newly-diagnosed-aml-undergoing-intensive-chemotherapy monthly 0.9 2025-04-02T12:39:00.000Z https://aml-hub.com/medical-information/post-hoc-analysis-of-the-admiral-and-commodore-trials-timing-of-response-with-gilteritinib-monotherapy-in-rr-flt3m-aml monthly 0.9 2025-04-02T12:40:00.000Z https://aml-hub.com/medical-information/aml-hub-spotlight-key-findings-from-the-komet-001-trial-of-ziftomenib-in-rr-aml monthly 0.9 2025-08-14T09:20:00.000Z https://aml-hub.com/medical-information/menin-inhibitors-for-aml-current-status-and-insights-from-ash-2024 monthly 0.9 2025-09-08T11:56:00.000Z https://aml-hub.com/medical-information/mrd-as-predictor-of-late-relapses-after-transplant-in-aml-or-mdsaml monthly 0.9 2025-02-26T10:13:00.000Z https://aml-hub.com/medical-information/aml-hub-spotlight-findings-from-the-quiwi-trial-of-quizartinib-in-aml monthly 0.9 2025-08-14T09:21:00.000Z https://aml-hub.com/medical-information/fda-grants-fast-track-designation-to-oral-kat2ab-degrader-autx-703-in-rr-aml monthly 0.9 2025-02-26T14:57:00.000Z https://aml-hub.com/medical-information/2025-tandem-meetings-or-transplantation-and-cellular-therapy-meetings-of-astct-and-cibmtr-congress-coverage monthly 0.9 2025-05-13T16:14:00.000Z https://aml-hub.com/medical-information/precog-0905-trial-gilteritinib-vs-midostaurin-intensive-chemotherapy-in-patients-with-newly-diagnosed-flt3-mutated-aml monthly 0.9 2025-02-20T15:58:00.000Z https://aml-hub.com/medical-information/7th-european-car-t-cell-meeting-congress-coverage-catchup monthly 0.9 2025-02-21T09:28:00.000Z https://aml-hub.com/medical-information/calgb-10603ratify-10-year-follow-up-midostaurin-vs-placebo-plus-intensive-chemotherapy-in-newly-diagnosed-flt3-mutated-aml monthly 0.9 2025-02-18T09:29:00.000Z https://aml-hub.com/medical-information/a-novel-prognostic-risk-model-for-patients-with-rr-aml-receiving-venetoclax-plus-hypomethylating-agents monthly 0.9 2025-02-11T12:08:00.000Z https://aml-hub.com/medical-information/post-marketing-pharmacovigilance-study-of-gilteritinib-and-midostaurin-from-the-faers-database monthly 0.9 2025-02-07T14:22:00.000Z https://aml-hub.com/medical-information/phase-ib-caveat-trial-venetoclax-plus-chemotherapy-in-elderly-patients-with-npm1-or-idh1idh2-mutated-de-novo-aml monthly 0.9 2025-02-07T06:39:00.000Z https://aml-hub.com/medical-information/morpho-post-hoc-analysis-association-between-mrd-and-rfs-in-patients-with-flt3-itd-mutated-aml monthly 0.9 2025-04-02T12:39:00.000Z https://aml-hub.com/medical-information/olutasidenib-azacitidine-in-patients-with-idh1mutated-rr-aml-pooled-analysis-from-a-phase-iii-trial monthly 0.9 2025-01-30T11:42:00.000Z https://aml-hub.com/medical-information/gilteritinib-and-quizartinib-single-agent-salvage-therapy-in-flt3-mutated-rr-aml-real-world-study-by-the-cetlam-and-pethema-groups monthly 0.9 2025-01-28T12:00:00.000Z https://aml-hub.com/medical-information/fda-approves-treosulfan-plus-fludarabine-as-an-allo-hsct-preparative-regimen-in-patients-with-aml-or-mds monthly 0.9 2025-01-24T14:11:00.000Z https://aml-hub.com/medical-information/quantum-first-exploratory-analysis-quizartinib-maintenance-in-patients-with-newly-diagnosed-flt3-itd-aml monthly 0.9 2025-04-29T05:41:00.000Z https://aml-hub.com/medical-information/how-i-treat-post-transplant-relapse-of-aml monthly 0.9 2025-01-21T16:30:00.000Z https://aml-hub.com/medical-information/impact-of-baseline-gene-mutations-on-quizartinib-survival-benefits-in-patients-with-flt3-itd-aml-post-hoc-analysis-of-the-quantum-first-trial monthly 0.9 2025-01-16T14:44:00.000Z https://aml-hub.com/medical-information/eln-2024-recommendations-genetic-risk-stratification-in-patients-with-aml-receiving-less-intensive-therapies monthly 0.9 2025-01-13T09:31:00.000Z https://aml-hub.com/medical-information/fda-grants-fast-track-designation-for-lyt-200-in-rr-aml-and-mds monthly 0.9 2025-01-13T04:29:00.000Z https://aml-hub.com/medical-information/cpx-351-vs-flag-ida-post-hoc-subgroup-analysis-of-the-uk-ncri-aml19-trial monthly 0.9 2025-01-07T16:28:00.000Z https://aml-hub.com/medical-information/validation-of-updated-eln-2022-risk-stratification-in-adult-patients-with-aml monthly 0.9 2024-12-22T08:47:00.000Z https://aml-hub.com/medical-information/ash24-treatments-for-rr-aml-maintenance-strategies-and-mutation-and-mrd-informed-decisions monthly 0.9 2024-12-20T12:43:00.000Z https://aml-hub.com/medical-information/ash24-treatments-for-newly-diagnosed-aml monthly 0.9 2024-12-20T12:43:00.000Z https://aml-hub.com/medical-information/2024-ash-annual-meeting-live-congress-feed monthly 0.9 2025-12-04T11:35:00.000Z https://aml-hub.com/medical-information/prognostic-utility-of-eln-risk-criteria-for-stratifying-survival-outcomes-in-patients-with-nd-aml-ineligible-for-intensive-chemotherapy monthly 0.9 2024-12-16T17:12:00.000Z https://aml-hub.com/medical-information/outcomes-of-patients-with-aml-treated-with-intensive-chemotherapy-during-1997-2016-a-harmony-alliance-analysis monthly 0.9 2024-12-12T16:55:00.000Z https://aml-hub.com/medical-information/real-world-long-term-efficacy-of-cpx-351-and-the-impact-of-mrd-in-patients-with-t-aml-or-aml-mrc monthly 0.9 2024-12-10T13:47:00.000Z https://aml-hub.com/medical-information/ash-2024-top-abstracts-in-aml monthly 0.9 2025-12-04T11:35:00.000Z https://aml-hub.com/medical-information/the-impact-of-post-remission-g-csf-on-outcomes-in-the-viale-a-and-viale-c-trials monthly 0.9 2024-11-25T16:28:00.000Z https://aml-hub.com/medical-information/how-i-treat-a-patient-with-aml-in-remission-after-intensive-chemotherapy-not-proceeding-to-hsct monthly 0.9 2025-01-21T12:35:00.000Z https://aml-hub.com/medical-information/u-s-fda-grants-fast-track-designation-to-cell-cycle-inhibitor-lbs-007 monthly 0.9 2024-11-27T16:15:00.000Z https://aml-hub.com/medical-information/revumenib-receives-fda-approval-for-adult-and-pediatric-patients-aged-1-year-with-rr-acute-leukemia-and-a-kmt2a-translocation monthly 0.9 2024-11-25T11:09:00.000Z https://aml-hub.com/medical-information/how-i-treat-using-maintenance-approaches-in-patients-with-aml-in-clinical-practice monthly 0.9 2025-12-04T11:33:00.000Z https://aml-hub.com/medical-information/cpx-351-in-older-patients-with-secondary-or-high-risk-aml-results-from-the-phase-ii-pethema-lamvyx-trial monthly 0.9 2024-11-14T10:56:00.000Z https://aml-hub.com/medical-information/long-term-survival-outcomes-in-patients-with-aml-who-were-alive-and-disease-free-2-years-after-allo-hsct monthly 0.9 2024-11-14T10:42:00.000Z https://aml-hub.com/medical-information/eln-refined-2024-beat-aml-risk-stratification-for-older-patients-with-newly-diagnosed-aml monthly 0.9 2024-11-08T11:55:00.000Z https://aml-hub.com/medical-information/maintenance-therapy-in-aml-treatment-options-and-clinical-considerations monthly 0.9 2025-03-05T12:29:00.000Z https://aml-hub.com/medical-information/induction-with-lower-intensity-cpx-351-venetoclax-in-patients-with-aml-results-from-a-phase-1b-trial monthly 0.9 2024-11-07T15:31:00.000Z https://aml-hub.com/medical-information/how-i-treat-older-unfit-patients-with-aml-using-aza-ven-a-case-series monthly 0.9 2024-10-31T10:56:00.000Z https://aml-hub.com/medical-information/midostaurin-plus-decitabine-in-older-unfit-patients-with-aml-or-higher-risk-mds-final-analysis-from-the-phase-ii-hovon-155-trial monthly 0.9 2024-10-28T10:44:00.000Z https://aml-hub.com/medical-information/ginema-aml1310-trial-6-year-update-on-risk-adapted-mrd-directed-therapy-for-younger-patients-with-aml monthly 0.9 2024-10-24T15:07:00.000Z https://aml-hub.com/medical-information/u-s-fda-grants-fast-track-designation-to-hc-7366-for-the-treatment-of-rr-aml monthly 0.9 2024-10-24T15:33:00.000Z https://aml-hub.com/medical-information/tamibarotene-ven-aza-combination-in-patients-with-aml-interim-results-from-the-select-aml-1-phase-ii-trial monthly 0.9 2024-10-18T10:48:00.000Z https://aml-hub.com/medical-information/gilteritinib-vs-salvage-chemotherapy-in-asian-patients-with-rr-flt3-mutated-aml-results-from-the-phase-iii-commodore-trial monthly 0.9 2024-10-14T09:08:00.000Z https://aml-hub.com/medical-information/olutasidenib-in-patients-with-aml-following-venetoclax-exposure-final-5-year-results-from-a-phase-ii-trial monthly 0.9 2024-10-08T15:13:00.000Z https://aml-hub.com/medical-information/prognostic-factors-in-patients-with-npm1-mutated-aml-analysis-from-the-aml17-and-aml19-trials monthly 0.9 2024-10-04T13:41:00.000Z https://aml-hub.com/medical-information/iach-2024-live-congress-feed monthly 0.9 2024-10-03T12:59:00.000Z https://aml-hub.com/medical-information/recent-advancements-in-menin-inhibitors-for-aml-highlights-from-eha-2024 monthly 0.9 2026-01-14T10:12:00.000Z https://aml-hub.com/medical-information/iadademstat-azacitidine-in-adult-patients-with-newly-diagnosed-aml-the-phase-iia-alice-study monthly 0.9 2025-10-01T10:01:00.000Z https://aml-hub.com/medical-information/u-s-fda-grants-fast-track-designation-to-ict01-for-the-treatment-of-newly-diagnosed-aml monthly 0.9 2024-09-20T03:52:00.000Z https://aml-hub.com/medical-information/how-can-we-intervene-with-mrd-directed-therapy-within-and-outside-of-transplantation monthly 0.9 2025-08-05T15:28:00.000Z https://aml-hub.com/medical-information/how-can-we-apply-mrd-guidelines-to-low-intensity-therapy-in-aml monthly 0.9 2025-08-05T15:29:00.000Z https://aml-hub.com/medical-information/impact-of-donor-age-and-type-in-patients-with-aml-undergoing-allo-hsct monthly 0.9 2024-09-05T18:30:00.000Z https://aml-hub.com/medical-information/should-mrd-negativity-post-remission-impact-treatment-decisions-in-eln-intermediate-risk-aml monthly 0.9 2025-08-05T15:29:00.000Z https://aml-hub.com/medical-information/soho-2024-live-congress-feed monthly 0.9 2024-09-16T12:46:00.000Z https://aml-hub.com/medical-information/u-s-fda-grants-fast-track-designation-to-cb-012-for-the-treatment-of-rr-aml monthly 0.9 2024-09-04T13:55:00.000Z https://aml-hub.com/medical-information/what-is-the-impact-of-the-5th-who-classification-and-icc-of-aml-on-diagnosis-and-treatment-of-high-risk-aml monthly 0.9 2024-09-17T13:36:00.000Z https://aml-hub.com/medical-information/induction-chemotherapy-options-for-older-patients-with-aml monthly 0.9 2025-08-05T15:30:00.000Z https://aml-hub.com/medical-information/impact-of-10-day-decitabine-vs-standard-intensive-chemotherapy-on-hrqol-in-older-patients-with-aml monthly 0.9 2024-08-29T10:25:00.000Z https://aml-hub.com/medical-information/how-might-olutasidenib-long-term-data-impact-treatment-strategies-in-patients-with-idh1-mutated-rr-aml monthly 0.9 2024-08-22T13:46:00.000Z https://aml-hub.com/medical-information/consensus-based-guidelines-for-the-management-of-patients-with-aml-in-gulf-cooperation-council-countries monthly 0.9 2024-08-21T06:02:00.000Z https://aml-hub.com/medical-information/safety-and-efficacy-of-azacitidine-for-treating-mrd-in-patients-with-mds-and-aml-long-term-findings-of-relaza2 monthly 0.9 2024-08-15T14:53:00.000Z https://aml-hub.com/medical-information/liposomal-drug-delivery-in-acute-myeloid-leukemia monthly 0.9 2025-02-07T14:54:00.000Z https://aml-hub.com/medical-information/how-i-treat-a-patient-with-dnmt3a-mutated-aml-in-remission-post-intensive-chemotherapy monthly 0.9 2024-10-03T10:23:00.000Z https://aml-hub.com/medical-information/eha-2024-topline-findings-of-the-tud-apollo-064-trial-and-their-potential-clinical-implications monthly 0.9 2024-08-01T12:42:00.000Z https://aml-hub.com/medical-information/quantum-first-efficacy-analysis-in-newly-diagnosed-flt3-itd-positive-aml monthly 0.9 2024-07-29T10:10:00.000Z https://aml-hub.com/medical-information/cpx-351-as-first-line-treatment-in-aml-real-world-data monthly 0.9 2024-10-01T11:18:00.000Z https://aml-hub.com/medical-information/venetoclax-10-day-decitabine-in-olderunfit-patients-with-nd-or-rr-aml-or-hr-mds monthly 0.9 2025-04-29T10:23:00.000Z https://aml-hub.com/medical-information/u-s-fda-grants-fast-track-designation-to-dsp-5336-for-the-treatment-of-rr-aml monthly 0.9 2026-01-14T10:11:00.000Z https://aml-hub.com/medical-information/sls009-granted-orphan-drug-designation-by-the-ema monthly 0.9 2024-07-09T14:48:00.000Z https://aml-hub.com/medical-information/long-term-survival-patterns-in-aml-across-age-groups-in-nordic-countries monthly 0.9 2024-07-08T11:30:00.000Z https://aml-hub.com/medical-information/eha2024-early-phase-trials-in-aml monthly 0.9 2026-01-14T10:09:00.000Z https://aml-hub.com/medical-information/eha2024-late-phase-trials-in-aml monthly 0.9 2024-07-31T09:14:00.000Z https://aml-hub.com/medical-information/eha2024-real-world-studies-in-aml monthly 0.9 2024-07-31T09:14:00.000Z https://aml-hub.com/medical-information/what-is-the-optimal-prognostic-threshold-for-mfc-mrd-positivity-in-patients-with-aml monthly 0.9 2024-06-27T11:01:00.000Z https://aml-hub.com/medical-information/impact-of-delayed-venetoclax-based-treatment-on-overall-survival-in-newly-diagnosed-aml monthly 0.9 2024-07-03T12:32:00.000Z https://aml-hub.com/medical-information/patient-outcomes-in-aml-comparison-between-randomized-clinical-trials-and-registry-data monthly 0.9 2024-07-03T12:40:00.000Z https://aml-hub.com/medical-information/u-s-fda-grants-orphan-drug-designation-to-sl-172154 monthly 0.9 2024-06-11T16:35:00.000Z https://aml-hub.com/medical-information/eha-2024-top-abstracts-what-s-hot-in-aml monthly 0.9 2024-06-18T10:00:00.000Z https://aml-hub.com/medical-information/sierra-trial-post-hoc-analysis-outcomes-of-patients-with-a-tp53-mutation-vs-wild-type monthly 0.9 2024-06-06T19:02:00.000Z https://aml-hub.com/medical-information/salvage-chemotherapy-to-induce-remission-prior-to-allo-hsct-vs-immediate-transplant-in-patients-with-rr-aml monthly 0.9 2024-05-29T13:43:00.000Z https://aml-hub.com/medical-information/impact-of-disease-stage-and-mrd-treatment-on-outcomes-in-patients-with-npm1-mutated-aml-proceeding-to-allo-hsct monthly 0.9 2024-05-28T08:47:00.000Z https://aml-hub.com/medical-information/allo-hsct-vs-consolidation-therapy-to-improve-leukemia-free-survival-in-elderly-patients-with-aml monthly 0.9 2024-05-28T09:13:00.000Z https://aml-hub.com/medical-information/impact-of-number-of-induction-courses-to-achieve-complete-remission-in-patients-with-aml-prior-to-allo-hsct monthly 0.9 2024-05-17T09:36:00.000Z https://aml-hub.com/medical-information/impact-of-molecular-ontogeny-on-outcomes-in-patients-with-newly-diagnosed-aml-treated-with-hma-venetoclax monthly 0.9 2024-04-29T11:58:00.000Z https://aml-hub.com/medical-information/hma-venetoclax-in-adults-with-tp53-mutated-aml monthly 0.9 2024-05-13T13:36:00.000Z https://aml-hub.com/medical-information/idhentify-trial-impact-of-mutational-burden-and-pattern-on-outcomes-in-patients-with-rr-idh2-mutated-aml monthly 0.9 2024-05-09T08:40:00.000Z https://aml-hub.com/medical-information/the-pre-measure-study-how-does-pretransplant-idh1-and-idh2-mrd-affect-posttransplant-outcomes-in-patients-with-aml monthly 0.9 2024-04-22T13:41:00.000Z https://aml-hub.com/medical-information/low-dose-azacitidine-venetoclax-as-maintenance-therapy-for-patients-with-aml-in-remission monthly 0.9 2024-05-02T09:11:00.000Z https://aml-hub.com/medical-information/u-s-fda-grants-orphan-drug-designation-to-the-nk-cell-therapy-ignk001 monthly 0.9 2024-05-01T16:10:00.000Z https://aml-hub.com/medical-information/crenolanib-plus-intensive-chemotherapy-for-the-treatment-of-flt3-mutated-aml monthly 0.9 2024-05-01T10:38:00.000Z https://aml-hub.com/medical-information/gemtuzumab-ozogamicin-plus-7-3-induction-therapy-in-patients-with-intermediate-risk-nd-aml monthly 0.9 2024-04-26T13:26:00.000Z https://aml-hub.com/medical-information/validation-of-automated-semiconductor-based-ngs-in-myeloid-neoplasms monthly 0.9 2024-05-01T14:17:00.000Z https://aml-hub.com/medical-information/u-s-fda-grants-breakthrough-therapy-designation-for-ziftomenib monthly 0.9 2024-04-23T13:47:00.000Z https://aml-hub.com/medical-information/what-are-the-challenges-associated-with-car-t-cell-therapy-in-patients-with-aml monthly 0.9 2024-04-24T09:52:00.000Z https://aml-hub.com/medical-information/ivosidenib-for-patients-with-idh1-mutated-rr-aml-after-allo-hsct monthly 0.9 2024-04-09T16:43:00.000Z https://aml-hub.com/medical-information/bvx001-granted-orphan-drug-designation-by-the-u-s-fda monthly 0.9 2024-04-19T14:58:00.000Z https://aml-hub.com/medical-information/annamycin-granted-orphan-drug-designation-by-the-ema monthly 0.9 2024-04-24T10:41:00.000Z https://aml-hub.com/medical-information/oral-decitabine-and-cedazuridine-venetoclax-for-the-treatment-of-older-patients-with-newly-diagnosed-aml monthly 0.9 2024-04-09T13:12:00.000Z https://aml-hub.com/medical-information/tamibarotene-granted-fast-track-designation-by-the-u-s-fda monthly 0.9 2024-04-10T08:31:00.000Z https://aml-hub.com/medical-information/valdac-a-prospective-study-of-venetoclax-and-low-dose-cytarabine-for-mrd-and-oligoblastic-relapse-in-aml monthly 0.9 2024-04-18T15:38:00.000Z https://aml-hub.com/medical-information/reduced-toxicity-conditioning-regimen-for-older-patients-with-aml-fludarabine-plus-treosulfan monthly 0.9 2024-04-03T12:12:00.000Z https://aml-hub.com/medical-information/safety-and-efficacy-of-pivekimab-sunirine-in-rr-aml-phase-iii-study monthly 0.9 2024-04-03T11:49:00.000Z https://aml-hub.com/medical-information/role-of-mrd-in-treatment-decisions-for-aml-latest-insights-from-ash-2023 monthly 0.9 2024-04-03T09:40:00.000Z https://aml-hub.com/medical-information/priority-review-of-a-new-drug-application-for-revumenib-in-the-treatment-of-patients-with-rr-kmt2ar-aml-and-all monthly 0.9 2024-03-28T15:40:00.000Z https://aml-hub.com/medical-information/visual-abstract-or-phase-iii-randomized-open-label-study-of-guadecitabine-vs-treatment-choice-in-previously-treated-aml-astral-2 monthly 0.9 2025-01-22T09:53:00.000Z https://aml-hub.com/medical-information/the-impact-of-concomitant-ivosidenib-on-triazole-levels-in-patients-with-aml-or-mds monthly 0.9 2024-03-20T16:19:00.000Z https://aml-hub.com/medical-information/optimizing-induction-regimens-in-younger-patients-with-aml-the-uk-aml19-trial monthly 0.9 2024-04-30T12:25:00.000Z https://aml-hub.com/medical-information/real-world-study-of-hma-ven-in-older-patients-with-newly-diagnosed-aml monthly 0.9 2024-03-22T10:12:00.000Z https://aml-hub.com/medical-information/lyt-200-granted-orphan-drug-designation-by-the-u-s-fda monthly 0.9 2024-03-14T15:03:00.000Z https://aml-hub.com/medical-information/viale-a-trial-long-term-efficacy-and-safety-follow-up monthly 0.9 2024-04-09T13:09:00.000Z https://aml-hub.com/medical-information/azacitidine-venetoclax-and-gilteritinib-in-patients-with-flt3-mutated-aml monthly 0.9 2024-03-12T17:20:00.000Z https://aml-hub.com/medical-information/maintenance-therapy-in-aml-latest-updates-from-ash-2023 monthly 0.9 2024-03-01T12:10:00.000Z https://aml-hub.com/medical-information/how-might-the-morpho-trial-of-gilteritinib-impact-clinical-practice monthly 0.9 2024-06-25T15:34:00.000Z https://aml-hub.com/medical-information/long-term-follow-up-of-the-eortc-ginema-aml-10-trial monthly 0.9 2024-03-06T09:26:00.000Z https://aml-hub.com/medical-information/what-were-your-highlights-from-ash-2023-2 monthly 0.9 2024-04-29T15:03:00.000Z https://aml-hub.com/medical-information/venetoclax-plus-decitabine-vs-intensive-chemotherapy-for-young-patients-with-nd-aml monthly 0.9 2024-02-29T09:19:00.000Z https://aml-hub.com/medical-information/do-older-patients-benefit-from-hmas-venetoclax-in-acute-leukemias-of-ambiguous-lineage monthly 0.9 2024-02-23T15:03:00.000Z https://aml-hub.com/medical-information/how-to-approach-patients-who-are-mrd-positive-after-initial-induction-chemotherapy monthly 0.9 2024-02-23T15:04:00.000Z https://aml-hub.com/medical-information/the-potential-of-menin-kmt2a-inhibitors-in-the-treatment-of-aml monthly 0.9 2024-02-15T11:28:00.000Z https://aml-hub.com/medical-information/ocifisertib-granted-orphan-drug-designation-by-the-u-s-fda monthly 0.9 2024-02-21T17:11:00.000Z https://aml-hub.com/medical-information/what-were-your-highlights-from-ash-2023 monthly 0.9 2024-02-20T15:32:00.000Z https://aml-hub.com/medical-information/the-quantum-first-trial-what-is-the-impact-of-mrd-on-the-management-of-patients-with-flt3-mutated-aml monthly 0.9 2024-02-15T16:51:00.000Z https://aml-hub.com/medical-information/are-all-oral-based-induction-combinations-the-future-for-aml-treatment monthly 0.9 2024-02-15T10:11:00.000Z https://aml-hub.com/medical-information/the-quiwi-trial-what-is-the-potential-of-quizartinib-in-patients-with-wild-type-flt3 monthly 0.9 2024-02-12T16:36:00.000Z https://aml-hub.com/medical-information/the-latest-on-oral-azacitidine-maintenance-therapy-in-aml monthly 0.9 2024-02-09T11:29:00.000Z https://aml-hub.com/medical-information/what-exciting-updates-on-maintenance-therapy-in-aml-were-presented-at-ash-2023 monthly 0.9 2024-02-07T12:00:00.000Z https://aml-hub.com/medical-information/latest-updates-on-the-quantum-first-study-from-ash-2023 monthly 0.9 2024-02-07T11:34:00.000Z https://aml-hub.com/medical-information/cusatuzumab-azacitidine-in-aml-results-from-the-phase-ii-culminate-trial monthly 0.9 2024-01-26T15:16:00.000Z https://aml-hub.com/medical-information/how-i-treat-case-studies-in-relapsedrefractory-acute-myeloid-leukemia monthly 0.9 2024-01-26T15:16:00.000Z https://aml-hub.com/medical-information/risk-stratification-and-guidelines-in-aml-management monthly 0.9 2024-01-22T14:07:00.000Z https://aml-hub.com/medical-information/eln-david-recommendations-for-mrd-assessment-in-patients-with-aml monthly 0.9 2024-01-19T14:52:00.000Z https://aml-hub.com/medical-information/ptx-252-granted-orphan-drug-designation-by-the-fda monthly 0.9 2024-01-17T16:26:00.000Z https://aml-hub.com/medical-information/editorial-theme-navigating-the-recent-updates-to-the-classification-of-aml-validation-and-refinement-of-the-2022-eln-classification monthly 0.9 2024-02-13T17:38:00.000Z https://aml-hub.com/medical-information/sls009-granted-fast-track-designation-by-the-u-s-fda monthly 0.9 2024-01-11T09:27:00.000Z https://aml-hub.com/medical-information/elpis-efficacy-and-safety-of-aspacytarabine-in-patients-with-aml-who-are-ineligible-for-intensive-chemotherapy monthly 0.9 2024-01-02T14:38:00.000Z https://aml-hub.com/medical-information/which-patients-should-be-considered-for-allo-hsct monthly 0.9 2025-08-05T15:30:00.000Z https://aml-hub.com/medical-information/post-remission-therapy-for-patients-not-proceeding-to-hsct monthly 0.9 2025-08-05T15:31:00.000Z https://aml-hub.com/medical-information/recommendations-from-siog-for-the-treatment-of-older-patients-with-aml monthly 0.9 2023-12-20T09:15:00.000Z https://aml-hub.com/medical-information/venetoclax-based-combination-therapies-for-aml-in-patients-ineligible-for-intensive-chemotherapy monthly 0.9 2023-12-18T10:12:00.000Z https://aml-hub.com/medical-information/efficacy-and-safety-of-decitabine-monotherapy-vs-intensive-chemotherapy-in-older-patients-with-aml monthly 0.9 2023-12-14T16:06:00.000Z https://aml-hub.com/medical-information/the-long-term-benefit-of-luspatercept-analysis-from-the-phase-iii-medalist-trial monthly 0.9 2024-01-05T11:31:00.000Z https://aml-hub.com/medical-information/ash2023-abstracts-what-s-hot-in-aml monthly 0.9 2023-12-06T09:55:00.000Z https://aml-hub.com/medical-information/impact-of-fungal-infections-on-transplant-outcomes-a-cibmtr-analysis monthly 0.9 2023-11-30T12:38:00.000Z https://aml-hub.com/medical-information/mocravimod-granted-orphan-drug-designation-by-the-fda monthly 0.9 2023-11-27T18:38:00.000Z https://aml-hub.com/medical-information/latest-updates-from-the-phase-iii-quantum-first-trial monthly 0.9 2023-11-22T23:32:00.000Z https://aml-hub.com/medical-information/quizartinib-granted-approval-by-the-ec-for-patients-with-newly-diagnosed-flt3-itd-mutated-aml monthly 0.9 2023-11-09T15:19:00.000Z https://aml-hub.com/medical-information/bemcentinib-in-patients-with-hr-mds-or-aml-who-are-rr-to-hmas-results-from-the-phase-ii-bergamo-trial monthly 0.9 2024-01-05T10:50:00.000Z https://aml-hub.com/medical-information/allo-hsct-in-patients-with-high-risk-mds-analysis-from-the-bmt-ctn-1102-trial monthly 0.9 2024-01-04T11:32:00.000Z https://aml-hub.com/medical-information/fla-ida-with-or-without-venetoclax-in-patients-with-relapsedrefractory-acute-myeloid-leukemia monthly 0.9 2023-11-03T13:01:00.000Z https://aml-hub.com/medical-information/efficacy-and-safety-of-midostaurin-plus-intensive-chemotherapy-in-newly-diagnosed-patients-with-flt3-mutated-aml monthly 0.9 2023-10-25T10:24:00.000Z https://aml-hub.com/medical-information/sls009-granted-orphan-drug-designation-by-the-u-s-fda monthly 0.9 2023-10-17T09:21:00.000Z https://aml-hub.com/medical-information/editorial-theme-navigating-the-recent-updates-to-the-classification-of-aml-the-international-consensus-classification monthly 0.9 2023-10-17T13:18:00.000Z https://aml-hub.com/medical-information/editorial-theme-or-navigating-the-latest-updates-in-classification-systems-for-aml-the-2022-eln-recommendations monthly 0.9 2023-09-28T16:16:00.000Z https://aml-hub.com/medical-information/initiation-of-the-phase-iii-reset-02-trial-of-smart101-for-the-treatment-of-aml monthly 0.9 2024-01-05T10:50:00.000Z https://aml-hub.com/medical-information/what-were-your-highlights-from-eha-2023 monthly 0.9 2023-09-20T11:12:00.000Z https://aml-hub.com/medical-information/oral-decitabine-and-cedazuridine-granted-approval-by-the-european-commission-for-the-treatment-of-adults-with-newly-diagnosed-aml monthly 0.9 2023-09-19T12:24:00.000Z https://aml-hub.com/medical-information/quizartinib-recommended-for-approval-in-the-eu monthly 0.9 2023-09-18T13:00:00.000Z https://aml-hub.com/medical-information/the-impact-of-post-transplant-mrd-on-survival-in-aml-and-mds-an-analysis-from-the-phase-ii-figaro-trial monthly 0.9 2024-01-05T10:57:00.000Z https://aml-hub.com/medical-information/vididencel-received-fast-track-designation-from-the-u-s-fda monthly 0.9 2023-09-11T14:39:00.000Z https://aml-hub.com/medical-information/long-term-follow-up-post-hoc-analysis-of-sorafenib-maintenance-therapy-after-allo-hsct-in-patients-with-flt3-mutated-aml monthly 0.9 2023-09-05T14:52:00.000Z https://aml-hub.com/medical-information/bexmarilimab-granted-orphan-drug-designation-by-the-u-s-fda monthly 0.9 2024-07-24T14:51:00.000Z https://aml-hub.com/medical-information/an-overview-of-developments-in-immune-based-therapies-in-the-treatment-of-aml-and-mds-updates-from-asco23 monthly 0.9 2024-01-05T10:58:00.000Z https://aml-hub.com/medical-information/wu-nk-101-granted-orphan-drug-designation-by-the-fda monthly 0.9 2023-08-16T16:33:00.000Z https://aml-hub.com/medical-information/updates-from-asco-and-eha-on-the-efficacy-and-safety-of-ivosidenib-including-molecular-characterization-and-long-term-follow-up-in-patients-with-mutant-idh1-aml-and-rr-mds monthly 0.9 2024-01-05T10:58:00.000Z https://aml-hub.com/medical-information/how-might-treatment-with-venetoclax-plus-hmas-improve-quality-of-life-and-post-transplant-outcomes monthly 0.9 2023-08-01T15:01:00.000Z https://aml-hub.com/medical-information/the-latest-developments-on-novel-agents-in-the-treatment-of-aml-updates-from-asco-and-eha monthly 0.9 2024-04-23T12:01:00.000Z https://aml-hub.com/medical-information/what-time-is-the-right-time-for-transplantation monthly 0.9 2023-07-27T11:44:00.000Z https://aml-hub.com/medical-information/the-latest-updates-on-oral-azacitidine-in-aml monthly 0.9 2023-10-01T09:50:00.000Z https://aml-hub.com/medical-information/the-latest-on-trials-of-quizartinib-from-eha-2023 monthly 0.9 2023-08-08T09:33:00.000Z https://aml-hub.com/medical-information/luspatercept-for-esa-naive-td-patients-with-lr-mds-interim-analysis-from-the-commands-study monthly 0.9 2024-01-04T11:15:00.000Z https://aml-hub.com/medical-information/visual-abstract-or-phase-iii-trial-of-sar443579-in-patients-with-rr-aml-b-all-or-hr-mds monthly 0.9 2024-07-18T10:48:00.000Z https://aml-hub.com/medical-information/quizartinib-granted-fda-approval-for-patients-with-newly-diagnosed-flt3-itd-mutated-aml monthly 0.9 2023-10-01T09:50:00.000Z https://aml-hub.com/medical-information/visual-abstract-or-phase-iii-trial-of-gilteritinib-maintenance-therapy-in-patients-with-mutated-flt3-itd-aml-morpho monthly 0.9 2024-07-18T10:49:00.000Z https://aml-hub.com/medical-information/zedenoleucel-mt-401-granted-orphan-drug-designation-by-the-ema monthly 0.9 2023-07-13T10:58:00.000Z https://aml-hub.com/medical-information/does-the-mutational-profile-impact-outcomes-following-transplant monthly 0.9 2023-07-11T11:34:00.000Z https://aml-hub.com/medical-information/imetelstat-in-patients-with-lower-risk-mds-updates-from-the-imerge-trial monthly 0.9 2024-01-08T15:51:00.000Z https://aml-hub.com/medical-information/fda-lifts-partial-clinical-hold-on-phase-iii-takeaim-leukemia-trial-of-emavusertib-in-patients-with-aml-and-mds monthly 0.9 2024-01-05T10:58:00.000Z https://aml-hub.com/medical-information/optimizing-transplant-outcomes-in-patients-allografted-for-aml monthly 0.9 2025-08-05T15:31:00.000Z https://aml-hub.com/medical-information/impact-on-outcomes-of-non-t-depleted-haplo-sct-and-ptcy-in-patients-with-saml-vs-de-novo-aml monthly 0.9 2023-06-20T11:26:00.000Z https://aml-hub.com/medical-information/cpx-351-versus-flag-ida-in-patients-with-adverse-karyotype-aml-and-high-risk-mds-analysis-from-ncri-aml19-trial monthly 0.9 2024-01-05T10:59:00.000Z https://aml-hub.com/medical-information/fda-grants-orphan-drug-designation-to-kt-253-for-the-treatment-of-patients-with-aml monthly 0.9 2023-06-23T15:47:00.000Z https://aml-hub.com/medical-information/survival-outcomes-with-midostaurin-in-patients-with-flt3-mutated-aml-retrospective-cohort-from-the-aml-12-trial monthly 0.9 2023-06-13T13:07:00.000Z https://aml-hub.com/medical-information/admiral-trial-patient-reported-outcomes-in-patients-with-flt3-mutated-relapsedrefractory-aml monthly 0.9 2023-06-07T10:53:00.000Z https://aml-hub.com/medical-information/eha-2023 monthly 0.9 2023-06-06T08:37:00.000Z https://aml-hub.com/medical-information/in-the-current-aml-treatment-landscape-when-is-anti-infection-and-anti-fungal-prophylaxis-recommended monthly 0.9 2023-06-05T09:53:00.000Z https://aml-hub.com/medical-information/eha2023-abstracts-what-s-hot-in-aml monthly 0.9 2023-06-06T14:24:00.000Z https://aml-hub.com/medical-information/fda-lifts-clinical-hold-on-phase-i-study-of-fhd-286-in-patients-with-rr-aml-or-mds monthly 0.9 2023-06-06T14:19:00.000Z https://aml-hub.com/medical-information/asco-2023 monthly 0.9 2023-05-31T11:07:00.000Z https://aml-hub.com/medical-information/optimizing-induction-therapy-in-older-patients-with-aml-undergoing-allo-hsct monthly 0.9 2023-06-01T09:09:00.000Z https://aml-hub.com/medical-information/impact-of-mrd-status-on-outcomes-in-patients-with-aml-treated-with-different-treatment-regimens monthly 0.9 2023-05-25T15:20:00.000Z https://aml-hub.com/medical-information/quizartinib-granted-approval-in-japan-for-the-treatment-of-patients-with-newly-diagnosed-aml-with-flt3-itd-mutations monthly 0.9 2024-07-24T13:32:00.000Z https://aml-hub.com/medical-information/clinical-characteristics-and-outcomes-of-patients-with-aml-with-inv-3-q21q26-2-t-33-q21q26-2 monthly 0.9 2023-05-25T10:01:00.000Z https://aml-hub.com/medical-information/ivosidenib-granted-approval-by-the-european-commission-for-the-treatment-of-adult-patients-with-idh1-mutated-aml monthly 0.9 2024-07-24T13:32:00.000Z https://aml-hub.com/medical-information/clinical-outcomes-and-prognostic-value-of-mrd-in-patients-with-npm1-mutated-aml monthly 0.9 2023-05-02T14:37:00.000Z https://aml-hub.com/medical-information/impact-of-allo-hsct-and-fried-s-frailty-phenotype-in-older-patients-with-aml monthly 0.9 2023-04-24T12:10:00.000Z https://aml-hub.com/medical-information/ebmt-2023 monthly 0.9 2023-04-26T14:51:00.000Z https://aml-hub.com/medical-information/phase-iv-trial-of-a-fractionated-dosing-schedule-of-gemtuzumab-ozogamicin monthly 0.9 2023-04-21T09:08:00.000Z https://aml-hub.com/medical-information/fda-grants-orphan-drug-designation-to-om-301-for-the-treatment-of-patients-with-aml monthly 0.9 2023-04-20T16:06:00.000Z https://aml-hub.com/medical-information/revised-international-working-group-2023-response-criteria-for-higher-risk-mds monthly 0.9 2024-01-08T16:13:00.000Z https://aml-hub.com/medical-information/omidubicel-onlv-granted-fda-approval-for-patients-with-hematologic-malignancies-eligible-for-umbilical-cord-blood-transplantation monthly 0.9 2024-01-05T10:59:00.000Z https://aml-hub.com/medical-information/how-i-treat-case-studies-incorporating-updated-classification-systems monthly 0.9 2024-01-05T10:59:00.000Z https://aml-hub.com/medical-information/asap-conditioning-vs-induction-allo-hsct-in-rr-aml monthly 0.9 2023-04-13T12:01:00.000Z https://aml-hub.com/medical-information/visual-abstract-or-key-updates-to-the-classification-of-mds-in-the-5th-who-classification-of-haematolymphoid-tumours monthly 0.9 2024-01-05T11:00:00.000Z https://aml-hub.com/medical-information/common-genomic-diagnostic-tests monthly 0.9 2024-01-05T11:00:00.000Z https://aml-hub.com/medical-information/allo-hsct-vs-consolidation-chemotherapy-in-younger-patients-with-intermediate-risk-aml monthly 0.9 2023-03-23T10:43:00.000Z https://aml-hub.com/medical-information/international-consensus-classification-of-mds-2022-updates monthly 0.9 2023-12-21T13:27:00.000Z https://aml-hub.com/medical-information/visual-abstract-or-phase-iii-trial-of-iomab-b-versus-conventional-conditioning-pre-hsct-in-patients-with-rr-aml-sierra monthly 0.9 2024-07-18T10:49:00.000Z https://aml-hub.com/medical-information/orca-t-in-patients-undergoing-allo-hsct-for-hematologic-malignancies monthly 0.9 2023-03-10T12:30:00.000Z https://aml-hub.com/medical-information/ep0042-granted-orphan-drug-designation-for-the-treatment-of-aml monthly 0.9 2023-03-20T09:13:00.000Z https://aml-hub.com/medical-information/ash-2022-roundup-idh-inhibitors monthly 0.9 2023-02-23T14:20:00.000Z https://aml-hub.com/medical-information/addition-of-gemtuzumab-ozogamicin-to-induction-chemotherapy monthly 0.9 2024-01-05T11:01:00.000Z https://aml-hub.com/medical-information/survival-outcomes-and-treatment-response-in-patients-with-cbf-aml monthly 0.9 2023-02-22T11:33:00.000Z https://aml-hub.com/medical-information/tct-2023 monthly 0.9 2023-02-15T09:03:00.000Z https://aml-hub.com/medical-information/inhibition-of-the-menin-kmt2a-interaction-in-aml-the-augment-101-and-komet-001-trials monthly 0.9 2024-02-15T08:59:00.000Z https://aml-hub.com/medical-information/visual-abstract-or-azacitidine-with-venetoclax-and-magrolimab-in-patients-with-nd-or-rr-aml monthly 0.9 2024-07-18T10:52:00.000Z https://aml-hub.com/medical-information/what-are-the-updates-from-the-ncri-aml18-and-aml19-clinical-trials monthly 0.9 2023-01-30T10:20:00.000Z https://aml-hub.com/medical-information/visual-abstract-or-phase-ii-trial-of-tamibarotene-combination-therapy-in-patients-with-newly-diagnosed-aml monthly 0.9 2024-07-18T10:53:00.000Z https://aml-hub.com/medical-information/real-world-validation-of-the-ipss-m-risk-stratification-model-for-mds-and-comparison-to-ipss-r monthly 0.9 2024-01-05T11:13:00.000Z https://aml-hub.com/medical-information/how-can-outcomes-be-improved-in-patients-with-molecularly-defined-high-risk-aml monthly 0.9 2024-06-25T15:37:00.000Z https://aml-hub.com/medical-information/induction-and-post-remission-treatment-strategies-for-a-fit-newly-diagnosed-patient-with-npm1dnmt3a-co-mutated-aml monthly 0.9 2023-01-26T15:48:00.000Z https://aml-hub.com/medical-information/what-do-long-term-data-from-the-viale-a-trial-tell-us-about-treatment-with-azacitidine-plus-venetoclax monthly 0.9 2023-05-26T09:39:00.000Z https://aml-hub.com/medical-information/latest-insights-on-tp53-mutations-in-aml-and-mds-from-ash-2022 monthly 0.9 2024-01-05T11:01:00.000Z https://aml-hub.com/medical-information/editorial-theme-ortransplant-outcomes-across-aml-mutational-subgroups monthly 0.9 2024-07-18T10:59:00.000Z https://aml-hub.com/medical-information/further-analysis-from-the-quazar-aml-001-trial-mrd-status-and-subsequent-therapies monthly 0.9 2023-01-12T11:06:00.000Z https://aml-hub.com/medical-information/jbi-802-granted-orphan-drug-designation-by-the-fda monthly 0.9 2023-01-10T13:47:00.000Z https://aml-hub.com/medical-information/what-does-the-future-hold-for-patients-with-relapse-aml monthly 0.9 2023-01-05T16:18:00.000Z https://aml-hub.com/medical-information/briquilimab-granted-orphan-drug-designation-by-the-european-commission monthly 0.9 2024-01-05T11:01:00.000Z https://aml-hub.com/medical-information/what-do-real-world-data-tell-us-about-outcomes-with-venetoclaxhma-vs-7-3-chemotherapy monthly 0.9 2023-05-26T09:41:00.000Z https://aml-hub.com/medical-information/safety-and-efficacy-of-olutasidenib-in-patients-with-idh1-mutated-relapsedrefractory-aml monthly 0.9 2022-12-23T10:39:00.000Z https://aml-hub.com/medical-information/how-can-serial-mrd-monitoring-be-utilized-to-improve-relapse-outcomes monthly 0.9 2023-05-26T09:32:00.000Z https://aml-hub.com/medical-information/menin-inhibition-in-relapsedrefractory-aml-what-do-the-data-tell-us monthly 0.9 2023-05-26T09:36:00.000Z https://aml-hub.com/medical-information/key-updates-to-the-classification-of-aml-in-the-5th-who-classification-of-haematolymphoid-tumours monthly 0.9 2022-12-16T14:53:00.000Z https://aml-hub.com/medical-information/is-ngs-a-useful-clinical-tool-for-the-risk-stratification-of-patients-pre-transplant monthly 0.9 2023-05-26T09:35:00.000Z https://aml-hub.com/medical-information/association-between-prior-lenalidomide-exposure-and-tp53-mutated-therapy-related-aml monthly 0.9 2022-12-13T15:08:00.000Z https://aml-hub.com/medical-information/ash-2022 monthly 0.9 2022-12-07T11:16:00.000Z https://aml-hub.com/medical-information/the-nopho-db-ship-consortium-recommendations-for-supportive-care-in-pediatric-aml monthly 0.9 2024-07-24T12:49:00.000Z https://aml-hub.com/medical-information/breakthrough-therapy-designation-granted-to-revumenib-by-the-fda monthly 0.9 2022-12-07T14:07:00.000Z https://aml-hub.com/medical-information/olutasidenib-granted-fda-approval-for-patients-with-idh1-mutated-rr-aml monthly 0.9 2024-07-24T13:32:00.000Z https://aml-hub.com/medical-information/impact-of-runx1-ras-and-del-7-del-7q-genetic-abnormalities-on-prognosis-and-response-to-venetoclax monthly 0.9 2022-12-01T09:28:00.000Z https://aml-hub.com/medical-information/ash-2022-abstracts-what-s-hot-in-acute-myeloid-leukemia monthly 0.9 2023-02-09T11:57:00.000Z https://aml-hub.com/medical-information/patient-and-physician-perceptions-of-palliative-care-during-transplant monthly 0.9 2022-11-15T11:30:00.000Z https://aml-hub.com/medical-information/visual-abstract-venetoclax-plus-azacitidine-for-patients-with-idh12-mutated-aml-who-are-ineligible-for-intensive-chemotherapy monthly 0.9 2024-07-18T10:53:00.000Z https://aml-hub.com/medical-information/visual-abstract-phase-iii-panther-trial-evaluating-pevonedistat-azacitidine-vs-azacitidine-alone-in-patients-with-higher-risk-mds-or-low-blast-percentage-aml monthly 0.9 2024-07-18T10:53:00.000Z https://aml-hub.com/medical-information/impact-of-mrd-status-and-number-of-remissions-on-hsct-outcomes monthly 0.9 2022-11-16T12:47:00.000Z https://aml-hub.com/medical-information/irene-g-a-prospective-rct-of-nutritional-support-following-allo-hsct monthly 0.9 2022-11-09T16:05:00.000Z https://aml-hub.com/medical-information/cd3-t-cells-as-biomarkers-of-frailty-in-elderly-patients-with-hematologic-malignancies monthly 0.9 2022-10-31T09:51:00.000Z https://aml-hub.com/medical-information/international-consensus-classification-of-aml monthly 0.9 2022-10-31T15:04:00.000Z https://aml-hub.com/medical-information/quizartinib-granted-priority-review-by-the-fda-for-patients-with-newly-diagnosed-flt3-itd-aml monthly 0.9 2022-10-26T11:01:00.000Z https://aml-hub.com/medical-information/orphan-drug-designation-granted-to-pclx-001-by-the-fda monthly 0.9 2022-10-19T09:53:00.000Z https://aml-hub.com/medical-information/the-impact-of-ngs-on-risk-stratification-of-patients-with-aml monthly 0.9 2022-10-05T14:42:00.000Z https://aml-hub.com/medical-information/guidelines-for-allo-hsct-in-the-treatment-of-pediatric-aml-and-mds monthly 0.9 2024-07-18T10:55:00.000Z https://aml-hub.com/medical-information/kite-222-granted-orphan-drug-designation-by-the-fda monthly 0.9 2022-10-04T13:38:00.000Z https://aml-hub.com/medical-information/a-proposed-molecular-framework-for-disease-classification-and-risk-stratification-in-aml monthly 0.9 2022-10-03T09:29:00.000Z https://aml-hub.com/medical-information/2022-eln-recommendations-for-the-management-of-aml-in-adults monthly 0.9 2024-01-24T10:31:00.000Z https://aml-hub.com/medical-information/gilteritinib-plus-azacitidine-in-patients-with-flt3-mutated-aml-updated-results-from-the-lacewing-trial monthly 0.9 2022-09-26T14:34:00.000Z https://aml-hub.com/medical-information/ncri-aml-congress-2022 monthly 0.9 2022-09-23T08:46:00.000Z https://aml-hub.com/medical-information/reduced-intensity-transplantation-in-older-patients-with-acute-myeloblastic-leukemia-ncri-aml16-trial monthly 0.9 2022-09-21T11:54:00.000Z https://aml-hub.com/medical-information/eprenetapopt-plus-azacitidine-as-a-post-allo-hct-treatment-for-patients-with-tp53-mutated-aml-and-mds-results-from-a-phase-ii-trial monthly 0.9 2022-10-28T16:06:00.000Z https://aml-hub.com/medical-information/2022-eln-recommendations-for-the-diagnosis-of-aml-in-adults monthly 0.9 2024-07-24T13:17:00.000Z https://aml-hub.com/medical-information/update-on-triplet-therapy-with-ivosidenib-venetoclax-and-azacitidine monthly 0.9 2022-09-07T08:43:00.000Z https://aml-hub.com/medical-information/updated-guidelines-on-antifungal-prophylaxis-in-adult-patients-with-acute-myeloid-leukemia monthly 0.9 2024-07-18T10:56:00.000Z https://aml-hub.com/medical-information/decitabine-shows-comparable-os-to-standard-induction-chemotherapy-and-better-safety-in-patients-with-aml monthly 0.9 2024-08-29T09:10:00.000Z https://aml-hub.com/medical-information/quizartinib-decitabine-and-venetoclax-combination-therapy-in-patients-with-aml-and-prior-exposure-to-flt3-inhibitors monthly 0.9 2022-10-26T11:44:00.000Z https://aml-hub.com/medical-information/clinical-practice-guidelines-on-infectious-complications-of-targeted-drugs-and-biotherapies-european-conference-on-infections-in-leukaemia-ecil monthly 0.9 2022-08-16T16:02:00.000Z https://aml-hub.com/medical-information/real-world-prognostic-significance-of-pretransplant-ngs-mrd-testing monthly 0.9 2022-08-15T09:18:00.000Z https://aml-hub.com/medical-information/does-10-day-decitabine-improve-post-transplant-outcomes-in-older-patients-compared-with-3-7-chemo monthly 0.9 2022-08-05T13:09:00.000Z https://aml-hub.com/medical-information/the-quantum-first-study monthly 0.9 2022-08-16T13:37:00.000Z https://aml-hub.com/medical-information/what-is-the-clinical-significance-of-secondary-aml-type-mutations-in-de-novo-aml monthly 0.9 2022-08-04T09:21:00.000Z https://aml-hub.com/medical-information/dsp-5336-granted-orphan-drug-designation-by-the-fda monthly 0.9 2026-01-14T10:05:00.000Z https://aml-hub.com/medical-information/what-is-the-clinical-significance-of-co-mutational-patterns-in-aml monthly 0.9 2022-08-05T08:48:00.000Z https://aml-hub.com/medical-information/clofarabine-with-fludarabine-and-busulfan-in-pretransplant-conditioning-regimen-for-amlmds-results-from-a-phase-iii-study monthly 0.9 2022-08-01T10:48:00.000Z https://aml-hub.com/medical-information/https-twitter-comcarmelogurnaristatus1552020434270437378 monthly 0.9 2022-07-28T10:18:00.000Z https://aml-hub.com/medical-information/evorpacept-granted-orphan-drug-designation-by-the-fda monthly 0.9 2022-08-01T10:33:00.000Z https://aml-hub.com/medical-information/could-the-use-of-g-csf-post-remission-improve-outcome monthly 0.9 2022-07-27T14:27:00.000Z https://aml-hub.com/medical-information/discussion-2-how-to-provide-better-supportive-care monthly 0.9 2025-08-05T15:32:00.000Z https://aml-hub.com/medical-information/steering-comittee-discussion-1-what-results-are-needed-prior-to-therapy-initiation-in-newly-diagnosed-aml monthly 0.9 2025-08-05T15:32:00.000Z https://aml-hub.com/medical-information/va monthly 0.9 2024-07-18T10:54:00.000Z https://aml-hub.com/medical-information/2022-asco-annual-meeting-roundup-ivosidenib monthly 0.9 2022-10-19T11:37:00.000Z https://aml-hub.com/medical-information/can-pre-transplant-mrd-testing-predict-patients-who-are-more-likely-to-relapse monthly 0.9 2022-07-12T14:53:00.000Z https://aml-hub.com/medical-information/article-title-required-character-limit-75-90-excluding-spaces-tp53-mutated-complex-karyotype-in-patients-with-de-novo-or-therapy-related-mds-and-aml monthly 0.9 2022-07-07T09:40:00.000Z https://aml-hub.com/medical-information/magrolimab-in-tp53-mutated-aml-and-mds-what-are-the-latest-updates-from-eha2022 monthly 0.9 2022-07-06T15:21:00.000Z https://aml-hub.com/medical-information/how-could-new-treatment-options-improve-outcomes-in-flt3-mutated-aml monthly 0.9 2022-07-06T15:16:00.000Z https://aml-hub.com/medical-information/what-factors-affect-how-a-patient-responds-to-ivosidenib-treatment monthly 0.9 2022-07-06T15:16:00.000Z https://aml-hub.com/medical-information/what-are-the-long-term-outcomes-for-patients-treated-with-cenolanib-combination-therapy monthly 0.9 2024-06-25T15:26:00.000Z https://aml-hub.com/medical-information/long-term-survival-with-oral-azacitidine-an-update-from-the-quazar-aml-001-trial monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/neutralizing-antibody-responses-to-sars-cov-2-in-patients-with-aml-or-mds monthly 0.9 2022-06-17T11:49:00.000Z https://aml-hub.com/medical-information/triplet-combination-of-hma-flt3-inhibitors-and-venetoclax-in-flt3-mutated-newly-diagnosed-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/efficacy-and-safety-of-midostaurin-in-younger-and-older-patients-with-flt3-itd-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/article-title-required-outcomes-of-second-allogeneic-hematopoietic-cell-transplantation-for-patients-with-secondary-aml-treated-with-varying-conditioning-intensities monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/secondary-vs-de-novo-acute-myeloid-leukemia monthly 0.9 2022-09-15T14:43:00.000Z https://aml-hub.com/medical-information/eha-2022 monthly 0.9 2022-07-29T14:59:00.000Z https://aml-hub.com/medical-information/eha2022-abstracts-what-s-hot-in-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/asco-2022 monthly 0.9 2022-09-02T10:03:00.000Z https://aml-hub.com/medical-information/next-generation-sequencing-based-analysis-in-patients-from-the-phase-iii-admiral-trial monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/ivosidenib-in-combination-with-azacitidine-receives-fda-approval-for-the-treatment-of-idh1-mutated-newly-diagnosed-aml monthly 0.9 2024-07-24T13:33:00.000Z https://aml-hub.com/medical-information/validation-of-the-eln-2017-risk-stratification-for-acute-myeloid-leukemia monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/the-prognostic-impact-of-flt3-itd-mutations-in-cbf-aml monthly 0.9 2022-05-26T10:02:00.000Z https://aml-hub.com/medical-information/what-does-the-figaro-trial-reveal-about-predictors-of-outcome-post-transplant monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/conditioning-regimens-prior-to-allo-hsct-updates-from-the-48th-annual-meeting-of-the-ebmt-2022 monthly 0.9 2022-05-05T10:29:00.000Z https://aml-hub.com/medical-information/how-are-new-fludarabine-conditioning-combinations-impacting-transplant-outcomes monthly 0.9 2022-04-25T09:17:00.000Z https://aml-hub.com/medical-information/editorial-theme-induction-therapy-for-aml-recent-progress monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/decitabine-maintenance-therapy-benefits-patients-with-cbf-aml-and-persistent-fusion-transcripts-at-a-low-level-after-a-flag-based-regimen monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/outcomes-with-venetoclax-in-treating-aml-in-real-world-settings monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/healthcare-inequalities-in-bone-marrow-transplants monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/should-covid-19-vaccination-be-postponed-after-aml-therapy monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/what-does-real-world-data-tell-us-about-frontline-therapy-with-cpx-351-vs-ven-aza monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/molecular-analysis-of-tp53-mutant-aml-and-mds-eb monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/which-aml-patients-benefit-most-from-treatment-with-cpx-351 monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/which-aml-patients-benefit-most-from-flt3-inhibitor-treatment monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/how-can-venetoclax-combinations-improve-outcome-for-flt3-mutant-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/intensive-induction-shows-greater-remission-rates-and-better-os-compared-to-nonintensive-induction-for-patients-with-intermediate-or-adverse-risk-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/what-factors-should-be-considered-when-selecting-treatment-for-an-elderly-aml-patient monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/comparison-of-allo-hsct-outcomes-in-younger-versus-older-patients-with-aml-findings-from-two-prospective-studies monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/quizartinib-combined-with-venetoclax-and-decitabine-in-flt3-mutant-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/patients-with-poor-risk-cytogenetics-and-tp53wt-treated-with-venetoclax-and-hma-show-increases-in-overall-survival-compared-to-treatment-with-azacitidine-only monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/editorial-theme-or-impact-of-using-a-fixed-blast-percentage-threshold-on-aml-and-mds-treatment-options monthly 0.9 2024-07-18T11:00:00.000Z https://aml-hub.com/medical-information/treatment-options-available-for-transplant-ineligible-relapsed-aml-patients-after-ven-aza-therapy monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/which-aml-patients-benefit-most-from-venetoclax-treatment monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/single-cell-analysis-at-ash-drivers-of-leukemic-transformation monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/is-sorafenib-the-new-standard-maintenance-treatment-for-flt3-mutant-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/disparities-in-survival-and-treatment-outcomes-between-black-and-white-ayas-with-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/what-does-real-world-data-tell-us-about-frontline-therapy-with-cpx-351-vs-venetoclax-azacitidine monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/novel-induction-approaches-with-gemtuzumab-ozogamicin-for-de-novo-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/visual-abstract-azacitidine-lenalidomide-and-dli-as-salvage-therapy-for-mds-cmml-and-saml-after-allo-hsct-azalena monthly 0.9 2024-07-18T10:54:00.000Z https://aml-hub.com/medical-information/visual-abstract-or-agile-study-of-ivosidenib-azacitidine-versus-placebo-azacitidine-in-newly-diagnosed-patients-with-an-idh1-mutation monthly 0.9 2024-07-18T10:55:00.000Z https://aml-hub.com/medical-information/survival-outcomes-in-older-patients-receiving-cpx-351-versus-hma-venetoclax-as-frontline-aml-therapy monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/mrd-in-aml-prognosis-treatment-and-surrogate-endpoints monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/the-latest-on-venetoclax-combinations-in-aml-from-ash-2021 monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/efficacy-and-safety-of-clad-and-ldac-plus-ven-alternating-with-aza-in-older-patients-with-de-novo-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/a-new-method-for-developing-a-consensus-guideline-in-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/how-do-you-incorporate-mrd-into-treatment-decision-making-in-clinical-practice monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/efficacy-and-safety-of-eprenetapopt-apr-246-combined-with-azacitidine-in-patients-with-tp53-mutant-mds-and-oligoblastic-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/management-of-adverse-events-during-oral-azacitidine-maintenance-a-trial-update-from-quazar-aml-001 monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/hla-mis-matching-in-haploidentical-transplantation monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/how-can-venetoclax-combinations-be-used-in-preparation-for-transplant monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/clinical-characteristics-treatment-patterns-and-outcomes-in-secondary-aml-a-large-scale-registry-study monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/increased-risk-of-nrm-and-its-associated-factors-in-patients-with-chronic-gvhd-an-updated-analysis monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/low-intensity-decitabine-plus-venetoclax-versus-ic-in-patients-with-rr-aml-a-propensity-score-matched-analysis monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/liposomal-cytarabine-cpx-351-in-patients-with-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/ash2021-abstracts-what-s-hot-in-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/should-venetoclax-based-induction-regimens-be-considered-soc-for-60-adults monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/the-efficacy-and-safety-of-ofatumumab-plus-prednisone-in-cgvhd monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/mrd-aml-is-ric-enough monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/venetoclax-with-intensive-chemotherapy-for-younger-patients-with-nd-aml-or-mds monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/the-impact-of-raceethnicity-on-survival-in-aml-and-associated-cytogenetic-subgroups monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/venetoclax-plus-flag-ida-as-frontline-and-salvage-therapy-in-patients-with-nd-and-rr-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/how-would-you-treat-newly-diagnosed-induction-eligible-patients-with-acute-myeloid-leukemia monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/long-term-effects-of-midostaurin-in-flt3-mutant-aml-the-ratify-trial monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/post-transplant-maintenance-therapy-low-dose-decitabine-venetoclax-is-safe-and-effective-for-high-risk-aml-and-mds monthly 0.9 2021-10-26T14:32:00.000Z https://aml-hub.com/medical-information/geriatric-hematology-in-low-resource-settings-improving-care-for-older-people-through-the-implementation-of-geriatric-hematology-programs monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/what-are-the-future-prospects-for-flt3-mutated-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/the-eha-research-roadmap-updates-for-malignant-myeloid-disorders monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/impact-of-type-of-blood-cancer-on-the-outcome-following-stem-cell-transplantation monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/how-could-new-immunotherapy-modalities-in-aml-change-current-practice monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/how-has-aml-treatment-in-elderly-people-changed-in-2021 monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/eha2021or-should-pre-transplant-mrd-be-used-to-guide-treatment-in-aml monthly 0.9 2021-09-21T10:43:00.000Z https://aml-hub.com/medical-information/how-could-new-treatment-combinations-improve-outcomes-in-tp53-mutant-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/safety-and-effectiveness-of-dec-plus-ven-as-a-maintenance-therapy-in-patients-with-high-risk-aml-and-mds monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/the-impact-of-donor-type-on-long-term-survival-outcomes-of-patients-receiving-allo-hsct monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/clofarabine-or-cladribine-with-ldac-in-elderly-patients-with-newly-diagnosed-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/the-role-of-dynamic-mrd-in-treatment-decision-making-for-intermediate-risk-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/outcomes-of-decitabine-and-venetoclax-treatment-in-mutant-tp53-aml-vs-wild-type-tp53-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/epicovideha-registry-epidemiology-and-outcomes-in-patients-with-hematologic-malignancies-infected-with-covid-19 monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/quazar-aml-001-update-from-eha2021-on-survival-outcomes-according-to-npm1-and-flt3-gene-mutational-status-at-diagnosis monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/severity-of-sars-cov-2-infection-and-the-safety-of-covid-19-vaccination-in-patients-receiving-hsct monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/chemotherapy-with-or-without-oblimersen-g3139-in-older-patients-with-aml-results-from-the-phase-iii-calgb-10201-trial monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/sabatolimab-for-the-treatment-of-poor-prognosis-myelodysplastic-syndromes-and-acute-myeloid-leukemia monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/post-hoc-analysis-of-cpx-351-versus-7-3-to-determine-quality-of-patient-survival monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/an-overview-of-eha-guidelines-for-the-use-of-antifungal-prophylactic-agents-in-acute-myeloid-leukemia monthly 0.9 2024-07-18T10:56:00.000Z https://aml-hub.com/medical-information/fungal-superinfections-and-covid-19-in-the-icu monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/quantifying-patient-and-physician-preferences-in-post-hsct-maintenance-treatment-of-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/rvu120-a-cdk8-inhibitor-for-the-treatment-of-anemia-in-mds-and-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/when-is-it-safe-to-schedule-an-allo-hsct-after-covid-19-infection monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/fda-has-granted-breakthrough-therapy-designation-to-venetoclax-in-combination-with-azacitidine-for-mds monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/standardizing-next-generation-sequencing-mrd-assessment-in-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/prognostic-value-of-ngs-mrd-before-and-after-allogeneic-hematopoietic-cell-transplantation-in-patients-with-aml-a-longitudinal-study monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/editorial-theme-or-frequency-of-oral-mucositis-in-patients-with-aml-post-allogeneic-hematopoietic-cell-transplantation monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/should-pre-transplant-mrd-be-used-to-guide-treatment-in-aml-eha2021 monthly 0.9 2021-07-22T09:33:00.000Z https://aml-hub.com/medical-information/mrd-response-in-patients-with-newly-diagnosed-aml-treated-with-venetoclax-and-azacitidine-in-the-viale-a-trial monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/hot-off-the-press-or-understanding-patient-s-burden-quality-of-life-and-alignment-of-patient-reported-outcome-measures-to-capture-changes-in-high-risk-mdsaml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/editorial-theme-or-collateral-effects-of-adding-arsenic-trioxide-to-the-treatment-regimen-for-patients-with-acute-promyelocytic-leukemia monthly 0.9 2024-07-18T11:00:00.000Z https://aml-hub.com/medical-information/editorial-theme-or-management-of-treatment-related-toxicities-for-oral-azacitidine-in-aml-patients-an-update-on-the-phase-iii-quazar-aml-001-trial monthly 0.9 2024-07-18T11:01:00.000Z https://aml-hub.com/medical-information/how-efficacious-is-car-t-in-childhood-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/how-does-pre-transplant-mrd-affect-outcome-in-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/should-pre-transplant-mrd-be-used-to-guide-treatment-in-aml monthly 0.9 2021-06-24T14:20:00.000Z https://aml-hub.com/medical-information/how-does-an-expanded-targeted-gene-panel-influence-clinical-decision-making-for-patients-with-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/azacitidine-tablets-cc-486-have-been-approved-by-the-european-commission-as-a-maintenance-therapy-for-aml monthly 0.9 2024-07-24T13:33:00.000Z https://aml-hub.com/medical-information/how-does-covid-19-affect-outcomes-in-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/should-antifungal-prophylaxis-be-used-in-patients-with-aml-who-are-treated-with-novel-agents monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/how-well-do-patients-cope-with-intensive-induction-therapy monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/which-rr-aml-subgroups-would-benefit-from-enasidenib-treatment monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/what-is-the-real-world-experience-of-rr-aml-treatment-with-venetoclax-hmas monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/hma-venetoclax-may-improve-outcomes-in-patients-with-splicing-mutations monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/what-advances-have-there-been-in-biomarkers-for-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/the-use-of-whole-genome-sequencing-as-an-alternative-diagnostic-tool-for-cytogenetic-analysis-in-myeloid-cancers monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/long-term-analysis-of-phase-ii-bright-aml-1003-trial-of-glasdegib-ldac-in-patients-with-aml-who-were-ineligible-for-intensive-chemotherapy monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/fda-grants-orphan-drug-designation-to-gdx012-for-rr-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/venetoclax-in-combination-with-a-hma-has-been-approved-by-the-european-commission-for-patients-with-newly-diagnosed-aml monthly 0.9 2024-07-24T13:33:00.000Z https://aml-hub.com/medical-information/enasidenib-or-ivosidenib-in-combination-with-intensive-chemotherapy-in-patients-with-newly-diagnosed-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/low-dose-chemotherapy-regimen-in-de-novo-pediatric-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/initiation-of-a-phase-ii-trial-of-lemzoparlimab-combined-with-azacitidine-to-treat-amlmds monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/initiation-of-the-first-in-human-trial-of-fhd-286-a-first-in-class-dual-inhibitor-to-treat-rr-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/novel-targeted-therapies-post-hsct-for-amlmds monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/encouraging-interim-phase-i-data-for-ft516-and-ft538-cellular-products-to-treat-rr-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/covid-19-vaccination-for-hematopoietic-stem-cell-transplant-patients monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/allo-hsct-in-patients-with-therapy-related-aml-or-mds monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/investigational-new-drug-status-and-fast-track-designation-granted-by-fda-to-smart-101-a-progenitor-t-cell-product-for-aml-and-all monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/combination-of-myeloablative-conditioning-with-regulatory-and-conventional-t-cell-immunotherapy-for-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/how-do-you-treat-aml-that-has-evolved-from-mpd monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/how-can-advances-in-polycythemia-vera-research-help-us-to-better-understand-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/venetoclax-with-hma-a-bridge-to-transplant-in-high-risk-acute-myeloid-leukemia monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/prognostic-impact-of-flt3-itd-and-cebpa-mutations-in-cytogenetically-normal-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/interim-but-promising-updates-on-first-in-human-phase-iii-clinical-trial-for-gtb-3550-triketm-to-treat-rr-mdsaml-patients monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/ema-chmp-grants-positive-opinion-for-venetoclax-in-combination-with-hypomethylating-agents-for-the-treatment-of-patients-with-newly-diagnosed-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/cc-486-receives-positive-chmp-opinion-for-the-treatment-of-adult-patients-with-aml-in-first-remission monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/in-what-patients-would-you-replace-7-3-with-venetoclax-based-therapies monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/sndx-5613-shows-encouraging-overall-response-rate-in-relapsedrefractory-acute-leukemias monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/germline-mutations-in-patients-with-hematologic-malignancies monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/flugaza-trial-azacitidine-vs-semi-intensive-chemotherapy-for-older-patients-with-newly-diagnosed-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/progress-in-immunotherapy-for-hematologic-malignancies monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/how-has-the-covid-19-pandemic-impacted-patients-with-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/how-can-mrd-testing-be-put-to-best-use-in-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/how-can-crispr-be-used-for-adoptive-t-cell-therapy-in-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/fda-grants-orphan-drug-designation-to-eprenetapopt-for-tp53-mutated-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/what-challenges-arise-in-the-management-of-aml-in-complete-remission monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/ca-4948-is-granted-orphan-drug-designation-by-fda-for-the-treatment-of-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/what-is-the-outcome-of-transplantation-in-fit-patients-over-64-years monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/does-disease-burden-affect-outcome-in-de-novo-versus-secondary-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/lower-overall-survival-in-eln-favorable-risk-aml-with-dna-mr-mutations monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/evaluating-predictive-factors-for-post-hsct-survival-in-secondary-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/comparing-flamsa-bu-and-flubu2-conditioning-treatments-in-patients-with-rr-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/flamsa-like-regimens-when-should-we-use-these-for-transplantation-conditioning-in-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/fda-approves-extended-indication-of-daunorubicin-plus-cytarabine-to-include-pediatric-patients-with-aml monthly 0.9 2024-07-24T13:33:00.000Z https://aml-hub.com/medical-information/augmented-reduced-intensity-allo-hsct-in-patients-with-high-risk-aml-or-mds-results-of-the-figaro-trial monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/predicting-venetoclax-response-and-eliminating-resistance-to-venetoclax monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/how-cytogenetic-risk-impacts-the-outcome-of-allogeneic-stem-cell-transplantation monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/initiation-of-the-first-in-human-trial-of-allogeneic-nkg2d-directed-car-nk-cell-therapy-to-treat-rr-aml-or-high-risk-rr-mds monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/is-a-tp53-mutation-always-a-poor-prognostic-marker-for-transplantation-in-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/phase-iii-trial-of-entospletinib-is-first-to-evaluate-mrd-negative-cr-as-primary-endpoint-in-aml-setting monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/has-the-role-of-haploidentical-transplant-changed-in-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/nccn-covid-19-vaccination-recommendations-for-patients-with-hematologic-malignancies monthly 0.9 2024-07-24T13:17:00.000Z https://aml-hub.com/medical-information/can-hma-maintenance-therapy-improve-eligibility-for-hsct monthly 0.9 2021-06-24T14:19:00.000Z https://aml-hub.com/medical-information/eprenetapopt-with-azacitidine-for-tp53-mutant-mdsaml-results-from-two-ongoing-clinical-trials monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/lenalidomide-maintenance-in-high-risk-aml-not-eligible-for-an-immediate-transplant monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/preliminary-data-from-novel-dli-strategies-show-a-lower-risk-of-gvhd monthly 0.9 2023-02-09T11:49:00.000Z https://aml-hub.com/medical-information/post-hsct-outcomes-following-treatment-with-gemtuzumab-ozogamicin monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/sierra-trial-does-iomab-b-conditioning-spare-side-effects-compared-with-conventional-conditioning monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/does-omidubicel-lead-to-better-outcomes-than-conventional-cord-blood-transplantation monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/how-does-the-mutation-profile-differ-between-patients-with-mdsaml-and-de-novo-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/how-can-we-improve-efficacy-of-car-t-cell-therapy-in-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/cpx-351-in-patients-with-a-high-risk-of-mortality monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/how-do-methylation-regulatory-gene-mutations-affect-outcome-in-patients-with-eln-favorable-risk-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/cpx-351-in-combination-with-venetoclax-a-phase-ii-study-in-patients-with-rr-or-newly-diagnosed-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/jsp191-conditioning-for-patients-with-aml-or-mds-preliminary-results-from-a-phase-i-clinical-trial monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/how-safe-and-efficacious-is-conditioning-with-radiolabeled-anti-cd45-antibody-211-at-bc8-b10 monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/what-are-the-advantages-of-mechanism-based-therapies-to-prevent-aml-relapse monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/what-is-the-optimal-timepoint-for-post-transplant-mrd-assessment monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/fda-grants-orphan-drug-designation-to-iadademstat monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/how-does-cytogenetic-risk-affect-outcome-of-allo-sct-in-patients-with-flt3-npm1-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/type-i-and-type-ii-flt3-inhibitors-demonstrate-differing-patterns-of-secondary-resistance-in-patients-with-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/what-has-ash-2020-taught-us-about-advancing-frontline-chemotherapy-in-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/effect-of-gilteritinib-treatment-response-and-flt3-mutation-clearance-on-overall-survival-in-rr-flt3-mutated-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/flag-ida-venetoclax-for-the-treatment-of-patients-with-newly-diagnosed-or-rr-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/allg-amlm16-does-sorafenib-plus-intensive-chemotherapy-improve-outcome-in-flt3-itd-aml monthly 0.9 2021-02-03T11:28:00.000Z https://aml-hub.com/medical-information/sorafenib-versus-placebo-in-combination-with-intensive-chemotherapy-in-previously-untreated-flt3-itd-aml-results-of-a-phase-ii-study monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/patterns-of-response-to-venetoclax-hypomethylating-agents-in-idh-mutated-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/venetoclax-combinations-in-mutant-aml-subtypes-idh12 monthly 0.9 2021-01-28T10:35:00.000Z https://aml-hub.com/medical-information/venetoclax-combinations-in-mutant-aml-subtypes-podcast-flt3 monthly 0.9 2021-01-28T10:35:00.000Z https://aml-hub.com/medical-information/how-does-sequencing-of-flt3-inhibitor-therapy-affect-outcome monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/introduction-to-a-series-of-podcasts-on-the-use-of-venetoclax-combinations-in-mutation-subtypes-of-aml monthly 0.9 2021-01-28T10:35:00.000Z https://aml-hub.com/medical-information/do-older-patients-with-flt3-aml-benefit-from-midostaurin-plus-chemotherapy monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/ash-2020-highlights-for-patients-with-tp53-mutated-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/investigational-new-drug-application-for-vor33-cleared-by-the-fda monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/venetoclax-plus-hypomethylating-agents-for-the-treatment-of-chemotherapy-ineligible-or-high-risk-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/sodium-bicarbonate-gives-exhausted-tumor-killing-t-cells-a-lift-after-allogeneic-stem-cell-transplantation monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/fda-lifts-partial-hold-on-the-phase-ii-trial-evaluating-mt-401-for-posttransplant-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/bcl-2-inhibitor-apg-2575-receives-fda-orphan-drug-designation-for-the-treatment-of-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/china-nmpa-issue-breakthrough-therapy-designation-to-apl-106-for-relapsedrefractory-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/does-enasidenib-and-azacitidine-sequential-therapy-improve-outcomes-in-older-patients-with-idh2-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/highlights-for-patients-with-relapsedrefractory-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/does-cpx-351-induce-deeper-responses-compared-to-7-3 monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/highlights-for-mrd-assessment-in-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/old-and-new-adcs-for-the-treatment-of-all-and-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/what-patients-benefit-most-from-the-addition-of-venetoclax-to-flag-ida monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/phase-ib-cimon-trial-of-maat033-receives-positive-first-dsmb-safety-review-in-patients-with-aml-and-mds monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/does-race-affect-treatment-outcome-in-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/does-the-bispecific-vibecotamab-hold-promise-for-rr-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/what-is-the-impact-of-venetoclax-combinations-on-the-qol-of-unfit-elderly-patients-with-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/phase-iii-lacewing-trial-of-gilteritinib-in-combination-with-azacitidine-fails-to-meet-its-primary-endpoint monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/is-venetoclax-combined-with-low-dose-chemo-and-hma-safe-and-efficacious-in-older-patients-with-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/sal-daunodouble-trial-can-we-omit-a-second-induction-cycle-in-patients-with-good-early-response monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/why-should-we-assess-variant-allelic-frequency-in-tp53-mutated-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/fda-fast-track-designation-granted-to-devimistat-for-the-treatment-of-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/does-gilteritinib-improve-outcome-post-midostaurin-or-sorafenib-treatment monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/phase-i-study-ca-4948-monotherapy-in-rr-aml-shows-positive-preliminary-results monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/does-the-addition-of-venetoclax-to-low-dose-conditioning-improve-outcome-after-allo-hsct monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/bisantrene-demonstrates-clinical-response-for-rr-aml-in-a-phase-ii-clinical-trial monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/single-cell-analysis-in-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/azacitidine-maintenance-after-hsct-for-amlmds-provides-no-improvement-in-relapse-free-survival-in-phase-iii-study monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/tp53-mutations-linked-to-increased-immune-infiltration-and-ifn-g-signaling-in-patients-with-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/venetoclax-for-the-treatment-of-aml-developments-and-progress-in-2020 monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/tp53-mutations-in-the-determination-of-azacitidine-response-for-older-patients-with-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/eprenetapopt-receives-fda-fast-track-designation-for-the-treatment-of-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/positive-topline-results-from-a-phase-ii-trial-of-antroquinonol-for-patients-with-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/ash-2019-round-up-magrolimab monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/molecular-mechanisms-associated-with-leukemic-transformation-of-pv-and-et monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/antibody-immunotherapy-current-challenges-and-achievements monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/reduced-toxicity-conditioning-regimens-a-comparison-of-irradiation-vs-chemotherapy-for-the-treatment-of-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/expert-safety-recommendations-and-management-for-gemtuzumab-ozogamicin-treatment-in-aml monthly 0.9 2024-07-24T13:18:00.000Z https://aml-hub.com/medical-information/prospective-study-on-the-impact-of-tp53-mutations-in-patients-with-aml-treated-with-azacitidine monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/the-impact-of-specific-loci-mismatches-in-910-hla-transplants monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/the-history-and-evolution-of-the-role-of-venetoclax-in-the-treatment-of-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/outcomes-of-hsct-in-blast-phase-of-bcr-abl1-mpn-compared-with-de-novo-and-post-mds-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/how-should-we-monitor-patients-on-novel-agents-such-as-venetoclax monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/beat-aml-master-trial-can-we-use-precision-medicine-to-treat-older-patients-with-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/io-202-anti-lilrb4-receives-fda-orphan-drug-designation-for-the-treatment-of-rr-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/combination-of-ivosidenib-and-azacitidine-in-patients-with-newly-diagnosed-idh1-mutated-aml monthly 0.9 2020-11-11T12:19:00.000Z https://aml-hub.com/medical-information/addition-of-nucleoside-analogues-to-7-3-a-case-report-of-high-risk-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/actimab-a-clag-m-demonstrates-100percent-remission-rate-in-patients-with-rr-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/predictive-factors-of-mortality-in-patients-with-hematological-malignancies-diagnosed-with-covid-19 monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/venetoclax-plus-10-day-decitabine-in-chemotherapy-ineligible-patients-with-newly-diagnosed-or-rr-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/updates-from-ncri-aml18-and-aml-19-trials monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/treating-mrd-after-allogeneic-transplant-in-patients-with-aml-a-real-world-analysis monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/safety-and-efficacy-of-flotetuzumab-in-patients-with-rr-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/positive-topline-data-from-phase-ii-clinical-trial-of-olutasidenib-in-rr-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/an-update-on-the-ncri-aml20-trial monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/what-is-new-in-targeted-therapies-for-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/withdrawal-of-european-marketing-association-application-for-ivosidenib-for-patients-with-rr-idh1-mutated-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/fda-grants-full-approval-of-venetoclax-for-the-treatment-of-newly-diagnosed-aml monthly 0.9 2024-07-24T13:34:00.000Z https://aml-hub.com/medical-information/phase-iii-astral-2-and-3-trials-of-guadecitabine-in-patients-with-previously-treated-aml-mds-or-cmml-fail-to-meet-primary-endpoints monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/hovon-116-trial-epigenetic-therapy-with-panobinostat-andor-decitabine-after-allo-sct-for-poor-risk-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/regenerative-medicine-advanced-therapy-and-orphan-drug-designation-given-to-orca-t monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/coinhibition-of-bcl-2-and-nhe1-pathways-may-have-a-potential-to-overcome-venetoclax-resistance monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/inherited-hematologic-malignancies-predisposition-syndromes monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/fda-grants-apg-115-orphan-drug-designation-for-the-treatment-of-aml-and-mds monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/editorial-theme-tp53-mutant-aml monthly 0.9 2024-07-18T11:01:00.000Z https://aml-hub.com/medical-information/what-can-we-learn-from-studying-familial-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/phase-iii-study-of-omidubicel-in-patients-with-high-risk-hematologic-malignancies-meets-all-3-secondary-endpoints monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/the-spectrum-of-clonal-hematopoiesis monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/what-are-the-2020-highlights-for-high-risk-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/transcriptional-alterations-may-play-a-role-in-leukemic-escape-and-relapse-following-allo-hsct monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/is-hsct-an-option-for-refractory-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/what-has-the-samba-trial-taught-us-about-the-treatment-of-elderly-high-risk-amlmds-patients monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/what-s-next-in-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/what-are-the-highlights-of-soho-2020 monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/immune-modulation-and-dysregulation-in-mds-and-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/american-society-of-hematology-2020-treatment-guidelines-for-older-adults-with-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/aml-hub-satellite-symposium-highlights-how-does-mrd-impact-outcome-of-stem-cell-transplantation-in-aml-now-and-in-the-future monthly 0.9 2025-08-05T15:16:00.000Z https://aml-hub.com/medical-information/aml-hub-satellite-symposium-round-table-discussion-and-conclusions-from-the-chair monthly 0.9 2025-08-05T15:18:00.000Z https://aml-hub.com/medical-information/gilteritinib-in-flt3-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/addition-of-gemtuzumab-ozogamicin-to-frontline-7-3-a-case-report monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/why-should-we-use-mrd-assessment-post-hematopoietic-stem-cell-transplantation monthly 0.9 2025-08-05T15:19:00.000Z https://aml-hub.com/medical-information/update-in-t-cell-recruiting-antibody-constructs-for-the-treatment-of-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/fda-grants-oxi4503-rare-pediatric-disease-designation-for-the-treatment-of-children-with-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/staying-on-track-in-a-rapidly-changing-treatment-landscape monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/does-current-evidence-support-the-use-of-mrd-guided-treatment-before-transplant-in-patients-with-aml monthly 0.9 2025-08-05T15:19:00.000Z https://aml-hub.com/medical-information/use-of-ruxolitinib-in-patients-with-severe-covid-19 monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/new-developments-in-molecular-mrd-assessment-in-aml monthly 0.9 2025-08-05T15:19:00.000Z https://aml-hub.com/medical-information/the-effect-of-gemtuzumab-ozogamicin-on-mrd-and-relapse-in-patients-with-npm1-mutated-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/how-have-venetoclax-combinations-changed-the-way-we-treat-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/challenges-in-mrd-measurement-by-multiparameter-flow-cytometry-in-aml monthly 0.9 2025-08-05T15:20:00.000Z https://aml-hub.com/medical-information/the-microbiome-and-its-effects-on-the-immune-system monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/jorge-sierra-outlines-the-most-relevant-aml-abstracts-from-ebmt monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/is-mrd-testing-for-aml-being-performed-extensively-in-ebmt-transplant-centers monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/residual-circulating-tumor-dna-as-a-prognostic-biomarker-in-patients-with-amlmds monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/which-is-more-relevant-for-allo-hsct-outcome-cytogenetic-risk-or-mrd-status monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/what-are-the-differences-and-similarities-between-transplant-practices-in-north-america-and-europe monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/highlights-of-the-aml-hub-satellite-symposium monthly 0.9 2025-08-05T15:26:00.000Z https://aml-hub.com/medical-information/how-should-sequential-therapy-be-performed-in-patients-with-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/why-do-we-see-improved-survival-after-allo-hsct-for-young-patients-with-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/fda-approval-of-cc-486-for-the-treatment-of-adults-with-aml-in-first-remission monthly 0.9 2024-07-24T13:34:00.000Z https://aml-hub.com/medical-information/what-are-the-immunological-changes-driving-relapse-after-transplantation monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/can-haploidentical-hsct-be-performed-safely-and-effectively-in-patients-with-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/gemtuzumab-ozogamicin-for-salvage-cbf-aml-a-case-report monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/idhentify-phase-iii-trial-fails-to-meet-primary-end-point monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/patients-with-pretransplant-mrd-may-benefit-from-conditioning-intensification monthly 0.9 2025-08-05T15:26:00.000Z https://aml-hub.com/medical-information/cd33cll1-compound-car-t-cells-in-relapsedrefractory-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/gert-ossenkoppele-explains-why-you-should-join-the-virtual-aml-hub-satellite-symposium monthly 0.9 2025-08-05T15:25:00.000Z https://aml-hub.com/medical-information/decider-study-the-addition-of-all-trans-retinoic-acid-to-decitabine-improves-survival-in-elderly-patients-with-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/addition-of-midostaurin-to-frontline-7-3-a-case-report monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/christian-thiede-explains-why-you-should-join-the-virtual-aml-hub-satellite-symposium monthly 0.9 2025-08-05T15:25:00.000Z https://aml-hub.com/medical-information/non-myeloablative-allo-hsct-for-patients-with-hematological-malignancies-a-20-year-summary-of-clinical-changes monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/posttransplant-cyclophosphamide-for-gvhd-prophylaxis-after-allogeneic-hematopoietic-stem-cell-transplantation monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/azacitidine-versus-decitabine-for-patients-with-naive-aml-not-eligible-for-intensive-chemotherapy monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/prognostic-significance-of-concomitant-gene-mutations-in-intensively-treated-patients-with-idh12-mutated-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/outcomes-of-two-or-more-hla-loci-mismatched-unrelated-donor-allo-hct-an-acute-leukemia-working-party-study monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/ldac-plus-ac220-results-from-the-li-1-trial-in-older-patients-with-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/charles-craddock-explains-why-you-should-join-the-virtual-aml-hub-satellite-symposium monthly 0.9 2025-08-05T15:24:00.000Z https://aml-hub.com/medical-information/fda-grants-bst-236-fast-track-designation-for-the-treatment-of-older-patients-with-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/apr-246-plus-azacitidine-for-patients-with-tp53-mutated-mds-and-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/adriano-venditti-explains-how-you-can-get-involved-with-the-virtual-aml-hub-satellite-symposium monthly 0.9 2025-08-05T15:24:00.000Z https://aml-hub.com/medical-information/molecular-landscape-and-prognostic-impact-of-flt3-itd-insertion-site-in-aml-an-analysis-of-the-ratify-study monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/aml-hub-satellite-symposium-how-does-mrd-impact-outcome-of-stem-cell-transplantation-in-aml-now-and-in-the-future monthly 0.9 2025-08-05T15:23:00.000Z https://aml-hub.com/medical-information/emerging-mutations-at-relapse-in-patients-with-flt3-muated-rr-aml-who-were-treated-with-gilteritinib-in-the-admiral-trial monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/concomitant-dna-repair-inhibition-and-chemotherapy-with-cpx-351-reduces-leukemia-preclinically monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/what-is-the-optimal-gene-panel-to-be-assessed-for-risk-stratification monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/jacqueline-cloos-explains-how-you-can-get-involved-with-the-virtual-aml-hub-satellite-symposium monthly 0.9 2025-08-05T15:23:00.000Z https://aml-hub.com/medical-information/expansion-of-trial-of-eprenetapopt-in-combination-with-venetoclax-and-azacitidine-in-patients-with-tp53-mutated-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/nice-supports-gilteritinib-for-adults-with-relapsedrefractory-flt3-mutated-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/is-venetoclax-combined-with-low-dose-cytarabine-and-actinomycin-d-safe-and-effective-in-patients-with-aml-who-relapse-after-allo-hsct monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/6-month-update-on-the-phase-iii-viale-c-trial monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/aaml1421-phase-iii-trial-of-cpx-351-followed-by-flag-in-children-with-rr-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/how-close-are-we-to-offering-treatment-tailored-to-mutational-profile monthly 0.9 2020-08-26T12:50:00.000Z https://aml-hub.com/medical-information/quazar-aml-001-or-updates-from-eha-2020 monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/tmyeloid-interface-acute-leukemias monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/how-do-i-treat-older-patients-with-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/what-patients-with-aml-benefit-from-therapy-with-checkpoint-inhibitors monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/what-has-flow-identification-taught-us-about-leukemia-stem-cells monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/phase-iii-trial-of-pracinostat-discontinued-following-results-from-interim-analysis monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/glasdegib-receives-approval-from-the-european-commission-for-the-treatment-of-adult-patients-with-newly-diagnosed-aml monthly 0.9 2024-07-24T13:34:00.000Z https://aml-hub.com/medical-information/viale-a-trial-update-or-venetoclax-and-azacitidine-combination-for-the-treatment-of-older-patients-with-newly-diagnosed-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/fda-grants-cg-806-investigational-new-drug-allowance-for-the-treatment-of-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/approaches-and-emerging-therapies-for-tp53-aml monthly 0.9 2020-08-26T12:50:00.000Z https://aml-hub.com/medical-information/molecular-diagnostics-and-therapeutics monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/magrolimab-plus-azacytidine-in-patients-with-myelodysplastic-syndromes-and-acute-myeloid-leukemia-asco-2020 monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/how-can-we-use-the-microbiome-to-improve-cancer-immunotherapy-and-alleviate-side-effect-such-as-graft-versus-host-disease monthly 0.9 2020-08-26T12:49:00.000Z https://aml-hub.com/medical-information/mini-review-or-the-value-of-flt3-targeting-in-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/treating-older-patients-with-aml-in-2020-what-is-new-and-promising monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/viale-a-trial-should-azacitidine-plus-venetoclax-become-soc-for-elderly-patients-with-nd-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/can-cd47-antibody-therapy-be-safely-used-for-aml-and-mds monthly 0.9 2020-08-26T12:49:00.000Z https://aml-hub.com/medical-information/risk-stratification-using-flt3-and-npm1-in-patients-with-acute-myeloid-leukemia-autografted-in-first-complete-remission-a-retrospective-multicenter-analysis-study monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/fda-extends-approval-for-gemtuzumab-ozogamicin-in-newly-diagnosed-cd33-positive-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/what-mechanisms-lead-to-aml-transformation-in-down-s-syndrome-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/the-role-of-the-nlrp3-inflammasome-in-hematological-pathologies monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/ivosidenib-with-venetoclax-azacitidine-in-idh1-mutated-myeloid-malignancies monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/aml18-trial-how-should-gemtuzumab-ozogamicin-be-applied-in-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/have-big-data-changed-the-view-on-aml-risk-classification monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/what-drives-the-transition-from-benign-clonal-hematopoiesis-to-preleukemia monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/do-you-see-improved-outcomes-when-adding-magrolimab-to-azacitidine-in-mds-and-aml-treatment monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/the-use-of-ptcy-as-gvhd-prophylaxis-in-patients-treated-with-checkpoint-inhibitors-prior-to-allo-hct-improves-outcomes monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/how-can-a-variant-of-csf2rb-drive-leukemogenesis-in-down-s-syndrome monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/eha-2019-round-up-mrd monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/how-does-the-type-of-prior-treatment-affect-the-risk-of-therapy-related-myeloid-neoplasms monthly 0.9 2020-08-26T12:48:00.000Z https://aml-hub.com/medical-information/to-what-extent-can-cpx-351-contribute-to-long-term-remissions-in-high-risk-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/does-10-day-treatment-with-decitabine-venetoclax-improve-response-in-aml-and-high-risk-mds monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/the-impact-of-cd33-and-abcb1-snps-on-clinical-outcomes-in-aml-a-retrospective-analysis-of-a-phase-ii-decitabine-and-gemtuzumab-ozogamicin-go-study-in-aml-and-high-risk-mds monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/mitoxantrone-etoposide-and-cytarabine-versus-mitoxantrone-and-high-dose-cytarabine-for-rr-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/eha-2019-round-up-flt3-mutations-in-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/the-value-of-event-free-survival-as-a-clinical-endpoint-for-aml monthly 0.9 2025-12-23T10:23:00.000Z https://aml-hub.com/medical-information/what-factors-contribute-to-the-development-of-therapy-related-aml-or-mds monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/fda-clears-io-202-a-novel-lilrb4-antibody-for-investigation-as-a-new-drug-in-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/phase-iii-study-of-the-flt3-inhibitor-pexidartinib-in-patients-with-relapsedrefractory-aml-with-flt3-itd-mutations monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/a-step-forward-to-implement-leukemic-stem-cell-assessment-in-the-diagnostic-workup-of-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/fda-clears-ft538-the-first-crispr-edited-ipsc-derived-cell-therapy-for-investigation-as-a-new-drug-in-aml-and-mm monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/pretransplant-flt3itd-status-as-a-prognostic-marker-for-outcome-in-flt3-mutated-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/the-effect-of-cd34-cell-dose-on-responses-to-haploidentical-allo-hsct-results-from-a-retrospective-analysis monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/clonal-hematopoiesis-and-mrd-assessment-in-acute-myeloid-leukemia monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/venetoclax-in-combination-with-hypomethylating-agents-for-the-treatment-of-older-patients-with-npm1-mutated-acute-myeloid-leukemia monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/safety-of-trial-participants-is-fda-s-top-priority-in-ongoing-clinical-trials-during-the-covid-19-outbreak monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/phase-iii-study-of-omidubicel-in-patients-with-high-risk-hematologic-malignancies-meets-primary-endpoint monthly 0.9 2023-07-25T14:54:00.000Z https://aml-hub.com/medical-information/can-we-use-ch-assessment-to-predict-the-risk-of-therapy-related-myeloid-neoplasms monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/venetoclax-plus-low-dose-cytarabine-for-aml-results-of-a-phase-iii-trial monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/high-immune-checkpoint-expression-levels-in-patients-with-aml-correlated-with-poor-outcome monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/fda-grants-cc-486-priority-review-for-the-treatment-of-adult-patients-with-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/aacr-2020-or-patients-with-altered-tp53-rr-aml-have-increased-tumor-immune-infiltration-and-show-sensitivity-to-flotetuzumab monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/covid-heme-forum-supports-hematologists-during-covid-19-pandemic monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/glasdegib-given-positive-opinion-by-the-ema-chmp-for-use-in-patients-with-newly-diagnosed-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/ebmt-alwp-recommendations-for-transplantation-in-patients-with-flt3-itd-aml monthly 0.9 2024-07-24T13:18:00.000Z https://aml-hub.com/medical-information/aacr-2020-or-preliminary-phase-i-results-of-the-augment-101-trial-demonstrate-clinical-activity-of-sndx-5613-in-adults-with-relapsedrefractory-acute-leukemias monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/fda-grants-orphan-drug-designation-to-a-multi-tumor-associated-antigen-multitaa-specific-t-cell-therapy-for-acute-myeloid-leukemia monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/management-of-covid-19-outbreak-on-transplant-wards monthly 0.9 2025-12-23T10:22:00.000Z https://aml-hub.com/medical-information/phase-i-trial-demonstrates-the-safety-of-annamycin-in-patients-with-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/summary-of-highlights-from-tct-2020-part-2-transplant-outcomes-in-patients-with-adverse-risk-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/summary-tct-2020-highlights-part-1-conditioning-regimens-for-aml-and-mds monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/secondary-acute-myeloid-leukemia-a-risk-factor-for-allogeneic-stem-cell-transplantation-in-first-complete-remission monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/the-late-effects-of-allogenic-hematopoietic-cell-therapy-in-adolescent-and-young-adults-with-acute-myeloid-leukemia monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/aml-world-awareness-day-2020-or-the-evolution-of-aml-treatment-through-clinical-trials monthly 0.9 2023-07-25T14:25:00.000Z https://aml-hub.com/medical-information/aml-world-awareness-day-2020-or-the-value-of-measurable-residual-disease-in-acute-myeloid-leukemia monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/aml-wad-or-clinical-trials-involving-novel-agents-in-aml monthly 0.9 2024-06-25T15:26:00.000Z https://aml-hub.com/medical-information/aml-world-awareness-day-2020-or-epigenetic-therapies-in-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/caring-for-patients-with-hematological-malignancies-during-the-covid-19-pandemic-recommendations-from-iach-eha-and-ebmt monthly 0.9 2024-07-24T13:18:00.000Z https://aml-hub.com/medical-information/aml-world-awareness-day-or-outcomes-of-long-term-survivors-after-hematopoietic-stem-cell-transplantation monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/editorial-theme-or-use-of-checkpoint-inhibitors-in-aml-therapy monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/the-impact-of-targeted-treatment-and-immunotherapies-on-the-role-of-hematopoietic-stem-cell-transplantation-in-the-treatment-of-blood-cancers monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/sel120-receives-orphan-drug-designation-from-fda monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/fda-grants-approval-to-luspatercept-aamt-for-the-treatment-of-anemia-in-adults-with-myelodysplastic-syndromes monthly 0.9 2024-07-24T13:34:00.000Z https://aml-hub.com/medical-information/the-impact-of-leukapheresis-on-clinical-outcomes-in-patients-with-aml-and-hyperleukocytosis-results-from-a-large-retrospective-study monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/molecular-mrd-status-as-a-predictor-of-outcome-in-patients-with-npm1-mutated-acute-myeloid-leukemia-aml monthly 0.9 2025-08-05T15:22:00.000Z https://aml-hub.com/medical-information/post-transplant-cyclophosphamide-for-the-management-of-gvhd-in-patients-receiving-immune-checkpoint-inhibitors-for-amlmds monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/transplant-using-a-kir-b-donor-offers-relapse-protection-to-patients-with-aml-undergoing-reduced-intensity-conditioning monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/covid-19-and-ebmt-recommendations-for-patients-with-hematological-malignancies monthly 0.9 2024-07-24T13:18:00.000Z https://aml-hub.com/medical-information/viale-a-study-of-venetoclax-plus-azacitidine-meets-dual-primary-endpoints monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/long-term-follow-up-from-mavric-trial monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/results-from-a-cibmtr-study-of-patients-with-mll-rearranged-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/subgroup-analysis-of-outcomes-in-patients-with-aml-mrc-who-achieved-remission-with-cpx-351-versus-7-3 monthly 0.9 2023-07-25T14:26:00.000Z https://aml-hub.com/medical-information/adding-ex-vivo-chemosensitivity-assay-to-mutational-profiling-improves-the-ability-to-predict-the-outcome-of-patients-with-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/does-intensifying-post-remission-chemotherapy-improve-the-outcomes-of-older-patients-with-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/the-benefit-of-gemtuzumab-ozogamicin-in-patients-with-aml-depends-on-mutational-status-and-level-of-cd33-expression monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/the-passing-of-professor-clara-d-bloomfield-a-revolutionary-advancing-the-understanding-of-acute-myeloid-leukemia monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/phase-iii-viale-c-trial-or-venetoclax-ldac-fails-to-show-improvement-in-os-for-newly-diagnosed-patients-with-aml-who-are-ineligible-for-intensive-induction-therapy monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/car-t-2020-or-cytopenia-in-cart-the-prolonged-threat-of-infection monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/aml-hub-symposium-or-how-does-mrd-impact-outcome-of-stem-cell-transplantation-in-aml-now-and-in-the-future monthly 0.9 2025-08-05T15:22:00.000Z https://aml-hub.com/medical-information/early-results-from-the-phase-iii-amlsg-09-09-trial monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/implementation-of-car-t-cell-therapy-in-the-real-world-a-round-table-discussion monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/ebmt-and-jacie-recommendations-for-the-management-of-car-t-cell-therapy monthly 0.9 2024-07-24T13:19:00.000Z https://aml-hub.com/medical-information/selinexor-combined-with-cladribine-cytarabine-and-g-csf-for-the-treatment-of-relapsed-or-refractory-acute-myeloid-leukemia monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/decitabine-containing-conditioning-regimens-for-allo-hsct-may-reduce-rates-of-grade-iiiv-agvhd monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/editorial-theme-or-novel-combination-therapies-using-targeted-agents monthly 0.9 2024-07-18T11:01:00.000Z https://aml-hub.com/medical-information/interim-phase-ii-results-from-the-ongoing-ag221-aml-005-study-on-enasidenib-plus-azacitidine-in-patients-with-newly-diagnosed-acute-myeloid-leukemia-with-idh2-mutations monthly 0.9 2020-11-16T11:10:00.000Z https://aml-hub.com/medical-information/impact-of-gene-mutations-on-the-efficacy-of-cpx-351-versus-7-3-in-older-patients-with-newly-diagnosed-high-risksecondary-acute-myeloid-leukemia monthly 0.9 2023-07-25T14:26:00.000Z https://aml-hub.com/medical-information/how-does-the-ebmt-support-the-development-of-car-t-therapies monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/what-new-technologies-are-available-in-the-field-of-car-t-manufacturing monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/what-are-the-main-challenges-of-car-t-in-aml-compared-to-lymphoma-and-multiple-myeloma monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/impact-of-atg-on-post-allo-hsct-outcomes-by-pre-transplant-mrd-status monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/is-car-t-cell-therapy-advanced-enough-to-be-used-for-the-treatment-of-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/how-could-nanobody-based-tri-specific-car-t-cells-improve-the-treatment-of-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/what-impact-does-time-from-diagnosis-to-treatment-have-on-patient-outcome-in-newly-diagnosed-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/long-term-clonal-dynamics-of-post-remission-clonal-hematopoiesis-in-patients-with-acute-myeloid-leukemia-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/flag-ida-for-acute-myeloid-leukemia monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/using-cusatuzumab-to-target-cd70-has-shown-to-eliminate-acute-myeloid-leukemia-stem-cells-in-humans monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/correlation-of-responses-to-venetoclax-combination-treatment-and-aml-mutations-or-bcl-2-expression monthly 0.9 2023-07-25T14:36:00.000Z https://aml-hub.com/medical-information/comparison-of-reduced-intensity-sct-conditioning-regimens-in-poor-risk-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/mrd-monitoring-before-and-after-allo-hsct-predicts-outcomes monthly 0.9 2025-08-05T15:21:00.000Z https://aml-hub.com/medical-information/prgn-3006-is-granted-orphan-drug-designation-for-relapsed-or-refractory-acute-myeloid-leukemia-by-the-u-s-fda monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/impact-of-donor-clonal-hematopoiesis-in-older-matched-related-transplantation monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/post-transplant-outcomes-of-elderly-patients-with-newly-diagnosed-aml-ineligible-for-induction-chemotherapy-following-venetoclax-based-treatment monthly 0.9 2021-04-09T14:53:00.000Z https://aml-hub.com/medical-information/ash-clinical-practice-guidelines-for-the-treatment-of-older-adults-with-aml monthly 0.9 2024-07-18T10:57:00.000Z https://aml-hub.com/medical-information/analysis-of-transcriptomic-and-genomic-sequencing-in-acute-myeloid-leukemia monthly 0.9 2020-11-13T10:37:00.000Z https://aml-hub.com/medical-information/response-to-flotetuzumab-a-bispecific-cd123-cd3-molecule-is-seen-in-refractory-patients-with-acute-myeloid-leukemia-and-may-be-dependent-on-the-tumor-microenvironment monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/molecular-profiling-at-diagnosis-for-risk-stratification-of-patients-with-aml-undergoing-allogeneic-transplant-in-first-remission monthly 0.9 2020-11-13T10:36:00.000Z https://aml-hub.com/medical-information/phase-iii-quazar-aml-001-trial-results monthly 0.9 2020-11-13T10:36:00.000Z https://aml-hub.com/medical-information/updated-results-of-the-ecog-acrin-e2906-randomized-study monthly 0.9 2020-11-16T11:18:00.000Z https://aml-hub.com/medical-information/emerging-immunotherapy-modalities-in-aml-and-exciting-data-from-ash-2019 monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/aml-hub-aml-global-portal-a-note-from-the-editor-in-chief monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/what-are-the-most-important-and-recent-advances-made-in-aml-treatment monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/quazar-should-maintenance-with-cc-486-become-standard-of-care-following-induction-chemotherapy monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/what-is-the-impact-of-genetic-characterization-and-mrd-assessment-on-the-prognosis-and-treatment-of-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/could-aspacytarabine-be-a-new-frontline-therapy-option-for-patients-with-aml-that-are-unfit-for-ic monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/based-on-your-analysis-should-current-aml-risk-stratification-be-revised monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/why-could-imgn632-be-an-important-treatment-option-for-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/practice-changing-abstracts-in-aml-from-ash-2019 monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/what-is-the-role-of-immune-checkpoint-directed-therapy-in-the-treatment-of-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/key-take-home-messages-from-the-astral-1-study monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/how-can-we-improve-outcomes-after-allo-hsct-in-patients-with-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/how-does-the-splicing-modulator-h3b-8800-work-and-can-it-be-safely-applied-in-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/should-quizartinib-maintenance-be-soc-after-sct-for-patients-with-flt3-mutated-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/is-the-bispecific-dart-flotetuzumab-effective-as-salvage-therapy-in-patients-with-rr-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/should-all-elderly-patients-with-aml-receive-azacitidine-as-post-remission-therapy monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/how-has-the-treatment-landscape-of-aml-evolved-in-the-last-five-years monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/are-germline-runx1-mutations-different-to-somatic-runx1-mutations monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/what-are-the-most-important-drivers-of-cost-in-aml-and-how-can-they-be-ameliorated monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/how-can-precision-medicine-improve-outcomes-in-older-patients-with-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/are-there-germline-runx1-mutations-which-predispose-to-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/why-could-vosaroxin-improve-responses-to-induction-chemotherapy-in-patients-with-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/does-the-improvement-in-rfs-after-flag-ida-go-lead-to-more-severe-toxicities-in-cbf-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/results-of-single-agent-cc-90009-in-rr-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/how-should-family-members-with-familial-runx1-germline-mutations-be-monitored monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/how-close-are-we-to-implementing-germline-precision-medicine-in-acute-myeloid-leukemia monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/how-i-treat-case-studies-to-address-new-challenges-encountered-in-the-treatment-of-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/gimema-aml1310-trial-of-risk-adapted-mrd-guided-therapy-for-young-patients-with-newly-diagnosed-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/monthly-editorial-theme-maintenance-therapy-for-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/apvo436-receives-orphan-drug-designation-for-acute-myeloid-leukemia-from-the-fda monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/mrd-guided-timing-of-allogenic-transplantation-for-aml monthly 0.9 2025-08-05T15:21:00.000Z https://aml-hub.com/medical-information/serum-mir-223-expression-in-patients-with-acute-myeloid-leukemia monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/treatment-of-older-or-unfit-patients-with-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/ab8939-receives-orphan-drug-designation-for-acute-myeloid-leukemia-from-the-fda monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/non-myeloablative-conditioning-prior-to-allogeneic-stem-cell-transplantation-in-patients-with-acute-myeloid-leukemia monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/gilteritinib-or-chemotherapy-for-relapsed-or-refractory-flt3-mutated-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/treosulfan-or-busulfan-plus-fludarabine-as-conditioning-treatment-before-allogeneic-hemopoietic-stem-cell-transplantation monthly 0.9 2025-01-24T14:19:00.000Z https://aml-hub.com/medical-information/new-data-from-phase-ii-trial-of-sy-1425-combined-with-azacitidine-in-newly-diagnosed-unfit-patients-with-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/monthly-editorial-theme-or-an-introduction-to-the-use-of-transplantation-for-the-treatment-of-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/phase-ii-study-of-bemcentinib-for-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/esh-2019-or-how-will-the-use-of-flt3-inhibitors-evolve-in-the-future monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/impact-of-donor-type-on-outcomes-of-allogeneic-transplant monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/esh-2019-or-what-are-the-new-concepts-to-target-cancer-stem-cells-in-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/esh-2019-or-how-do-you-integrate-molecular-diagnostics-in-clinical-practice monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/esh-2019-or-is-there-a-need-to-change-aml-risk-stratification monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/esh-2019-or-why-should-we-target-runx1-in-aml-treatment monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/esh-2019-or-when-do-you-use-single-cell-mrd-assessment-in-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/esh-2019-or-can-genetic-testing-predict-aml-risk-in-healthy-individuals monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/esh-2019-or-how-do-canadian-patients-benefit-from-novel-agents-that-are-now-used-to-treat-patients-with-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/esh-2019-or-what-is-the-impact-of-ezh2-mutations-in-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/esh-2019-or-how-can-amino-acid-metabolism-drive-hematological-malignancies monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/esh-2019-or-how-do-genomic-and-epigenomic-alterations-synergize-in-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/effect-of-conditioning-regimen-intensity-after-haploidentical-transplantation monthly 0.9 2021-04-07T10:51:00.000Z https://aml-hub.com/medical-information/esh-2019-or-what-is-the-risk-of-developing-aml-in-women-previously-treated-for-breast-cancer monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/esh-2019-or-is-aml-susceptible-to-immunotherapy monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/esh-2019-or-normal-hematopoietic-cell-biology-to-gain-insight-into-leukemia monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/esh-2019-or-how-does-ageing-contribute-to-the-development-of-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/esh-2019-or-what-s-new-in-flow-cytometry-assessment-of-mrd monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/esh-2019-or-how-will-the-use-of-flt3-inhibitors-evolve-in-the-future-1 monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/esh-2019-or-how-will-targeted-therapies-be-used-in-the-future monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/esh-2019-or-why-should-we-target-cd70-in-leukemias monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/soho-2019-or-mrd-in-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/debate-or-advances-in-diagnostics-and-new-therapies-reduce-the-need-for-allogeneic-transplant-in-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/the-european-commission-grants-approval-to-gilteritinib-for-patients-with-relapsedrefractory-flt3-positive-acute-myeloid-leukemia-aml monthly 0.9 2024-07-24T13:35:00.000Z https://aml-hub.com/medical-information/bemcentinib-receives-fda-approval-for-fast-track-designation-for-the-treatment-for-relapsed-or-refractory-aml monthly 0.9 2024-07-24T13:35:00.000Z https://aml-hub.com/medical-information/quizartinib-refused-marketing-authorization-by-ema-chmp monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/soho-2019-or-flt3-inhibitors-in-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/bispecific-antibodies-in-lymphoma-myeloma-and-acute-myeloid-leukemia monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/post-transplant-outcomes-of-patients-with-therapy-related-aml-following-treatment-for-prior-lymphoid-malignancy monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/soho-2019-or-update-on-chemotherapy-free-treatments-for-rr-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/soho-2019-or-xpo7-as-a-novel-therapeutic-target-for-tp53-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/flt3-ligand-as-a-biomarker-for-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/the-first-of-a-series-of-patient-case-studies-incorporating-mrd-monitoring-case-1-normal-karyotype-aml-npm1-mutated-and-flt3-itd-positive monthly 0.9 2021-04-27T10:05:00.000Z https://aml-hub.com/medical-information/mrd-monitoring-and-clinical-guidance-for-aml-an-introduction-to-this-month-educational-theme monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/1st-ncri-aml-academy-meeting monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/pooled-analysis-of-associations-between-karyotype-and-outcome-in-npm1-mutated-aml monthly 0.9 2021-04-09T15:03:00.000Z https://aml-hub.com/medical-information/1st-ncri-aml-academy-meeting-or-what-is-the-optimum-treatment-strategy-for-high-risk-myelodysplastic-syndrome monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/1st-ncri-aml-academy-meeting-or-what-can-flt3-ligand-monitoring-tell-us-about-treatment-response-in-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/1st-ncri-aml-academy-meeting-or-the-david-grimwade-memorial-lecture monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/1st-ncri-aml-academy-meeting-or-what-is-the-optimum-treatment-strategy-for-elderly-or-frail-patients-with-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/1st-ncri-aml-academy-meeting-or-advances-in-intensive-chemotherapy-for-patients-with-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/1st-ncri-aml-academy-meeting-or-how-do-we-manage-aml-relapse-now-and-in-the-future monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/1st-ncri-aml-academy-meeting-or-how-can-translational-studies-improve-patient-outcomes monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/1st-ncri-aml-academy-meeting-or-how-can-genetic-studies-inform-the-treatment-of-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/1st-ncri-aml-academy-meeting-or-the-benefits-of-mrd-monitoring-in-clinical-practice-and-research monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/1st-ncri-aml-academy-meeting-or-can-the-new-treatments-for-aml-reduce-the-need-for-allo-hsct monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/1st-ncri-aml-academy-meeting-or-does-current-evidence-support-flt3-maintenance-therapy monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/1st-ncri-aml-academy-meeting-or-an-overview-of-the-uk-aml-trial-landscape monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/1st-ncri-aml-academy-meeting-or-welcome-to-the-1st-ncri-aml-academy-meeting monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/gilteritinib-receives-positive-recommendation-from-ema-chmp-for-the-treatment-of-flt3-mutated-aml monthly 0.9 2024-07-24T13:19:00.000Z https://aml-hub.com/medical-information/nivolumab-as-an-addition-to-frontline-therapy-of-aml-in-younger-patients monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/soho-2019-or-in-what-ways-can-the-immune-system-be-involved-in-treating-patients-with-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/soho-2019-or-is-aml-a-disease-susceptible-to-novel-immunotherapies-such-as-car-t-darts-and-bites monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/soho-2019-or-can-hypomethylating-agents-plus-venetoclax-replace-chemotherapy-induction-for-patients-with-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/soho-2019-or-what-are-the-recent-advances-in-the-treatment-of-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/soho-2019-or-what-is-the-role-of-maintenance-therapy-for-patients-with-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/phase-iii-study-of-cc-486-oral-azacitidine-maintenance-in-newly-diagnosed-aml-meets-primary-and-key-secondary-endpoints monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/bxcl701-granted-orphan-drug-designation-by-the-us-fda-for-the-treatment-of-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/what-is-the-familial-risk-of-developing-a-hematological-malignancy monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/fast-track-designation-granted-to-magrolimab-for-the-treatment-of-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/co-occurring-mutations-in-pediatric-flt3-itd-leukemia monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/genomic-and-epigenomic-influences-in-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/allogeneic-stem-cell-transplant-for-patients-in-second-complete-remission monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/1st-ncri-aml-academy-meeting-1 monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/integrating-resistance-functions-to-predict-response-to-induction-chemotherapy-in-de-novo-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/kit-mutations-in-pediatric-core-binding-factor-cbf-acute-myeloid-leukemia-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/medicare-announces-coverage-of-chimeric-antigen-receptor-car-t-cell-therapy-in-the-united-states-us monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/exploring-metabolic-vulnerabilities-for-personalized-therapy-in-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/august-2019-or-druggable-mutations-in-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/results-from-quantum-r-trial-of-quizartinib-versus-salvage-chemotherapy-in-flt3-itd-mutated-acute-myeloid-leukemia-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/car-t-therapy-receives-orphan-drug-designation-from-the-fda monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/is-intensive-care-unit-admission-advisable-in-older-patients-with-acute-myeloid-leukemia monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/impact-of-antithymocyte-globulin-and-total-body-irradiation-on-outcomes-of-allogeneic-hematopoietic-cell-transplantation-in-patients-with-acute-myeloid-leukemia monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/optimizing-the-dose-of-venetoclax-with-less-intensive-therapies-for-elderly-patients-with-newly-diagnosed-aml monthly 0.9 2021-04-09T14:54:00.000Z https://aml-hub.com/medical-information/july-2019-or-treating-unfit-and-elderly-patients-with-acute-myeloid-leukemia monthly 0.9 2023-07-25T14:48:00.000Z https://aml-hub.com/medical-information/mrd-monitoring-in-aml-results-of-amlsg-and-aml17-studies monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/adverse-events-in-acute-myeloid-leukemia-aml-treatment monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/potential-of-car-t-cell-therapy-in-acute-myeloid-leukemia monthly 0.9 2021-03-03T10:02:00.000Z https://aml-hub.com/medical-information/quizartinib-rejected-by-fda-for-flt3-itd-aml monthly 0.9 2025-12-19T11:17:00.000Z https://aml-hub.com/medical-information/eha-2019-or-phase-i-first-in-human-results-of-amv564-in-patients-with-relapsedrefractory-acute-myeloid-leukemia-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/eha-2019-or-phase-ii-results-of-the-sail-study-in-relapsedrefectory-acute-myeloid-leukemia-aml monthly 0.9 2021-04-09T15:02:00.000Z https://aml-hub.com/medical-information/eha-2019-or-results-from-phase-iii-astral-1-study-of-guadecitabine-versus-treatment-of-choice monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/eha-2019-or-what-are-the-current-treatment-recommendations-for-acute-gvhd-and-the-promotion-of-the-gvl-effect monthly 0.9 2024-07-24T13:19:00.000Z https://aml-hub.com/medical-information/eha-2019-or-should-we-use-ptcy-or-atg-as-gvhd-prophylaxis-in-haploidentical-stem-cell-transplantation monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/allogeneic-hematopoietic-cell-transplantation-versus-chemotherapy-consolidation-in-acute-myeloid-leukemia-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/eha-2019-or-recent-advances-in-the-field-of-allo-hsct monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/eha-2019-or-what-is-the-clinical-value-of-new-drugs-in-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/eha-2019-or-what-effect-does-gilteritinib-have-on-flt3-mutated-relapsedrefractory-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/eha-2019-or-combining-imids-and-bites-or-car-t-to-improve-outcomes-for-patients-with-rr-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/eha-2019-or-how-have-survival-rates-of-aml-changed-over-time monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/eha-2019-or-could-the-first-in-class-anti-cd47-antibody-hu5f9-g4-be-a-promising-treatment-strategy monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/eha-2019-or-why-does-flt3-testing-need-to-be-performed monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/eha-2019-or-bcl-2-as-a-universal-target-in-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/eha-2019-or-which-research-areas-hold-promise-for-future-treatments-for-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/eha-2019-or-what-impact-does-mrd-status-have-on-the-outcomes-of-patients-with-aml-undergoing-allo-sct monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/venetoclax-and-other-bh3-mimetics-in-acute-myeloid-leukemia-current-practice-and-future-perspective monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/asco-2019-or-effect-of-gilteritinib-on-survival-in-patients-with-flt3-mutated-relapsedrefractory-rr-aml-with-a-common-aml-co-mutations-or-a-high-flt3-itd-allelic-ratio monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/application-of-minimal-residual-disease-testing-in-assessing-response-to-treatment-of-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/asco-2019-or-what-are-the-current-challenges-facing-aml-treatment monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/asco-2019-or-impact-of-genetic-mutations-in-gilteritinib-treated-patients-with-flt-3-mutated-rr-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/asco-2019-or-combination-drugs-in-myeloid-disorders monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/asco-2019-or-how-should-hypomethylating-agents-be-used-in-combination-therapy monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/asco-2019-or-should-patients-with-flt3-itd-receive-allo-hsct monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/asco-2019-or-differences-in-treatment-approaches-to-flt3-mutated-acute-myeloid-leukemia-between-europe-and-the-united-states monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/hot-off-the-asco-press-leukemia-and-transplant-highlights monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/asco-2019-or-who-should-get-azacitidine-after-transplant monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/asco-2019-or-what-is-the-role-of-low-dose-hypomethylating-agents-in-myeloid-disorders monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/asco-2019-or-activity-of-venetoclax-based-therapy-in-tp53-mutated-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/establishing-precision-medicine-and-novel-molecular-target-therapies-in-japanese-patients-with-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/addition-of-survival-data-on-gilteritinib-labeling-approved-by-fda monthly 0.9 2024-07-24T13:35:00.000Z https://aml-hub.com/medical-information/getitd-for-flt3-itd-based-mrd-monitoring-in-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/autologous-hematopoietic-stem-cell-transplantation-in-acute-myeloid-leukemia monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/dendritic-cell-based-immunotherapy-of-acute-myeloid-leukemia monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/sorafenib-associated-with-improved-outcomes-for-patients-with-flt3-itd-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/ivosidenib-approved-as-first-line-treatment-for-aml-with-idh1-mutation monthly 0.9 2023-07-25T14:33:00.000Z https://aml-hub.com/medical-information/conditioning-regimens-for-patients-with-relapsedrefractory-acute-myeloid-leukemia-undergoing-stem-cell-transplantation-ft-versus-tbf-versus-flamsa monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/acute-myeloid-leukemia-with-t-69-a-retrospective-analysis-of-patient-outcomes monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/fda-grants-annamycin-fast-track-designation-for-relapsed-or-refractory-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/the-prognostic-role-of-circulating-tumor-dna-post-transplant-in-patients-with-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/venetoclax-combined-with-low-dose-cytarabine-for-elderly-patients-with-untreated-aml monthly 0.9 2023-07-25T14:49:00.000Z https://aml-hub.com/medical-information/aml-world-awareness-day-2019-or-latest-updates-from-clinical-trials monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/aml-world-awareness-day-or-recent-advances-in-aml-treatment-options monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/aml-world-awareness-day-or-outcomes-for-patients-with-aml-following-transplantation monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/aml-world-awareness-day-or-current-therapies-and-treatments monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/ebmt-2019-or-strategies-to-optimize-the-gvl-effect monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/ebmt-2019-or-prevention-of-relapse-following-allogeneic-stem-cell-transplantation-using-azacitidine-in-patients-with-high-risk-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/ebmt-2019-or-graft-versus-host-disease-prophylaxis-with-reduced-intensity-conditioning-regimen-combined-with-anti-thymocyte-globulin-and-post-transplantation-cyclophosphamide-for-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/ebmt-2019-or-umbilical-cord-blood-transplantation-in-adolescents-and-young-adults-with-acute-myeloid-leukemia monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/ebmt-2019-or-no-association-between-graft-versus-leukemia-effect-and-graft-versus-host-disease-in-patients-with-acute-myeloid-leukemia-receiving-haplo-identical-stem-cell-transplantation-with-post-transplant-cyclophosphamide monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/fda-grants-ivosidenib-tibsovo-r-in-combination-with-azacitidine-breakthrough-therapy-designation-for-the-treatment-of-patients-with-newly-diagnosed-idh1-mutant-aml monthly 0.9 2022-10-28T16:25:00.000Z https://aml-hub.com/medical-information/paresh-vyas-or-ebmt-2019-or-leukemic-stem-cells-and-clonal-structure-in-relapse-following-transplant monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/ebmt-2019-or-autologous-fecal-microbiota-transfer-is-safe-and-effective-in-patients-with-aml-results-from-the-odyssee-trial monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/ali-bazarbachi-or-ebmt-2019-or-maintenance-treatment-after-stem-cell-transplantation monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/arnon-nagler-or-ebmt-2019-or-haploidentical-hematopoietic-transplantation-current-status-and-future-perspectives monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/uwe-platzbecker-or-ebmt-2019-or-considerations-for-transplantation-in-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/richard-stone-or-ebmt-2019-or-role-of-flt3-inhibitors-in-the-treatment-landscape-of-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/charles-craddock-or-ebmt-2019-or-optimization-of-the-graft-versus-leukemia-effect monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/sorafenib-as-a-salvage-therapy-following-allogeneic-stem-cell-transplantation-in-patients-with-acute-myeloid-leukemia monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/isal-2019-or-therapeutic-advances-for-patients-with-acute-myeloid-leukemia monthly 0.9 2025-12-19T11:09:00.000Z https://aml-hub.com/medical-information/isal-2019-or-inhibitors-of-idh1-and-idh2-for-targeted-therapy-in-acute-myeloid-leukemia monthly 0.9 2025-12-19T11:09:00.000Z https://aml-hub.com/medical-information/isal-2019-or-the-role-of-minimal-residual-disease-guided-treatment-in-acute-myeloid-leukemia monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/isal-2019-or-novel-therapeutic-combinations-containing-venetoclax-for-the-treatment-of-acute-myeloid-leukemia monthly 0.9 2023-07-25T14:49:00.000Z https://aml-hub.com/medical-information/the-passing-of-professor-francesco-lo-coco-the-great-pioneer-of-targeted-therapy-leaves-the-leukemia-community monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/isal-2019-or-targets-for-immunotherapy-in-acute-myeloid-leukemia monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/isal-2019-or-a-multi-stage-prognostication-tool-for-acute-myeloid-leukemia monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/ema-grants-gilteritinib-xospata-r-regulatory-review-for-the-treatment-of-patients-with-relapsedrefractory-flt3-positive-acute-myeloid-leukemia monthly 0.9 2022-10-28T16:26:00.000Z https://aml-hub.com/medical-information/h-h-zhu-or-isal-2019-or-oral-arsenic-treatment-of-apl monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/kristoffer-hellstrand-or-isal-2019-or-immunotherapy-with-histamine-dihydrochloride-and-il-2-in-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/kristoffer-hellstrand-or-isal-2019-or-preventing-aml-relapse-with-histamine-dihydrochloride-and-low-dose-il-2 monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/herve-dombret-or-isal-2019-or-epigenetic-therapy-or-chemotherapy-in-patients-with-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/brian-huntly-or-isal-2019-or-epigenetic-mechanisms-as-targets-for-aml-therapy monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/alan-k-burnett-or-isal-2019-or-gemtuzumab-ozogamicin-in-cbf-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/jeffrey-e-lancet-or-isal-2019-or-the-role-of-cpx-351-in-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/gert-ossenkoppele-or-isal-2019-or-using-mrd-for-clinical-decision-making-in-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/isal-2019-or-precision-medicine-in-acute-myeloid-leukemia-fact-or-fiction monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/isal-2019-or-stratification-of-genetic-risk-factors-in-acute-myeloid-leukemia monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/gail-roboz-or-isal-2019-or-novel-immunotherapy-options-in-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/uwe-platzbecker-or-isal-2019-or-novel-agents-of-frontline-or-relapsed-aml-therapy monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/marina-konopleva-or-isal-2019-or-bcl2-antagonism-in-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/andrew-wei-or-isal-2019-or-targeting-cell-survival-in-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/ari-melnick-or-isal-2019-or-targeting-the-layers-of-the-epigenome-to-eradicate-leukemia-stem-cells monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/charles-craddock-or-isal-2019-or-final-results-of-the-viola-trial monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/saar-i-gill-or-isal-2019-or-car-t-cell-therapy-in-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/paresh-vyas-or-isal-2019-or-clonal-evolution-under-idh-inhibitor-treatment-in-patients-with-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/a-retrospective-comparative-study-of-haploidentical-versus-hla-matched-allogeneic-hematopoietic-stem-cell-transplantation-in-patients-with-relapsedrefractory-acute-myeloid-leukemia monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/fda-grants-ivosidenib-tibsovo-r-priority-review-for-the-treatment-of-patients-with-newly-diagnosed-idh1-mutant-acute-myeloid-leukemia monthly 0.9 2022-10-28T16:26:00.000Z https://aml-hub.com/medical-information/guadecitabine-therapy-following-treatment-failure-with-azacitidine-in-patients-with-acute-myeloid-leukemia monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/enasidenib-found-to-induce-molecular-remissions-in-idh2-mutated-relapsedrefractory-acute-myeloid-leukemia monthly 0.9 2023-07-25T14:30:00.000Z https://aml-hub.com/medical-information/car-t-cell-meeting-2019-or-car-t-cell-therapy-for-acute-myeloid-leukemia monthly 0.9 2025-12-19T11:10:00.000Z https://aml-hub.com/medical-information/the-flagm-regimen-in-younger-adult-patients-with-relapsed-or-refractory-acute-myeloid-leukemia monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/venetoclax-monotherapy-in-elderly-patients-with-secondary-acute-myeloid-leukemia monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/the-benefit-of-high-dose-mitoxantrone-based-5-1-induction-chemotherapy-in-elderly-patients-with-newly-diagnosed-acute-myeloid-leukemia monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/real-world-experience-of-non-intensive-regimens-in-elderly-patients-with-acute-myeloid-leukemia monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/continuous-intravenous-infusion-of-dfp-10917-is-well-tolerated-and-appears-effective-in-phase-iii-trials-in-patients-with-relapsed-or-refractory-acute-myeloid-leukemia monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/no-clinical-benefit-of-eltrombopag-versus-placebo-in-combination-with-induction-chemotherapy-in-patients-with-acute-myeloid-leukemia monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/deferasirox-improves-survival-outcomes-and-restores-the-graft-versus-leukemia-effect-following-allogeneic-stem-cell-transplantation-in-acute-myeloid-leukemia monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/a-novel-salvage-therapy-combination-lenalidomide-and-azacitidine-for-relapsed-acute-myeloid-leukemia monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/treatment-related-cardiotoxicity-in-pediatric-patients-with-acute-myeloid-leukemia-treated-in-the-aaml0531-clinical-trial monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/prognostic-impact-of-flt3-ligand-plasma-level-in-acute-myeloid-leukemia monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/international-study-of-the-genomic-landscape-of-acute-myeloid-leukemia-with-t-821 monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/midostaurin-combined-with-chemotherapy-and-single-agent-maintenance-therapy-in-patients-with-flt3-itd-mutant-acute-myeloid-leukemia monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/azacitidine-maintenance-after-intensive-chemotherapy-in-older-patients-with-acute-myeloid-leukemia-final-analysis-of-the-hovon97-study monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/venetoclax-plus-azacitidine-can-target-leukemia-stem-cells-and-metabolism-in-acute-myeloid-leukemia monthly 0.9 2023-07-25T14:37:00.000Z https://aml-hub.com/medical-information/ash-2018-or-indoximod-combined-with-standard-induction-chemotherapy-in-patients-with-newly-diagnosed-acute-myeloid-leukemia monthly 0.9 2025-12-19T11:11:00.000Z https://aml-hub.com/medical-information/ash-2018-or-flotetuzumab-in-patients-with-relapsed-or-refractory-acute-myeloid-leukemia monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/ash-2018-or-clinical-impact-of-insertion-site-in-flt3-itd-mutated-acute-myeloid-leukemia-analysis-from-the-phase-iii-ratify-trial monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/ash-2018-or-survival-differences-among-patients-with-acute-myeloid-leukemia-treated-with-or-without-allogeneic-hct monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/ash-2018-or-gilteritinib-in-combination-with-induction-and-consolidation-chemotherapy-in-patients-with-newly-diagnosed-acute-myeloid-leukemia monthly 0.9 2023-07-25T14:39:00.000Z https://aml-hub.com/medical-information/ash-2018-or-mrd-status-after-induction-therapy-in-older-adults-with-acute-myeloid-leukemia monthly 0.9 2020-11-13T10:47:00.000Z https://aml-hub.com/medical-information/ash-2018-or-phase-ii-radius-study-of-standard-of-care-with-or-without-midostaurin-after-allogeneic-sct-in-patients-with-flt3-itd-mutated-acute-myeloid-leukemia monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/ash-2018-or-ivosidenib-or-enasidenib-in-combination-with-induction-and-consolidation-therapy-in-newly-diagnosed-acute-myeloid-leukemia-with-idh-or-idh2-mutation monthly 0.9 2025-12-19T11:12:00.000Z https://aml-hub.com/medical-information/ash-2018-or-final-safety-and-efficacy-data-from-the-phase-iii-quantum-r-study monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/sabine-kayser-or-ash-2018-or-outcomes-of-older-patients-with-apl-treated-with-or-without-ato monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/ash-2018-or-maintenance-therapy-with-sorafenib-in-patients-with-flt3-itd-acute-myeloid-leukemia-sormain-trial monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/koichi-takahashi-or-ash-2018-or-clonal-heterogeneity-of-aml-and-its-evolution-at-relapse monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/daniel-pollyea-or-ash-2018-or-venetoclax-in-combination-with-hmas-in-patients-with-aml-ineligible-for-intensive-therapy monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/ash-2018-or-genetic-characterization-of-older-acute-myeloid-leukemia-patients-treated-in-the-phase-iii-nilg-0206-trial monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/ash-2018-or-ivosidenib-ag-120-in-patients-with-previously-untreated-idh1-mutant-acute-myeloid-leukemia monthly 0.9 2023-07-25T14:33:00.000Z https://aml-hub.com/medical-information/david-sallman-or-ash-2018-or-key-results-of-the-phase-i-think-trial-of-nkg2d-car-t-therapy-in-rr-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/joshua-zeidner-or-ash-2018-or-biomarker-guided-phase-ii-study-in-mcl-1-dependent-rr-aml-patients monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/ash-2018-or-defining-the-role-of-mrd-assessment-in-elderly-patients-with-acute-myeloid-leukemia monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/ellen-ritchie-or-ash-2018-or-clinical-trial-accrual-in-us monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/ash-2018-or-enasidenib-for-the-treatment-of-previously-untreated-idh2-mutated-acute-myeloid-leukemia-results-from-the-beat-aml-master-trial monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/naval-daver-or-ash-2018-or-key-highlights-of-immunotherapeutic-agents-for-aml-at-ash-2018 monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/ash-2018-or-uproleselan-gmi-1271-plus-chemotherapy-in-older-patients-with-acute-myeloid-leukemia monthly 0.9 2025-12-19T11:14:00.000Z https://aml-hub.com/medical-information/ash-2018-or-venetoclax-in-combination-with-chemotherapy-in-elderly-patients-with-acute-myeloid-leukemia-caveat-study monthly 0.9 2025-12-19T11:13:00.000Z https://aml-hub.com/medical-information/richard-maziarz-or-ash-2018-or-key-results-of-the-phase-ii-radius-study monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/ash-2018-or-venetoclax-based-therapies-for-patients-with-acute-myeloid-leukemia-who-are-ineligible-for-intensive-chemotherapy monthly 0.9 2025-12-19T11:16:00.000Z https://aml-hub.com/medical-information/ash-2018-or-phase-iii-study-of-gemtuzumab-ozogamicin-in-npm1-mutated-acute-myeloid-leukemia monthly 0.9 2025-12-19T11:13:00.000Z https://aml-hub.com/medical-information/ash-2018-or-clinical-outcomes-of-patients-with-acute-myeloid-leukemia-who-underwent-hsct-in-the-phase-iii-alfa-0701-study monthly 0.9 2025-12-19T11:11:00.000Z https://aml-hub.com/medical-information/amir-fathi-or-ash-2018-or-alisertib-in-combination-with-induction-chemotherapy-in-high-risk-patients-with-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/ash-2018-or-imgn632-a-cd123-targeting-antibody-drug-conjugate-in-patients-with-relapsedrefractory-acute-myeloid-leukemia monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/ash-2018-or-randomized-phase-ii-study-comparing-5-day-and-10-day-decitabine-schedule-in-newly-diagnosed-acute-myeloid-leukemia monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/gail-roboz-or-ash-2018-or-key-highlights-of-idh-inhibitors-at-ash-2018 monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/keith-pratz-or-ash-2018-or-gilteritinib-plus-intensive-chemotherapy-in-patients-with-newly-diagnosed-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/ash-2018-or-imgn779-in-patients-with-relapsedrefractory-acute-myeloid-leukemia monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/sangmin-lee-or-ash-2018-or-luspatercept-in-mds monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/bruno-paiva-or-ash-2018-or-the-role-of-mrd-in-redefining-cr-in-elderly-patients-with-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/andreas-burchert-or-ash-2018-or-key-highlights-of-the-sormain-trial monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/ash-2018-or-amg-330-a-bite-r-construct-in-patients-with-relapsedrefractory-acute-myeloid-leukemia monthly 0.9 2020-11-13T10:49:00.000Z https://aml-hub.com/medical-information/laura-michaelis-or-ash-2018-or-moving-beyond-7-3-in-acute-myeloid-leukemia monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/eytan-stein-or-ash-2018-or-early-results-from-the-beat-aml-master-trial monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/fda-grants-approval-to-gilteritinib-xospata-r-for-the-treatment-of-relapsed-or-refractory-acute-myeloid-leukemia-with-flt3-mutation monthly 0.9 2022-10-28T16:27:00.000Z https://aml-hub.com/medical-information/fda-grants-quizartinib-priority-review-for-the-treatment-of-relapsedrefractory-acute-myeloid-leukemia-with-flt3-itd-mutation monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/mrd-guided-preemptive-therapy-in-patients-with-acute-myeloid-leukemia-results-from-the-phase-ii-relaza2-study monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/fda-grants-venetoclax-venclexta-r-approval-for-the-treatment-of-newly-diagnosed-acute-myeloid-leukemia monthly 0.9 2023-11-24T10:03:00.000Z https://aml-hub.com/medical-information/fda-grants-approval-to-glasdegib-for-the-treatment-of-newly-diagnosed-aml-patients-who-are-ineligible-for-chemotherapy monthly 0.9 2024-07-24T13:36:00.000Z https://aml-hub.com/medical-information/nice-recommends-funding-for-gemtuzumab-ozogamicin-for-patients-with-untreated-cd33-acute-myeloid-leukemia monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/the-impact-of-2-hydroxyglutarate-levels-idh12-mutational-status-on-the-outcomes-of-patients-with-newly-diagnosed-acute-myeloid-leukemia monthly 0.9 2023-07-25T14:51:00.000Z https://aml-hub.com/medical-information/clag-m-therapy-for-patients-with-relapsed-or-refractory-acute-myeloid-leukemia monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/phase-ii-study-evaluating-azacitidine-plus-nivolumab-in-relapsedrefractory-acute-myeloid-leukemia monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/acute-myeloid-leukemia-cells-can-evade-immune-detection-at-post-transplant-relapse monthly 0.9 2021-04-09T15:14:00.000Z https://aml-hub.com/medical-information/clinical-impact-of-post-remission-therapy-after-midam-regimen-in-patients-with-acute-myeloid-leukemia monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/haploidentical-transplantation-may-be-a-feasible-option-for-patients-with-relapsedrefractory-acute-myeloid-leukemia monthly 0.9 2021-04-07T10:52:00.000Z https://aml-hub.com/medical-information/three-novel-regimens-for-relapsedrefractory-acute-myeloid-leukemia-a-randomized-phase-ii-trial monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/venetoclax-in-combination-with-decitabine-or-azacitidine-in-elderly-patients-with-acute-myeloid-leukemia monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/prognostic-impact-of-flt3-itd-allelic-ratio-and-npm1-mutation-in-acute-myeloid-leukemia monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/phase-ii-study-on-fludarabine-busulfan-and-cytarabine-versus-standard-bucy2-for-patients-with-acute-myeloid-leukemia monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/the-clinical-impact-of-samhd1-in-patients-with-acute-myeloid-leukemia-receiving-consolidation-chemotherapy-with-high-dose-cytarabine-regimens monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/subclonal-tp53-mutations-in-acute-myeloid-leukemia monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/deep-sequencing-of-npm1-mrd-can-predict-relapse-after-allogeneic-hct-in-acute-myeloid-leukemia monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/second-cycle-of-7-3-and-outcomes-in-patients-with-newly-diagnosed-acute-myeloid-leukemia monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/clinical-and-prognostic-importance-of-gata2-domains-in-patients-with-acute-myeloid-leukemia monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/soho-2018-or-uses-and-caveats-of-ngs-at-diagnosis-for-acute-myeloid-leukemia monthly 0.9 2025-12-19T11:16:00.000Z https://aml-hub.com/medical-information/outcomes-of-patients-with-acute-myeloid-leukemia-receiving-flag-re-induction monthly 0.9 2025-12-19T11:17:00.000Z https://aml-hub.com/medical-information/acute-promyelocytic-leukemia-with-alternative-retinoid-acid-receptor-fusions monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/addition-of-lomustine-to-chemotherapy-for-older-patients-with-acute-myeloid-leukemia-result-from-the-phase-iii-lam-sa-2007-trial monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/a-predictive-model-for-patients-with-acute-myeloid-leukemia-without-favorable-karyotype monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/alvocidib-cytarabine-and-mitoxantrone-versus-cytarabine-and-daunorubicin-7-3-in-newly-diagnosed-acute-myeloid-leukemia monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/soho-2018-or-addition-of-gemtuzumab-ozogamicin-to-flag-ida-for-induction-therapy-for-patients-with-acute-myeloid-leukemia monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/immunotherapy-approaches-in-acute-myeloid-leukemia-interview-with-dr-naval-daver monthly 0.9 2025-12-19T11:18:00.000Z https://aml-hub.com/medical-information/tamibarotene-as-maintenance-therapy-for-acute-promyelocytic-leukemia-improved-long-term-relapse-free-survival monthly 0.9 2024-04-10T08:39:00.000Z https://aml-hub.com/medical-information/phase-i-study-of-continuous-high-dosing-lenalidomide-in-patients-with-acute-myeloid-leukemia monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/orphan-drug-designation-granted-for-quizartinib-in-japan-for-the-treatment-of-flt3-mutated-acute-myeloid-leukemia monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/mrd-detection-by-ngs-before-allogeneic-hct-in-patients-with-acute-myeloid-leukemia monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/the-clinical-impact-of-persistent-idh-mutations-at-remission-in-acute-myeloid-leukemia monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/flag-ida-or-daunorubicin-combined-with-clofarabine-in-high-risk-acute-myeloid-leukemia-data-from-the-aml17-trial monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/thioridazine-in-combination-with-cytarabine-in-patients-with-acute-myeloid-leukemia-thoridal monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/kit-mutation-type-in-patients-with-t-821-acute-myeloid-leukemia-have-different-prognoses monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/post-transplant-monitoring-of-acute-myeloid-leukemia-using-next-generation-sequencing monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/fda-grants-fast-track-designation-to-cx-01-for-the-treatment-of-patients-with-newly-diagnosed-acute-myeloid-leukemia monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/vyxeos-r-cpx-351-granted-approval-in-the-eu-for-the-treatment-of-therapy-related-acute-myeloid-leukemia-or-aml-mrc monthly 0.9 2022-10-31T11:50:00.000Z https://aml-hub.com/medical-information/reduced-relapse-incidence-with-flamsa-ric-compared-to-busulfanfludarabine-conditioning-for-patients-with-acute-myeloid-leukemia monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/phase-ii-study-of-cladribine-plus-low-dose-cytarabine-alternating-with-decitabine-in-elderly-patients-with-acute-myeloid-leukemia monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/fda-grants-orphan-drug-designation-to-aslan003-for-the-treatment-of-acute-myeloid-leukemia monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/clonal-heterogeneity-in-differentiation-response-and-resistance-to-the-idh2-inhibitor-enasidenib-in-acute-myeloid-leukemia monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/long-term-results-from-the-phase-iii-randomized-study-of-attenuated-arsenic-trioxide-and-atra-for-patients-with-acute-promyelocytic-leukemia monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/mbd4-deficiency-may-lead-to-clonal-hematopoiesis-and-early-onset-of-acute-myeloid-leukemia monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/glasdegib-in-combination-with-intensive-chemotherapy-for-the-treatment-of-acute-myeloid-leukemia monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/anti-cll-1-antibody-drug-conjugate-for-the-treatment-of-acute-myeloid-leukemia monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/final-analysis-of-the-phase-iii-alfa-0701-study-of-gemtuzumab-ozogamicin-in-de-novo-acute-myeloid-leukemia monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/results-from-the-apl-2006-trial-of-arsenic-trioxide-in-patients-with-acute-promyelocytic-leukemia monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/fda-grants-breakthrough-therapy-designation-to-quizartinib-for-relapsedrefractory-flt3-itd-acute-myeloid-leukemia monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/ema-comp-grants-positive-opinion-recommending-pcm-075-for-orphan-drug-designation-for-the-treatment-of-acute-myeloid-leukemia monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/phase-ibiia-study-of-dasatinib-in-adult-patients-with-newly-diagnosed-core-binding-factor-acute-myeloid-leukemia monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/sorafenib-in-combination-with-azacitidine-in-older-patients-with-flt3-itd-mutated-acute-myeloid-leukemia monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/randomized-phase-iib-study-of-two-doses-of-quizartinib-in-patients-with-relapsed-or-refractory-acute-myeloid-leukemia monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/phase-iii-randomized-study-of-cpx-351-liposome-for-injection-in-older-patients-with-newly-diagnosed-secondary-acute-myeloid-leukemia monthly 0.9 2021-02-24T11:50:00.000Z https://aml-hub.com/medical-information/fda-grants-tibsovo-ivosidenib-approval-for-the-treatment-of-patients-with-relapsedrefractory-acute-myeloid-leukemia-with-idh1-mutation monthly 0.9 2023-07-25T14:34:00.000Z https://aml-hub.com/medical-information/eha-2018-or-panobinostat-decitabine-and-donor-lymphocyte-infusion-post-allogeneic-transplantation-in-newly-diagnosed-poor-risk-acute-myeloid-leukemia monthly 0.9 2025-12-19T11:19:00.000Z https://aml-hub.com/medical-information/flamsa-versus-busulfanfludarabine-conditioning-for-acute-myeloid-leukemia-patients monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/vyxeos-given-positive-opinion-by-the-ema-chmp-for-use-in-high-risk-acute-myeloid-leukemia-patients monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/prevalence-of-somatic-mutations-in-peripheral-blood-prior-to-the-development-of-acute-myeloid-leukemia monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/quizartinib-monotherapy-for-relapsedrefractory-acute-myeloid-leukemia monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/subgroup-analysis-of-the-phase-iii-valor-study-vosaroxincytarabine-in-60-years-old-patients-with-refractoryearly-relapsed-acute-myeloid-leukemia monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/phase-iii-trial-of-oral-arsenic-plus-retinoic-acid-versus-intravenous-arsenic-plus-retinoic-acid-for-non-high-risk-acute-promyelocytic-leukemia monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/fda-accepts-new-drug-application-and-grants-priority-review-status-to-glasdegib-for-the-treatment-of-patients-with-previously-untreated-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/eha-2018-or-clt-008-reduces-serious-infections-antibiotic-use-and-days-of-hospitalization-during-acute-myeloid-leukemia-induction monthly 0.9 2025-12-19T11:19:00.000Z https://aml-hub.com/medical-information/asco-2018-or-disease-monitoring-in-acute-myeloid-leukemia monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/eha-2018-or-phase-i-study-of-amv564-in-patients-with-relapsedrefractory-acute-myeloid-leukemia monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/jorge-sierra-or-eha-2018-or-are-we-moving-towards-targeting-of-metabolic-pathways-and-epigenetics-in-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/eha-2018-or-quizartinib-prolonged-survival-in-patients-with-flt3-itd-rr-aml-data-from-the-phase-iii-quantum-r-study monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/uwe-platzbecker-or-eha-2018-or-what-are-the-latest-treatment-management-strategies-for-patients-with-apl monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/andre-schuh-or-eha-2018-or-what-are-the-challenges-in-establishing-new-treatment-response-criteria-in-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/jordi-esteve-or-eha-2018-or-new-therapeutic-targets-for-leukemia-stem-cells-in-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/kimmo-porkka-or-eha-2018-or-precision-medicine-in-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/eha-2018-or-bcl-2-inhibitors-in-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/agnieszka-wierzbowska-or-eha-2018or-current-and-emerging-treatment-options-for-elderly-aml-patients monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/jan-cornelissen-or-eha-2018-or-panobinostat-decitabine-and-dli-post-allo-hsct-in-nd-poor-risk-aml-patients monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/isolda-fernandez-or-eha-2018-or-what-is-the-feasibility-of-mrd-detection-in-developing-countries monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/andrew-wei-or-eha-2018-or-targeting-apoptosis-in-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/bjorn-gjertsen-or-eha-2018-or-applications-of-proteomics-in-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/christopher-hourigan-or-eha-2018-or-mrd-based-risk-stratification-for-treatment-of-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/naval-daver-or-eha-2018-or-immune-based-therapy-in-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/christoph-rollig-or-eha-2018-or-90-mg-vs-60-mg-daunorubicin-in-7-3-standard-induction-for-nd-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/eha-2018-or-idh-mutant-inhibitors-in-aml monthly 0.9 2025-12-19T11:20:00.000Z https://aml-hub.com/medical-information/lars-bullinger-or-eha-2018-or-what-are-the-clinical-implications-of-mutations-in-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/pinkal-desai-or-eha-2018-or-clt008-reduces-serious-infections-antibiotic-use-and-days-of-hospitalization-during-aml-induction monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/julie-bergeron-or-eha-2018-or-what-are-the-latest-emerging-novel-approaches-for-treatment-in-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/jorge-cortes-or-eha-2018-or-highlights-of-the-randomized-phase-iii-quantum-r-study monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/eduardo-rego-or-eha-2018-or-overcoming-the-main-challenges-for-treating-amlapl-in-developing-countries monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/gert-ossenkoppele-or-eha-2018-or-non-intensive-treatment-strategies-in-aml-new-hope-for-unfit-aml-patients monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/asco-2018-or-new-agents-in-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/asco-2018-or-immune-checkpoints-in-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/asco-2018-or-impact-of-ngs-on-treatment-selection-in-aml monthly 0.9 2025-12-19T11:20:00.000Z https://aml-hub.com/medical-information/mark-levis-or-asco-2018-or-maintenance-therapy-with-gilteritinib-in-flt3-itd-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/asco-2018-or-a-phase-i-dose-escalation-study-of-ft-2102-in-idh1-mutated-aml-patients monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/musa-yilmaz-or-asco-2018-or-can-relapse-occur-in-aml-patients-after-a-long-period-of-remission monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/asco-2018-or-early-results-from-parallel-phase-i-studies-of-haploidentical-expanded-nk-cells-after-fludarabinecytarabine-in-rr-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/alice-mims-or-asco-2018-or-what-are-the-current-challenges-facing-aml-treatment monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/asco-2018-or-venetoclax-in-combination-with-decitabine-or-azacitidine-in-elderly-patients-with-aml-induces-durable-response monthly 0.9 2023-07-25T14:37:00.000Z https://aml-hub.com/medical-information/courtney-dinardo-or-asco-2018-or-venetoclax-plus-hmas-in-elderly-aml-patients monthly 0.9 2023-07-25T14:38:00.000Z https://aml-hub.com/medical-information/uma-borate-or-asco-2018-or-impact-of-targeted-therapy-on-treatment-of-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/eunice-wang-or-asco-2018-or-what-are-the-new-advances-in-aml-treatment monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/asco-2018-or-ivosidenib-induced-durable-responses-in-patients-with-idh1-mutated-rr-aml monthly 0.9 2023-07-25T14:34:00.000Z https://aml-hub.com/medical-information/daniel-pollyea-or-asco-2018-or-bcl-2-inhibition-in-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/jeffrey-lancet-or-asco-2018-or-managing-secondary-acute-myeloid-leukemia monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/fda-grants-gilteritinib-priority-review-for-the-treatment-of-rr-aml-with-flt3-mutation monthly 0.9 2023-07-25T14:40:00.000Z https://aml-hub.com/medical-information/esh-2018-or-targeting-cell-survival-in-aml monthly 0.9 2025-12-19T11:21:00.000Z https://aml-hub.com/medical-information/hmas-in-npm1-mutated-aml-patients-unfit-for-intensive-chemotherapy monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/esh-2018-or-therapy-of-apl monthly 0.9 2025-12-19T11:24:00.000Z https://aml-hub.com/medical-information/midostaurin-rydapt-approved-for-the-treatment-of-newly-diagnosed-flt3-aml-patients-in-australia monthly 0.9 2025-12-19T13:41:00.000Z https://aml-hub.com/medical-information/esh-2018-or-salvage-therapy-for-rr-aml monthly 0.9 2025-12-19T13:42:00.000Z https://aml-hub.com/medical-information/esh-2018-or-impact-of-flt3-itd-allelic-ratio-on-outcomes-therapy-for-flt3-positive-aml monthly 0.9 2025-12-19T13:42:00.000Z https://aml-hub.com/medical-information/esh-2018-or-how-to-use-standard-therapy-in-aml monthly 0.9 2025-12-19T13:43:00.000Z https://aml-hub.com/medical-information/esh-2018-or-mutant-idh-inhibitors-in-aml monthly 0.9 2025-12-19T13:44:00.000Z https://aml-hub.com/medical-information/gclam-with-dose-escalated-mitoxantrone-for-newly-diagnosed-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/esh-2018-or-mrd-assessment-in-aml monthly 0.9 2025-12-19T13:44:00.000Z https://aml-hub.com/medical-information/hmas-may-represent-a-feasible-therapeutic-option-for-patients-with-rr-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/the-prognostic-value-of-absolute-monocyte-count-post-transplant-in-aml-patients monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/somatic-mutation-clearance-at-cr-may-predict-survival-and-relapse-in-aml-patients monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/pre-transplant-regimen-for-autologous-sct-in-aml-patients-in-cr1-busulfan-and-melphalan-or-busulfan-and-cyclophosphamide monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/phase-i-study-evaluating-a-kmt2a-partial-tandem-duplication-targeted-regimen-in-rr-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/inhibition-of-grb2-with-bp1001-in-leukemias-a-phase-iib-study monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/mylotarg-gemtuzumab-ozogamicin-granted-approval-in-the-eu-for-use-in-previously-untreated-de-novo-cd33-positive-aml monthly 0.9 2024-07-24T13:36:00.000Z https://aml-hub.com/medical-information/secondary-aml-outcomes-after-haplo-hct-alwp-of-the-ebmt-study monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/long-term-efficacy-of-reduced-intensity-versus-myeloablative-conditioning-before-allogeneic-hct-in-patients-with-aml-in-cr1 monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/phase-iii-study-of-nk-cell-immunotherapy-for-high-risk-mds-and-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/sharing-advances-in-the-treatment-and-management-of-aml monthly 0.9 2025-12-19T13:46:00.000Z https://aml-hub.com/medical-information/comparison-of-anthracyclines-used-for-induction-chemotherapy-in-patients-with-flt3-itd-mutated-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/mutations-in-dnmt3a-u2af1-and-ezh2-may-predict-poor-outcomes-in-intermediate-risk-aml-patients-in-cr1 monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/runx1-mutations-in-pediatric-aml-a-japanese-study monthly 0.9 2025-12-19T13:47:00.000Z https://aml-hub.com/medical-information/mfc-mrd-may-stratify-outcomes-of-standard-risk-aml-patients monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/the-clinical-impact-of-microrna-99a-in-aml-patients-undergoing-allo-hsct-a-chinese-study monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/haplo-sct-may-be-an-effective-therapy-option-for-aml-patients-harboring-flt3-itd-mutation monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/ebmt-2018-or-a-phase-iii-study-comparing-treosulfan-based-conditioning-versus-busulfan-based-conditioning-before-allo-hsct-in-aml-or-mds monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/ebmt-2018-or-thiotepa-busulfan-fludarabine-versus-busulfan-cyclophosphamide-as-mac-conditioning-regimen-for-allo-sct-in-aml-patients monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/ebmt-2018-or-allo-hsct-from-unrelated-cord-blood-or-haploidentical-donor-grafts-in-saml-patients monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/molecular-mrd-detection-can-predict-survival-and-relapse-in-patients-with-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/fda-grants-orphan-drug-designation-to-max-40279-for-the-treatment-of-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/ebmt-2018-or-post-transplant-maintenance-with-sorafenib-improves-survival-of-flt3-mutated-aml-patients monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/cx-01-in-combination-with-standard-chemotherapy-for-aml-treatment-a-phase-i-study monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/ebmt-2018-or-the-impact-of-conditioning-regimens-on-post-transplant-outcomes-of-saml-patients-with-prior-hematologic-disease monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/ebmt-2018-or-salvage-therapy-with-sorafenib-improves-survival-of-flt3-mutated-aml-patients-experiencing-relapse-after-allo-hct monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/ebmt-2018-or-allo-hsct-for-cbf-aml-patients-in-cr2 monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/prof-arnon-nagler-or-ebmt-2018-or-prospects-of-immune-checkpoint-inhibitors-for-prevention-of-sct-relapse-in-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/ebmt-2018-or-mac-versus-ric-allo-hct-in-patients-with-aml-in-cr2 monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/dr-jonathan-canaani-or-ebmt-2018-or-are-transplant-outcomes-different-in-aml-patients monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/ebmt-2018-or-second-allogeneic-hct-improves-survival-in-children-with-relapsed-aml-after-first-transplantation monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/ebmt-2018-or-phase-iii-study-of-hsct-in-children-with-very-high-risk-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/dr-jordi-esteve-or-ebmt-2018-or-key-measures-for-prevention-of-post-transplant-relapse-in-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/ebmt-2018-or-prophylactic-or-preemptive-sorafenib-therapy-after-allo-hct-improves-survival-of-flt3-mutated-aml-patients monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/prof-charles-craddock-or-ebmt-2018-or-can-hypomethylating-agents-prevent-post-transplant-relapse-in-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/orphan-drug-designation-granted-for-gilteritinib-in-japan-for-the-treatment-of-flt3-mutated-aml monthly 0.9 2023-07-25T14:40:00.000Z https://aml-hub.com/medical-information/ebmt-2018-or-the-effect-of-sorafenib-on-post-transplant-outcomes-of-flt3-itd-mutated-aml-patients-a-report-from-a-chinese-study monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/dr-jacob-m-rowe-or-ebmt-2018-or-how-do-you-recommend-aml-patients-for-transplantation-in-cr1 monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/prof-richard-stone-or-ebmt-2018-or-what-are-the-latest-advances-in-monitoring-mrd-in-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/sox-gene-expression-in-adult-de-novo-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/fda-grants-investigational-new-drug-clearance-for-actimab-a-in-combination-with-clag-m-for-rr-aml-patients monthly 0.9 2020-12-03T16:07:00.000Z https://aml-hub.com/medical-information/analysis-of-the-2017-eln-risk-stratification-in-japanese-adult-aml-patients monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/post-transplant-relapse-is-a-main-cause-of-treatment-failure-in-patients-with-complex-karyotype-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/pretreatment-with-anti-thymocyte-globulin-versus-no-anti-thymocyte-globulin-in-patients-with-cd7-positive-aml-a-retrospective-analysis-from-japan monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/glutamine-dependence-in-treated-flt3-itd-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/wt1-rs16754-polymorphism-correlated-with-favorable-outcomes-in-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/nk-receptor-ligand-expression-impacts-outcomes-after-chemotherapy-in-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/mylotarg-gemtuzumab-ozogamicin-given-positive-opinion-by-the-ema-chmp-for-use-in-untreated-cd33-positive-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/can-dnmt3ar882h-be-used-as-a-marker-for-mrd-monitoring monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/extramedullary-relapses-after-allo-hct-in-aml-patients monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/pravastatin-in-combination-with-idarubicin-and-cytarabine-for-rr-aml-patients monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/modified-post-transplant-cyclophosphamide-pt-cy-regimen-provides-protection-against-gvhd-with-low-toxicity-in-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/fda-accepts-new-drug-application-and-grants-priority-review-status-to-ivosidenib-for-the-treatment-of-patients-with-idh1-mutated-rr-aml monthly 0.9 2023-07-25T14:34:00.000Z https://aml-hub.com/medical-information/decitabine-therapy-in-aml-patients-with-monosomal-karyotype monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/phase-ib-study-of-venetoclax-with-decitabine-or-azacitidine-in-elderly-aml-patients monthly 0.9 2023-07-25T14:38:00.000Z https://aml-hub.com/medical-information/multivalent-wt1-peptide-vaccine-galinpepimut-s-in-aml-patients-in-cr1 monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/does-flt3-itd-mutation-have-an-impact-on-prognosis-of-apl-patients monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/differentiation-syndrome-associated-with-enasidenib-in-aml-patients monthly 0.9 2023-07-25T14:31:00.000Z https://aml-hub.com/medical-information/allo-sct-in-older-flt3itd-aml-patients monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/transplant-conditioning-with-treosulfanfludarabine-with-or-without-tbi-in-patients-with-aml-and-mds monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/azacitidine-in-combination-with-chemotherapy-in-pediatric-aml-patients-a-phase-i-study monthly 0.9 2025-12-19T13:47:00.000Z https://aml-hub.com/medical-information/identification-of-phenotypic-profiles-in-children-and-adult-patients-with-aml-using-immune-gene-expression-profiling-aml-global-portal-coverage-at-2018-asco-sitc monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/synergistic-effect-of-vitamin-c-with-decitabine-in-aml-a-chinese-study monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/effect-of-pretransplant-leukemic-burden-in-aml-patients-undergoing-allo-sct-in-non-cr monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/cpx-351-therapy-for-less-fit-patients-with-untreated-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/predictors-of-relapse-in-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/gene-alterations-associated-with-myeloperoxidase-positivity-in-de-novo-aml-a-japanese-study monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/mrd-assessment-in-aml-recommendations-from-the-eln-mrd-working-party monthly 0.9 2024-07-24T13:19:00.000Z https://aml-hub.com/medical-information/phase-ib-study-of-pevonedistat-plus-azacitidine-in-older-aml-patients monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/ema-grants-orphan-drug-designation-to-gilteritinib-for-the-treatment-of-aml monthly 0.9 2023-07-25T14:40:00.000Z https://aml-hub.com/medical-information/venetoclax-combined-with-hmas-or-ldac-is-a-viable-salvage-option-in-patients-with-rr-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/feasibility-of-mrd-detection-by-multiparametric-flow-cytometry-for-aml-in-brazil monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/clinical-impact-and-dynamic-changes-of-cohesin-gene-mutations-in-de-novo-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/fda-grants-trisenox-r-arsenic-trioxide-injection-approval-for-the-treatment-of-newly-diagnosed-low-risk-apl monthly 0.9 2022-10-28T16:28:00.000Z https://aml-hub.com/medical-information/guadecitabine-demonstrates-encouraging-efficacy-in-rr-aml-patients monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/ema-grants-orphan-drug-designation-to-pracinostat-for-the-treatment-of-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/ash-2017-or-prevalence-of-aml-defining-mutations-in-peripheral-blood-years-prior-to-the-development-of-leukemia monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/ash-2017-or-crenolanib-in-combination-with-standard-chemotherapy-in-newly-diagnosed-flt3-mutated-aml-patients monthly 0.9 2025-12-19T13:48:00.000Z https://aml-hub.com/medical-information/ash-2017-or-mrd-risk-adapted-therapy-in-aml monthly 0.9 2025-12-23T10:04:00.000Z https://aml-hub.com/medical-information/fda-grants-orphan-drug-designation-to-cx-01-for-the-treatment-of-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/dr-lorena-figueiredo-pontes-or-ash-2017-or-highlights-of-aml-at-ash-2017 monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/molecular-mrd-detection-by-ngs-can-predict-survival-and-relapse-in-newly-diagnosed-aml-lba-from-ash-2017 monthly 0.9 2020-11-13T10:50:00.000Z https://aml-hub.com/medical-information/ash-2017-or-clonal-hematopoiesis-in-aml-patients-receiving-allo-hsct-in-cr monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/dr-roland-walter-or-ash-2017-or-gclam-in-rr-aml-patients monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/prof-hwei-fang-tien-or-ash-2017-or-dynamic-genetic-evolution-in-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/dr-isolda-fernandez-or-ash-2017-or-how-can-we-improve-aml-treatment-in-argentina monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/fda-grants-orphan-drug-designation-to-cg-806-for-the-treatment-of-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/ash-2017-or-emerging-molecularly-targeted-therapies-in-aml-focus-on-idh-inhibitors monthly 0.9 2023-07-25T14:35:00.000Z https://aml-hub.com/medical-information/assist-prof-courtney-dinardo-or-ash-2017-or-ivosidenib-in-idh1-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/ash-2017-or-combination-of-quizartinib-with-azacitidine-or-ldac-in-patients-with-flt3-itd-mutated-aml monthly 0.9 2025-12-23T10:04:00.000Z https://aml-hub.com/medical-information/prof-gert-ossenkoppele-or-ash-2017-or-hma-in-maintenance-treatment-of-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/ash-2017-or-long-term-follow-up-results-from-the-phase-ii-soraml-trial monthly 0.9 2025-12-23T10:04:00.000Z https://aml-hub.com/medical-information/fda-lifts-clinical-hold-on-the-phase-iii-trial-of-sel24-in-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/assoc-prof-tapan-kadia-or-ash-2017-or-new-novel-agents-in-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/ash-2017-or-gilteritinib-in-combination-with-induction-and-consolidation-chemotherapy-in-newly-diagnosed-aml-patients monthly 0.9 2025-12-23T10:06:00.000Z https://aml-hub.com/medical-information/prof-arnon-nagler-or-ash-2017-or-highlights-of-allogeneic-sct-at-ash-2017 monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/dr-prajwal-boddu-or-ash-2017-or-factors-predicting-survival-among-patients-with-cbf-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/ash-2017-or-novel-immune-based-approaches-for-therapy-in-aml monthly 0.9 2025-12-23T10:08:00.000Z https://aml-hub.com/medical-information/prof-yasushi-miyazaki-or-ash-2017-or-tamibarotene-as-maintenance-therapy-in-apl-jalsg-apl204 monthly 0.9 2024-04-10T08:39:00.000Z https://aml-hub.com/medical-information/ash-2017-or-lirilumab-maintenance-therapy-in-elderly-aml-patients-the-phase-ii-effikir-trial monthly 0.9 2025-12-23T10:09:00.000Z https://aml-hub.com/medical-information/dr-jordi-esteve-or-ash-2017-or-key-findings-from-the-aml-12-trial monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/prof-harry-erba-or-ash-2017-or-optimal-therapy-for-elderly-aml-patients monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/prof-agnieszka-wierzbowska-or-ash-2017-or-take-home-messages-for-poland-from-ash-2017 monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/prof-keith-pratz-or-ash-2017-or-gilteritinib-and-intensive-chemotherapy-in-newly-diagnosed-flt3-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/ash-2017-or-venetoclax-with-ldac-in-treatment-naive-elderly-patients-with-aml-a-phase-iii-study monthly 0.9 2025-12-23T10:07:00.000Z https://aml-hub.com/medical-information/ash-2017-or-sapacitabine-and-decitabine-administered-in-alternating-cycles-in-eldery-patients-with-newly-diagnosed-elderly-aml-phase-iii-seamless-study monthly 0.9 2025-12-23T10:07:00.000Z https://aml-hub.com/medical-information/prof-eduardo-rego-or-ash-2017-or-take-home-message-to-brazil-from-ash-2017 monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/ash-2017-or-impact-of-npm1flt3-itd-genotype-on-the-clinical-outcomes-of-patients-treated-in-the-phase-iii-ratify-study monthly 0.9 2025-12-23T10:10:00.000Z https://aml-hub.com/medical-information/ash-2017-or-two-versus-three-cycles-of-consolidation-chemotherapy-in-patients-with-cbf-aml monthly 0.9 2025-12-23T10:10:00.000Z https://aml-hub.com/medical-information/dr-jordi-esteve-or-ash-2017-or-role-of-allohct-in-aml-with-t-69 monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/ash-2017-or-novel-therapies-for-apl monthly 0.9 2025-12-19T13:48:00.000Z https://aml-hub.com/medical-information/assist-prof-duane-hassane-or-ash-2017-or-aml-patients-harbor-mutations-a-decade-before-aml-development monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/assist-prof-amir-fathi-or-ash-2017-or-updates-in-idh-inhibitors-in-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/ash-2017-or-two-alfa-studies-reporting-on-frontline-therapy-in-younger-and-older-patients-with-aml-clofarabine-based-consolidation-in-aml-alfa-0702-and-ric-sct-in-elderly-aml-patients-alfa-1200 monthly 0.9 2025-12-23T10:11:00.000Z https://aml-hub.com/medical-information/dr-pinkal-desai-or-ash-2017-or-prevalence-of-mutations-prior-to-development-of-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/ash-2017-or-azacitidine-maintenance-therapy-in-older-aml-patients monthly 0.9 2025-12-23T10:12:00.000Z https://aml-hub.com/medical-information/ash-2017-or-idh-inhibitors-in-midh1-and-midh2-aml-enasidenib-monotherapy-in-previously-untreated-idh2-mutated-aml-and-ivosidenib-and-enasidenib-in-combination-with-azacitidine-in-newly-diagnosed-idh-mutated-aml monthly 0.9 2025-12-23T10:13:00.000Z https://aml-hub.com/medical-information/prof-norbert-vey-or-ash-2017-or-key-findings-from-the-effikir-trial-lirilumab-in-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/prof-farhad-ravandi-or-ash-2017-or-nivolumab-with-cytarabine-and-idarubicin-in-newly-diagnosed-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/prof-gert-ossenkoppele-or-ash-2017-or-venetoclax-in-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/prof-gail-roboz-or-ash-2017-or-new-hope-in-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/prof-gunnar-juliusson-or-ash-2017-or-molecular-characterisation-and-epidemiology-of-aml-adults-in-sweden monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/prof-charles-craddock-or-ash-2017-or-key-findings-from-the-viola-trial monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/dr-elli-papaemmanuil-or-ash-2017-or-classification-and-risk-assessment-in-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/prof-jeffrey-lancet-or-ash-2017-or-cpx-351-in-aml-patients-with-raeb-t monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/prof-ross-levine-or-ash-2017-or-molecular-pathogenesis-of-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/prof-selina-luger-or-ash-2017-or-improving-standard-therapy-in-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/ash-2017-or-maintenance-therapy-with-midostaurin-in-flt3-mutated-aml-patients-sub-analysis-of-the-phase-iii-ratify-study monthly 0.9 2025-12-23T10:06:00.000Z https://aml-hub.com/medical-information/ash-2017-or-innovative-aml-treatment-with-approved-agents monthly 0.9 2025-12-23T10:15:00.000Z https://aml-hub.com/medical-information/prof-eunice-wang-or-ash-2017-or-crenolanib-and-sc-in-young-newly-diagnosed-flt3-mutated-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/prof-neil-shah-or-ash-2017-or-gilteritinib-resistance-in-rr-flt3-mutated-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/ash-2017-or-molecular-markers-in-the-diagnosis-and-prognosis-of-aml monthly 0.9 2025-12-23T10:15:00.000Z https://aml-hub.com/medical-information/prof-uwe-platzbecker-or-ash-2017-or-mrd-guided-treatment-in-aml-the-relaza2-trial monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/prof-mark-levis-or-ash-2017-or-overview-of-flt3-inhibitors-in-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/vadastuximab-talirine-as-monotherapy-achieves-responses-and-found-to-be-tolerable-in-cd33-positive-aml-patients monthly 0.9 2025-12-23T10:14:00.000Z https://aml-hub.com/medical-information/homing-in-on-allo-hsct-outcomes-in-aml-patients-with-t-711-p15p15 monthly 0.9 2025-12-23T10:14:00.000Z https://aml-hub.com/medical-information/fda-grants-fast-track-designation-to-crenolanib-for-the-treatment-of-patients-with-rr-flt3-positive-aml monthly 0.9 2021-03-03T09:51:00.000Z https://aml-hub.com/medical-information/fda-grants-orphan-drug-designation-to-amv564-for-the-treatment-of-aml monthly 0.9 2025-12-23T10:17:00.000Z https://aml-hub.com/medical-information/five-new-powerful-weapons-against-aml monthly 0.9 2025-12-23T10:17:00.000Z https://aml-hub.com/medical-information/quizartinib-plus-chemotherapy-for-newly-diagnosed-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/phase-i-study-of-quizartinib-as-post-transplant-maintenance-therapy-in-flt3-itd-mutated-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/phase-ii-randomized-study-of-high-dose-len-and-aza-in-newly-diagnosed-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/can-mirnas-predict-efs-in-pediatric-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/lenalidomide-plus-chemotherapy-for-the-reinduction-of-patients-with-rr-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/phase-i-study-of-wt1-specific-t-cell-receptor-gene-transduced-lymphocytes-in-aml-and-mds monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/does-abcg2-overexpression-in-aml-cause-resistance-to-deoxyadenosine-analogues monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/fda-lifts-clinical-hold-on-the-phase-i-trial-of-ucart123-in-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/mrd-in-older-aml-patients-treated-with-hmas-correlates-with-response monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/dac-plus-id-arac-followed-by-hla-mismatched-peripheral-blood-stem-cells-infusion-in-older-aml-patients monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/panobinostat-monotherapy-and-combination-therapy-in-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/clag-plus-imatinib-mesylate-for-rr-aml-a-phase-ii-study monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/small-bone-marrow-adipocytes-in-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/high-expression-of-vanin-1-can-predict-adverse-outcomes-in-patients-with-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/a-start-stop-go-story-in-aml-gemtuzumab-ozogamicin-mylotarg-r monthly 0.9 2025-12-23T10:19:00.000Z https://aml-hub.com/medical-information/a-rare-philadelphia-story-in-aml-outcomes-with-allogenic-sct-for-bcr-abl1-positive-aml-patients monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/phase-ii-study-of-low-dose-lenalidomide-plus-cytarabine-in-elderly-aml-patients monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/fda-halts-phase-iii-trial-of-sel24-in-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/phase-i-study-of-flotetuzumab-in-aml-and-mds-patients-oral-abstract-presented-at-esmo-2017-by-vey-et-al monthly 0.9 2025-12-23T10:20:00.000Z https://aml-hub.com/medical-information/fda-grants-gilteritinib-fast-track-designation-for-the-treatment-of-rr-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/fda-grants-orphan-drug-designation-to-pcm-075-for-the-treatment-of-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/phase-ii-trial-comparing-timed-sequential-cytosine-arabinoside-with-or-without-mk-8776-in-rr-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/prognostic-significance-of-baalc-expression-in-apl monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/phase-i-study-of-cabozantinib-in-patients-with-rr-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/prognostic-impact-of-pre-and-post-mrd-in-pediatric-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/is-aml-npm1mut-a-candidate-for-immune-checkpoint-inhibition monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/gvl-effect-of-allogenic-hsct-and-mrd-in-aml-patients-in-cr1 monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/fda-grants-annamycin-investigational-new-drug-application-approval-for-treatment-of-rr-aml monthly 0.9 2024-07-24T13:37:00.000Z https://aml-hub.com/medical-information/a-comparison-of-autologous-and-allogeneic-transplantation-in-aml-patients-in-first-molecular-remission monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/asco-sitc-clinical-immuno-oncology-symposium-abstract-submission-deadline-3rd-october monthly 0.9 2025-12-23T10:20:00.000Z https://aml-hub.com/medical-information/adi-peg20-in-rr-or-poor-risk-aml-patients-a-phase-ii-study monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/the-ema-grants-rydapt-r-midostaurin-approval-for-the-treatment-of-newly-diagnosed-flt3-aml-patients monthly 0.9 2022-10-28T16:30:00.000Z https://aml-hub.com/medical-information/prognostic-significance-of-mrd-status-in-high-risk-aml-patients-oral-abstract-in-aml-at-soho-2017 monthly 0.9 2025-12-23T10:21:00.000Z https://aml-hub.com/medical-information/timed-sequential-therapy-for-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/the-prognostic-significance-of-a-molecular-risk-score-in-apl-patients monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/azacitidine-in-mds-and-aml-patients-with-early-post-transplant-relapse-oral-abstract-in-aml-at-soho-2017 monthly 0.9 2025-12-23T10:21:00.000Z https://aml-hub.com/medical-information/the-clinical-significance-of-sox4-in-aml-a-taiwan-study monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/post-remission-and-pre-allogenic-hct-role-of-wt1-mrd-in-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/combination-of-everolimus-and-ldac-was-not-effective-in-elderly-aml-patients-a-phase-ib-study monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/fda-halts-phase-i-trial-of-ucart123-in-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/guadecitabine-in-elderly-patients-with-treatment-naive-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/fda-grants-mylotarg-r-gemtuzumab-ozogamicin-approval-for-the-treatment-of-cd33-positive-aml monthly 0.9 2022-10-31T11:53:00.000Z https://aml-hub.com/medical-information/post-remission-therapy-with-dc-vaccination-in-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/the-role-and-therapeutic-implications-of-mirnas-in-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/the-fda-to-review-annamycin-investigational-new-drug-application-for-rr-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/intensive-consolidation-in-elderly-aml-patients-a-phase-iv-study monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/the-clinical-impact-of-co-occurrence-of-flt3-tkd-and-npm1-mutations-in-aml-patients monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/revised-canadian-consensus-guidelines-for-diagnosis-and-treatment-of-elderly-patients-with-aml-comments-from-andre-schuh monthly 0.9 2025-12-23T10:22:00.000Z https://aml-hub.com/medical-information/the-fda-grants-sy-1425-orphan-drug-designation-for-the-treatment-of-aml monthly 0.9 2020-12-03T16:13:00.000Z https://aml-hub.com/medical-information/the-prognostic-impact-of-kit-mutations-in-pediatric-patients-with-cbf-aml-a-chinese-study monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/the-prognostic-impact-of-multiple-runx1-mutations-and-runx1-wild-type-loss-in-patients-with-runx1-mutated-aml monthly 0.9 2021-04-09T15:13:00.000Z https://aml-hub.com/medical-information/il-6-levels-can-predict-survival-in-pediatric-aml-patients monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/fda-grants-h3b-8800-orphan-drug-designation-for-the-treatment-of-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/increased-toxicity-seen-with-high-dose-daunorubicin-induction-in-young-aml-patients-a-brazilian-study monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/flag-ida-regimen-in-adult-rr-aml-patients-an-italian-study monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/molecular-response-in-aml-patients-with-npm1-and-flt3-mutations-undergoing-sct monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/ato-consolidation-allows-anthracycline-dose-reduction-in-pediatric-apl-patients-phase-iii-study monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/azacitidine-plus-vorinostat-does-not-improve-the-response-or-survival-of-aml-patients-ravva-study monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/missing-hla-c-group-1-ligand-is-associated-with-improved-outcomes-of-aml-and-mds-patients-after-hla-matched-sct-with-treosulfan-conditioning monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/the-prognostic-significance-of-socs1-in-aml-a-taiwan-study monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/fda-grants-vyxeos-r-cpx-351-approval-for-the-treatment-of-t-aml-and-aml-mrc-patients monthly 0.9 2021-02-24T11:52:00.000Z https://aml-hub.com/medical-information/treated-secondary-aml-is-a-distinct-high-risk-subset-with-adverse-prognosis monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/fda-grants-idhifa-r-enasidenib-approval-for-the-treatment-of-rr-aml-patients-with-idh2-mutation monthly 0.9 2024-07-24T13:38:00.000Z https://aml-hub.com/medical-information/the-fda-grants-venclexta-r-breakthrough-therapy-designation-for-the-treatment-of-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/the-prognostic-impact-of-cd25-expression-in-elderly-aml-patients-treated-with-plerixafor-and-decitabine monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/a-phase-iii-study-of-clofarabine-or-fludarabine-add-on-therapy-for-adults-with-rr-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/fda-approves-the-investigational-new-drug-application-for-pcm-075-for-the-treatment-of-aml monthly 0.9 2024-07-24T13:38:00.000Z https://aml-hub.com/medical-information/59th-ash-r-annual-meeting-and-exposition-abstract-submission-deadline-2nd-august monthly 0.9 2025-12-23T10:24:00.000Z https://aml-hub.com/medical-information/outcomes-of-older-apl-patients-treated-with-atra-plus-anthracycline monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/treosulfan-based-conditioning-regimen-improves-the-long-term-survival-of-aml-patients-receiving-allogenic-hct monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/vosaroxin-plus-decitabine-in-older-aml-and-mds-patients-a-phase-ii-study monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/the-efficacy-of-cytarabine-and-idarubicin-in-combination-with-clofarabine-or-fludarabine-was-similar-in-newly-diagnosed-aml-patients-a-phase-ii-study monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/midostaurin-rydapt-r-given-positive-opinion-by-the-ema-chmp-for-use-in-newly-diagnosed-flt3-aml-patients monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/overexpression-of-abcg2-and-cd200-is-associated-with-poor-outcome-in-aml-patients-in-the-eln-favorable-risk-group monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/midostaurin-in-combination-with-chemotherapy-prolongs-survival-in-flt3-mutated-aml-patients-ratify-study monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/the-fda-grants-gilteritinib-orphan-drug-designation-for-the-treatment-of-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/the-safety-and-efficacy-of-gemtuzumab-ozogamicin-in-infant-aml-patients monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/the-prognostic-impact-of-mrd-monitoring-of-dntmt3a-mutant-transcript-in-aml-patients-a-german-study monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/clinical-effects-of-nk-cells-after-ric-ucbt-in-aml-patients-a-french-study monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/cd33-splicing-polymorphism-can-predict-therapeutic-efficacy-of-gemtuzumab-ozogamicin-in-de-novo-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/the-fda-advisory-committee-recommends-approval-of-mylotarg-r-gemtuzumab-ozogamicin-for-aml monthly 0.9 2024-07-24T13:38:00.000Z https://aml-hub.com/medical-information/safety-and-efficacy-of-gilteritinib-asp2215-in-rr-aml-patients-phase-iii-dose-escalation-dose-expansion-chrysalis-trial monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/the-prognostic-impact-of-consolidation-history-in-mrd-negative-aml-patients-undergoing-allogenic-hct monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/molecular-diagnosis-and-treatment-for-aml-educational-session-at-the-22nd-congress-of-the-eha monthly 0.9 2025-12-23T10:24:00.000Z https://aml-hub.com/medical-information/comparison-of-idarubicin-and-high-dose-daunorubicin-in-the-induction-chemotherapy-for-aml-a-phase-iii-study monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/intensive-treatment-of-aml-oral-abstract-session-at-the-22nd-congress-of-the-eha monthly 0.9 2025-12-23T10:25:00.000Z https://aml-hub.com/medical-information/targeted-treatment-of-aml-oral-abstract-session-at-the-22nd-congress-of-the-eha monthly 0.9 2025-12-23T10:26:00.000Z https://aml-hub.com/medical-information/prof-norbert-vey-or-eha-2017-or-3-7-and-beyond monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/prof-jorge-cortes-or-eha-2017-or-glasdegib-in-combination-with-cytarabine-and-daunorubicin-in-untreated-aml-patients monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/prof-joseph-brandwein-or-eha-2017-or-cytogenetic-abnormalities-in-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/prof-charles-craddock-or-eha-2017or-ravva-study-molecular-predictors-of-response-to-azacytidine monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/assoc-prof-andrew-wei-or-eha-2017-or-phase-iii-study-of-venetoclax-plus-low-dose-cytarabine-in-elderly-aml-patients monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/prof-gert-ossenkoppele-or-highlights-of-aml-at-the-eha-2017-meeting monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/prof-eduardo-m-rego-or-eha-2017-or-management-of-apl-in-latin-america monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/prof-hwei-fang-tien-or-eha-2017-or-clinical-implications-of-mutations-in-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/asst-prof-amir-fathi-or-eha-2017-or-differentiation-syndrome-associated-with-enasidenib-ag-221-an-idh2i monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/prof-brian-huntly-or-eha-2017-or-molecular-landscape-of-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/asst-prof-naval-daver-or-eha-2017-or-immunotherapies-in-aml-nivolumab-with-azacytidine-in-patients-with-relapsed-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/asst-prof-keith-pratz-or-eha-2017-or-venetoclax-hma-in-elderly-aml-patients-non-pretreated monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/mrd-directed-treatment-in-aml-oral-abstract-session-at-the-22nd-congress-of-the-eha monthly 0.9 2025-12-23T10:26:00.000Z https://aml-hub.com/medical-information/dr-isolda-fernandez-or-eha-2017-or-treatment-of-aml-in-argentina monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/dr-jordi-esteve-or-eha-2017-or-new-therapeutic-targets-in-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/prof-farhad-ravandi-kashani-or-eha-2017-or-vadastuximab-talirine-hma-in-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/the-prognostic-significance-of-monosomal-karyotype-complex-karyotype-in-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/enasidenib-in-mutant-idh2-rr-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/the-prognostic-impact-of-bcrp-mrna-and-flt3-itd-in-adult-aml-patients-a-polish-study monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/maintenance-therapy-with-alternating-azacitidine-and-lenalidomide-in-elderly-aml-patients monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/epigenetic-priming-with-decitabine-followed-by-mec-in-adults-with-rr-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/molecular-response-to-flt3-inhibitor-enasidenib-in-mutant-idh2-and-the-correlation-between-somatic-mutation-clearance-and-clinical-outcomes-in-aml-patients-oral-abstracts-at-the-2017-asco-annual-meeting monthly 0.9 2025-12-23T10:27:00.000Z https://aml-hub.com/medical-information/the-fda-grants-oxi4503-fast-track-designation-for-the-treatment-of-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/secondary-aml-biology-and-therapy-educational-session-at-the-2017-asco-annual-meeting monthly 0.9 2025-12-23T10:27:00.000Z https://aml-hub.com/medical-information/prof-tapan-m-kadia-or-2017-asco-annual-meeting-or-highlights-of-the-oral-session-on-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/assoc-prof-alexander-e-perl-or-2017-asco-annual-meeting-or-phase-iii-study-of-gilteritinib-versus-salvage-chemotherapy-in-rr-flt3-mutation-positive-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/assoc-prof-jessica-k-altman-or-2017-asco-annual-meeting-or-molecular-response-to-gilteritinib-a-flt3-inhibitor-in-rr-aml-flt3 monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/idh-mutations-in-aml-educational-session-at-the-2017-asco-annual-meeting monthly 0.9 2025-12-23T10:28:00.000Z https://aml-hub.com/medical-information/targeted-therapy-for-flt3-mutated-aml-educational-session-at-the-2017-asco-annual-meeting monthly 0.9 2025-12-23T10:28:00.000Z https://aml-hub.com/medical-information/dr-prajwal-boddu-or-2017-asco-annual-meeting-or-mrd-negativity-after-hma-in-older-aml-patients monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/an-association-between-kir3dl1-and-hla-b-subtypes-and-aml-hct-outcomes monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/prof-jorge-e-cortes-or-2017-asco-annual-meeting-or-gilteritinib-in-the-treatment-of-newly-diagnosed-flt3-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/prof-eunice-wang-or-2017-asco-annual-meeting-or-phase-iii-cascade-study monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/prof-harry-erba-or-2017-asco-annual-meeting-or-amg-232-with-or-without-trametinib-in-rr-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/prof-jeffrey-e-lancet-or-2017-asco-annual-meeting-or-cpx-351-vs-7-3-in-older-adults-with-newly-diagnosed-therapy-related-aml-taml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/prof-koichi-takahashi-or-2017-asco-annual-meeting-or-correlation-between-mutation-clearance-and-clinical-response-in-elderly-patients-with-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/the-prognostic-impact-of-extramedullary-disease-on-the-outcomes-of-aml-patients-undergoing-allogenic-hct monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/the-fda-accepts-new-drug-application-for-vyxeos-r-for-the-treatment-of-aml-and-grants-priority-review-status monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/condensed-versus-standard-schedule-of-high-dose-cytarabine-consolidation-therapy-with-pegfilgrastim-in-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/the-ema-grants-gmi-1271-orphan-drug-designation-for-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/the-ema-grants-actimab-a-orphan-drug-designation-for-aml monthly 0.9 2020-12-03T16:07:00.000Z https://aml-hub.com/medical-information/autologous-versus-unrelated-transplants-in-cn-aml-patients-in-cr1-a-japanese-study monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/antileukemic-activity-of-artesunate-antimalarial-agent-in-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/the-impact-of-kir-and-hla-in-aml-immunotherapy-a-swedish-study monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/eradication-of-mrd-with-epigenetic-therapy-in-cbf-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/the-fda-grants-gmi-1271-breakthrough-therapy-designation-for-the-treatment-of-rr-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/wt1-molecular-assessment-combined-with-flow-cytometry-increases-the-prognostic-value-of-pre-transplant-mrd-in-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/the-impact-of-abnl-17p-on-the-outcomes-of-aml-patients-receiving-allogenic-hsct-a-japanese-study monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/health-canada-grants-clearance-for-phase-iii-sierra-trial-of-iomab-b-in-rr-aml monthly 0.9 2021-02-10T12:16:00.000Z https://aml-hub.com/medical-information/the-prognostic-significance-of-additional-cytogenetic-acquisition-in-aml-patients-in-first-relapse-a-japanese-study monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/is-wt1-gene-expression-a-biomarker-for-prognosis-and-mrd-in-nk-aml-a-serbian-study monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/decitabine-before-low-dose-cytarabine-in-combination-with-stem-cell-microtransplantation-in-elderly-aml-patients-a-chinese-study monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/prognostic-value-and-biologic-implications-of-long-coding-rnas-in-cn-aml-patients monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/long-term-follow-up-of-aml-patients-receiving-an-autologous-telomerase-based-dendritic-cell-vaccine monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/decitabine-prior-to-idarubicin-and-cytarabine-in-the-treatment-of-rr-aml-a-chinese-study monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/the-fda-grants-cd33-specific-car-t-cell-investigational-new-drug-application-clearance-for-treatment-of-rr-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/the-prognostic-significance-of-monosomal-karyotype-in-pediatric-aml-patients-a-german-study monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/the-fda-grants-ptx-200-orphan-drug-designation-for-the-treatment-of-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/the-impact-of-abo-incompatibility-on-the-outcomes-of-aml-patients-undergoing-mismatched-unrelated-donor-transplantation monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/the-extracellular-matrix-of-leukemic-cells-and-aml-a-finnish-study monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/the-fda-grants-midostaurin-rydapt-approval-for-the-treatment-of-newly-diagnosed-flt3-aml-patients monthly 0.9 2024-07-24T13:38:00.000Z https://aml-hub.com/medical-information/outcomes-of-older-patients-with-secondary-aml-according-to-treatment-strategy monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/sorafenib-as-a-maintenance-agent-after-allogenic-hsct-for-flt3-mutated-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/outcomes-of-therapy-related-apl-patients-treated-with-or-without-ato monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/the-significance-of-cd34-cd38-cell-burden-on-the-prognosis-of-aml-patients-receiving-allogenic-sct-a-german-study monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/the-prognostic-impact-of-copy-number-alterations-in-pediatric-aml-patients monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/impact-of-hyperleukocytosis-on-the-long-term-outcome-of-aml-patients-undergoing-allogeneic-hsct monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/amg-900-in-adult-aml-patients-a-phase-i-dose-escalation-study monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/aacr-2017-poster-405929-kpc34-for-therapy-in-aml-patients monthly 0.9 2025-12-23T10:29:00.000Z https://aml-hub.com/medical-information/aacr-2017-poster-347222-separase-overexpression-in-aml monthly 0.9 2025-12-23T10:30:00.000Z https://aml-hub.com/medical-information/overexpression-of-cd200-is-associated-with-poor-prognosis-in-aml-patients-an-italian-study monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/aacr-2017-poster-331114-impact-of-autophagy-alterations-in-aml monthly 0.9 2025-12-23T10:30:00.000Z https://aml-hub.com/medical-information/aacr-2017-poster-lb-0816-runx1-targeted-therapy-for-aml-with-runx1-mutation monthly 0.9 2025-12-23T10:31:00.000Z https://aml-hub.com/medical-information/aacr-2017-poster-238022-insertion-mutations-in-the-tyrosine-kinase-domain-of-flt3-in-aml monthly 0.9 2025-12-23T10:33:00.000Z https://aml-hub.com/medical-information/idarubicin-dose-escalation-during-consolidation-therapy-in-adult-aml-patients-phase-iii-allg-m12-study monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/aacr-2017-poster-35651-the-impact-of-germline-flt3-mutation-on-the-prognosis-of-aml-patients monthly 0.9 2025-12-23T10:33:00.000Z https://aml-hub.com/medical-information/aacr-2017-poster-209421-on150030-for-treatment-of-rr-aml monthly 0.9 2025-12-23T10:34:00.000Z https://aml-hub.com/medical-information/survival-and-relapse-risk-in-aml-patients-with-flt3-mutations-undergoing-sct monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/the-fda-to-review-vyxeos-new-drug-application-for-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/the-fda-lifts-clinical-hold-on-trials-of-selinexor-in-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/aacr-2017-poster-5151-pi3p-and-camp-pathway-alterations-in-aml-patients monthly 0.9 2025-12-23T10:35:00.000Z https://aml-hub.com/medical-information/aacr-2017-poster-176626-alterations-in-tp53-mutated-and-wild-type-aml-patients monthly 0.9 2025-12-23T10:29:00.000Z https://aml-hub.com/medical-information/aacr-2017-poster-24518-novel-copy-number-alterations-and-the-effect-of-chromothripsis-in-aml monthly 0.9 2025-12-23T10:31:00.000Z https://aml-hub.com/medical-information/cladribine-in-combination-with-standard-chemotherapy-in-elderly-aml-patients-results-from-the-palg-phase-ii-trial monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/a-predictive-model-for-prognosis-in-aml-and-mds-patients-receiving-haplo-sct monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/treosulfan-based-conditioning-regimen-in-aml-patients-receiving-allo-hct monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/the-effect-of-hopx-expression-in-aml-a-taiwan-study monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/selinexor-monotherapy-in-rr-aml-patients-a-phase-1-study monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/leveraging-cytoplasmic-nucleosides-kinases-in-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/the-fda-grants-annamycin-orphan-drug-designation-for-the-treatment-of-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/iomab-b-given-positive-scientific-advice-by-the-ema-chmp-for-the-treatment-of-rr-aml monthly 0.9 2021-02-10T12:16:00.000Z https://aml-hub.com/medical-information/pol-i-transcription-inhibition-can-treat-aggressive-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/fndc3b-rara-a-novel-fusion-gene-in-variant-apl monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/the-prognostic-impact-of-clone-specific-mrd-in-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/therapeutic-strategy-for-aml-patients-with-loss-of-aldh1a1 monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/chemosensitization-with-plerixafor-plus-g-csf-in-rr-aml-a-phase-12-study monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/mutation-burden-in-the-peripheral-blood-of-aml-and-mds-patients monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/the-fda-grants-fate-nk100-investigational-new-drug-application-clearance-for-treatment-of-rr-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/outcomes-of-apl-patients-treated-with-atra-ato-and-gemtuzumab monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/clofarabine-in-newly-diagnosed-aml-patients-hovon-102-study monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/pd-l1-methylation-can-predict-survival-in-aml-patients monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/somatic-tp53-mutations-can-mediate-aml-and-contribute-to-disease-resistance monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/the-fda-lifts-clinical-hold-on-the-phase-i-trials-of-vadastuximab-talirine-in-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/the-effect-of-abo-incompatibility-on-the-outcomes-of-aml-patients-undergoing-haplo-hct monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/the-role-of-galectin-3-in-newly-diagnosed-apl-patients-treated-with-atra-and-ato-based-regimens-a-chinese-study monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/prognostic-novel-markers-for-os-in-aml-patients-with-normal-karyotype-treated-in-7-swog-trials monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/types-of-donors-for-allogenic-hematopoietic-stem-cell-transplantation-in-aml-patients-in-cr1 monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/the-fda-grants-enasidenib-priority-review-for-treatment-of-rr-aml-with-idh2-mutation monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/car-t-cell-depletion-in-human-aml-xenograft-models monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/the-fda-grants-ucart123-investigational-new-drug-approval-for-treatment-of-aml monthly 0.9 2024-07-24T13:38:00.000Z https://aml-hub.com/medical-information/clofarabine-based-consolidation-in-young-adults-with-aml-in-first-remission-results-from-the-alfa-0702-trial-clara monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/the-creatine-kinase-pathway-is-a-therapeutic-target-for-evi1-positive-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/the-synergistic-role-for-runx1-and-flt3-itd-in-the-induction-of-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/can-mir-137-regulate-c-kit-expression-in-aml-a-chinese-study monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/the-role-of-granulocyte-colony-stimulating-factor-in-aml-patients-treated-with-anthracycline-based-chemotherapy-a-korean-study monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/a-comparison-of-reduced-intensity-and-myeloablative-before-hematopoietic-cell-transplantation-in-mds-and-aml-patients monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/retinoic-acid-and-arsenic-trioxide-improves-the-outcomes-of-non-high-risk-apl-patients-compared-to-retinoic-acid-and-chemotherapy-phase-iii-apl0406-trial monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/mrd-status-and-cytogenetic-classification-predicts-outcome-of-autologous-and-allogenic-stem-cell-transplantation-in-aml-patients-in-first-remission-a-chinese-study monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/inhibition-of-sphingosine-kinase-1-can-lead-to-mcl1-dependent-cell-death-in-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/eha-22nd-congress-abstract-submission-deadline-is-just-two-weeks-away monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/survival-outcomes-for-aml-patients-with-different-types-of-insurance-a-us-study monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/progression-from-cml-to-aml-with-e6a2-bcr-abl-fusion-transcript-a-patient-study monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/a-comparison-of-the-outcomes-in-adolescentsyoung-adults-and-pediatric-aml-and-apl-patients monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/treatment-of-flt-3-mutated-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/the-effect-of-salvage-therapy-on-the-response-and-survival-outcomes-of-aml-patients-with-induction-failure monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/bispecific-antibody-anti-cd3anti-cll-1-for-aml-treatment monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/the-function-of-s100a8-and-s100a9-in-the-differentiation-of-aml-a-canadian-study monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/is-there-an-effect-for-azacitidine-on-the-survival-and-prognosis-of-mds-and-aml-patients-with-high-bone-marrow-erythroblast-frequency-a-japanese-study monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/mylotarg-re-submitted-to-the-fda-and-ema-for-regulatory-review-in-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/the-ema-grants-bp1001-orphan-drug-designation-for-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/autologous-stem-cell-transplantation-consolidation-in-first-remission-is-well-tolerated-and-effective-in-elderly-aml-patients-a-swiss-study monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/muc1-induced-myeloid-derived-suppressor-cells-contributes-to-immune-suppression-in-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/the-impact-of-tetraploidynear-tetraploidy-karyotype-in-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/marker-chromosomes-can-predict-adverse-prognosis-in-aml-patients-a-german-study monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/the-effect-of-cpx-351-ex-vivo-cytotoxicity-on-flt3-itd-aml-blast-cells monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/chemotherapy-and-sorafenib-for-elderly-aml-patients-with-flt3-mutations-calgb-11001-study monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/the-ema-grants-crenolanib-orphan-drug-designation-for-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/tet2e2s-is-a-favorable-prognostic-factor-for-cytogenetically-normal-aml-a-french-study monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/the-fda-grants-mgd006-orphan-drug-designation-for-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/the-fda-grants-es-3000-orphan-drug-designation-for-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/investigating-copy-neutral-loss-of-heterozygosity-cn-loh-in-flt3-aml-patients-a-british-study monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/the-role-of-extramedullary-involvement-on-the-survival-and-characteristics-of-adult-aml-patients-with-t-821-a-korean-study monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/eln-recommendations-2017-on-diagnosis-and-management-of-acute-myeloid-leukemia-in-adults-comments-from-clara-d-bloomfield-co-author-of-the-paper-published-in-blood monthly 0.9 2024-07-24T13:19:00.000Z https://aml-hub.com/medical-information/the-international-consortium-on-acute-promyelocytic-leukemia-s-icl-apl-evaluations-on-mrd-monitoring-of-apl-in-economically-developing-countries monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/azacitidine-in-combination-with-nivolumab-in-relapsed-aml-patients monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/the-significance-of-mrd-detection-by-pcr-on-the-survival-and-relapse-of-aml-patients-with-flt3-mutation monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/mutational-landscape-of-aml-patients-with-monosomy-7 monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches monthly 0.9 2025-12-23T10:35:00.000Z https://aml-hub.com/medical-information/acute-graft-versus-host-disease-increases-due-to-chemotherapy-induced-immune-stimulation-in-aml-patients monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/all-trans-retinoic-acid-in-the-treatment-of-apl monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/prof-gail-roboz-or-ash-2016-or-new-classification-of-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/androgen-therapy-improves-survival-in-older-aml-patients monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/fda-halts-phase-i-trials-of-vadastuximab-talirine-in-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/the-genetics-of-myelodysplastic-syndrome-from-clonal-hematopoiesis-to-secondary-leukemia monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/calreticulin-exposure-is-a-novel-prognostic-marker-for-aml-patients monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/is-kir-gene-useful-in-predicting-the-clinical-outcome-of-mds monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/eha-22nd-congress-abstract-submissions-open monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/can-azacitidine-be-used-as-a-pre-hsct-treatment-in-pediatric-patients-with-advanced-mds monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/is-there-a-clinical-benefit-for-lestaurtinib-in-previously-untreated-aml-patients monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/prof-norbert-vey-or-ash-2016-or-anti-cd33-agents-in-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/ash-2016-flt3-inhibitors-an-overview-of-midostaurin monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/dr-duane-hassane-or-ash-2016-or-minimal-residual-disease-mrd-testing-in-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/prof-jorge-sierra-or-ash-2016-or-flt3-mutations-in-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/prof-gunnar-juliusson-or-ash-2016-or-ngs-performed-in-sweden-on-a-large-scale-in-2017 monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/therapy-related-aml-and-mds-mutational-profiles-should-determine-treatment-approach monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/prof-gunnar-juliusson-or-ash-2016-or-aml-patients-must-know-their-mutation monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/prof-gert-ossenkoppele-or-ash-2016-or-is-mrd-a-new-surrogate-endpoint monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/can-personalized-vaccines-induce-prolonged-remission-against-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/prof-gunnar-juliusson-or-ash-2016-or-mrd-testing monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/prof-gert-ossenkoppele-or-ash-2016-or-various-methods-to-measure-mrd monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/prof-gunnar-juliusson-or-ash-2016-or-will-allogeneic-transplantation-be-forgotten-one-day monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/prof-gert-ossenkoppele-or-ash-2016-or-mrd-measurable-residual-disease monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/prof-gunnar-juliussonor-ash-2016-or-flt3-and-idh12-inhibitors monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/prof-gert-ossenkoppele-or-ash-2016-or-is-mrd-testing-in-clinical-practice monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/assist-prof-amir-t-fathi-or-ash-2016-or-use-of-targeted-therapies-flt3-and-idh-12-inhibitors-in-various-settings monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/prof-gert-ossenkoppele-or-ash-2016-or-when-to-perform-mrd-testing monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/assist-prof-amir-t-fathi-or-ash-2016-or-highlights-on-idh1-and-2-inhibitors monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/assoc-prof-monica-guzman-or-ash-2016-or-car-t-cell-targeting-cd123-technology monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/dr-swami-p-iyer-or-ash-2016-or-salvage-therapy-for-refractory-aml-patients monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/assist-prof-amir-t-fathi-or-ash-2016-or-highlights-on-flt3-inhibitors monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/assist-prof-courtney-d-dinardo-or-ash-2016-or-idh-inhibitors monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/dr-swami-p-iyer-or-ash-2016-or-implication-of-ngs-testing-in-newly-diagnosed-aml-patients monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/prof-uwe-platzbecker-or-ash-2016-or-2nd-line-treatment-after-ato-atra-combination monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/prof-herve-dombret-or-ash-2016-or-mutation-targeted-agents monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/prof-uwe-platzbecker-or-ash-2016-or-management-of-the-combo-ato-atra-outside-clinical-trials monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/prof-herve-dombret-or-ash-2016-or-diagnosis-eln-recommendations monthly 0.9 2024-07-24T13:20:00.000Z https://aml-hub.com/medical-information/prof-uwe-platzbecker-or-ash-2016-or-toxicity-of-the-combo-ato-atra monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/prof-herve-dombret-or-ash-2016-or-what-are-the-surrogate-endpoints-in-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/prof-uwe-platzbecker-or-ash-2016-or-registration-of-atro-atra-combination-in-the-eu monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/assist-prof-courtney-d-dinaro-or-ash-2016-or-the-genomic-landscape-of-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/assist-prof-pinkal-desai-or-ash-2016-or-mrd-testing-in-aml monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/prof-uwe-platzbecker-or-ash-2016-or-a-new-combo-for-low-and-intermediate-risk-apl-patients-arsenic-trioxide-ato-atra monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/assist-prof-courtney-d-dinardo-or-ash-2016-or-mdm2-inhibitors monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/assist-prof-sangmin-lee-or-ash-2016-or-molecular-monitoring-in-mds monthly 0.9 2022-07-04T12:32:00.000Z https://aml-hub.com/medical-information/trisenox-r-granted-ema-approval-for-first-line-treatment-in-apl-patients monthly 0.9 2024-07-24T13:38:00.000Z https://aml-hub.com/medical-information/highlights-from-ash-2016-abstract-589-results-of-the-randomized-phase-ii-study-decider-amlsg-14-09-comparing-decitabine-dac-with-or-without-valproic-acid-vpa-and-with-or-without-all-trans-retinoic-acid-atra-add-on-in-newly-diagnosed-elderly-non-fit-aml-p monthly 0.9 2025-12-19T11:12:00.000Z https://aml-hub.com/medical-information/highlights-from-ash-2016-abstract-591-vadastuximab-talirine-plus-hypomethylating-agents-a-well-tolerated-regimen-with-high-remission-rate-in-frontline-older-patients-with-aml monthly 0.9 2025-12-23T10:36:00.000Z https://aml-hub.com/medical-information/genetic-mutations-in-aml-predicts-treatment-outcomes-different-types-of-aml-should-be-treated-differently monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/highlights-from-ash-2016-abstract-98-results-of-a-clinical-study-of-pevonedistat-a-first-in-class-nae-inhibitor-combined-with-azacitidine-in-older-patients-with-aml monthly 0.9 2025-12-23T10:37:00.000Z https://aml-hub.com/medical-information/highlights-from-ash-2016-abstract-102-safety-and-efficacy-of-venetoclax-plus-ldac-in-treatment-naive-patients-aged-65-years-with-aml monthly 0.9 2025-12-19T11:16:00.000Z https://aml-hub.com/medical-information/highlights-from-ash-2016-abstract-99-a-phase-ii-randomized-study-of-low-dose-ara-c-with-or-without-glasdegib-pf-04449913-in-untreated-patients-with-aml-or-high-risk-mds monthly 0.9 2025-12-19T11:13:00.000Z https://aml-hub.com/medical-information/highlights-from-ash-2016-abstract-100-a-phase-ii-study-of-pracinostat-and-azacitidine-in-elderly-patients-with-aml-not-eligible-for-induction-chemotherapy-response-and-long-term-survival-benefit monthly 0.9 2025-12-19T11:15:00.000Z https://aml-hub.com/medical-information/investigating-the-relationship-between-age-and-body-weight-on-toxicity-and-survival-in-pediatric-aml-results-from-nopho-aml-2004 monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/breaking-news-diagnosis-and-management-of-aml-in-adults-2017-eln-recommendations-from-an-international-expert-panel monthly 0.9 2024-07-24T13:20:00.000Z https://aml-hub.com/medical-information/decitabine-and-tp53-mutations-in-acute-myeloid-leukemia-and-myelodysplastic-syndromes monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/novel-immunotherapeutic-approaches-in-aml-vaccines monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/the-agp-will-be-at-ash-2016-2-weeks-to-go monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/targeting-the-cellular-metabolic-processes-in-acute-myeloid-leukemia-a-promising-novel-approach-in-cancer-treatment monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/midostaurin-multikinase-inhibitor-receives-fda-priority-review-for-flt3-mutated-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/just-one-test-to-diagnose-aml-experts-from-king-s-college-london-comment-on-ngs monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/prognostic-value-of-serum-crp-ferritin-and-albumin-prior-to-allosct-for-aml-and-mds monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/phase-i-study-of-selinexor-a-selective-inhibitor-of-nuclear-export-in-combination-with-fludarabine-and-cytarabine-in-pediatric-relapsed-or-refractory-acute-leukemia monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/down-for-the-count-in-aml-understanding-the-mechanisms-by-which-aml-blasts-might-induce-cytopenias monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/ciprofloxacin-versus-colistin-prophylaxis-during-neutropenia-in-aml-two-parallel-patient-cohorts-treated-in-a-single-center monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/predicting-outcome-of-patients-with-mds-after-failure-of-aza-validation-of-the-north-american-mds-consortium-scoring-system monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/acute-myeloid-leukemia-in-the-elderly-age-70-years-or-older-long-term-survivors monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/atra-synergizes-with-flt3-inhibition-to-eliminate-flt3itd1-leukemia-stem-cells-in-vitro-and-in-vivo monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/the-mcl1-inhibitor-s63845-is-tolerable-and-effective-in-diverse-cancer-models monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/long-lasting-protective-effect-of-posaconazole-prophylaxis-in-patients-with-aml-receiving-allo-hsct monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/enhancing-cytotoxicity-of-immunotoxins-in-aml-focus-on-bi-836858-a-fc-engineered-cd33-antibody monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/targeting-flt3-itd-signaling-mediates-ceramide-dependent-mitophagy-and-attenuates-drug-resistance-in-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/hag-regimen-for-the-treatment-of-aml-and-mds-a-meta-analysis-with-2314-participants monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/improved-outcome-in-aml-patients-enrolled-in-clinical-trials-a-national-population-based-cohort-study-of-danish-intensive-chemotherapy-patients monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/an-editorial-on-acute-myeloid-leukemia-evidence-weak-for-maintenance-in-adults-in-cr monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/esmo-2016-congress monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/alantolactone-selectively-ablates-aml-stem-and-progenitor-cells monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/imaging-of-cxcr4-expression-in-patients-with-aml-using-targeted-positron-emission-tomography monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/cytoprotective-autophagy-maintains-leukemia-initiating-cells-in-murine-myeloid-leukemia monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/importance-of-high-early-nk-cell-recovery-after-allogeneic-hsct monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/4th-international-conference-on-acute-myeloid-leukemia-molecular-and-translational-advances-in-biology-and-treatment monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/karyotype-plus-npm1-mutation-status-defines-a-group-of-elderly-patients-with-aml-60-years-who-benefit-from-intensive-post-induction-consolidation-therapy monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/highlights-from-the-last-eacr-meeting-abstracts-of-interest-for-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/unrelated-donor-versus-matched-sibling-donor-in-adults-with-acute-myeloid-leukemia-in-first-relapse-an-alwp-ebmt-study monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/treatment-of-cd33-directed-chimeric-antigen-receptor-modified-t-cells-in-one-patient-with-relapsed-and-refractory-acute-myeloid-leukemia monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/therapeutic-mutations-in-acute-myeloid-leukemia-flt3-itd-mutations monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/acute-leukemiamds-patients-with-mrd-receiving-cord-blood-transplantation-higher-os-and-lower-risk-of-relapse monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/patients-with-acute-myeloid-leukemia-admitted-to-intensive-care-units-outcome-analysis-and-risk-prediction monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/therapeutic-mutations-in-aml-idh-mutations monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/extramedullary-disease-in-adult-acute-myeloid-leukemia-is-common-but-lacks-independent-significance-analysis-of-patients-in-ecog-acrin-cancer-research-group-trials-1980-2008 monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/high-intensity-chemotherapy-versus-palliative-chemotherapy-in-patients-over-60-years-with-acute-myeloid-leukemia monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/sequential-rt-qpcr-monitoring-in-prediction-of-relapse-among-patients-with-npm1-mutations monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/a-clinical-measure-of-dna-methylation-predicts-outcome-in-de-novo-acute-myeloid-leukemia monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/overcoming-the-challenges-of-treating-the-older-patient-with-aml monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/expression-of-mir-155-in-acute-myeloid-leukemia-and-its-clinical-significance monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/precision-medicine-for-acute-myeloid-leukemia monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/effect-of-linezolid-on-hematologic-recovery-in-newly-diagnosed-acute-myeloid-leukemia-patients-following-induction-chemotherapy monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/spectrum-and-prognostic-relevance-of-driver-gene-mutations-in-acute-myeloid-leukemia monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/how-i-treat-acute-myeloid-leukemia-patients-presenting-with-pre-existing-comorbidities monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/evaluation-of-minimal-residual-disease-in-acute-myeloid-leukemia-with-npm1-marker monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/the-expression-of-p-glycoprotein-in-leukemia-cells-is-associated-with-the-upregulated-expression-of-nestin-a-class-6-filament-protein monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/flt3itd-are-present-in-leukemic-stem-cells-lscs-and-may-be-a-primary-event-in-the-leukemogenesis monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/response-to-hmas-in-aml-patients-harboring-mutations-in-dnmt3-idh12-andor-tet2-retrospective-analysis-of-a-mskccmcc-cohort monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/ipilimumab-for-patients-with-relapse-after-allogeneic-transplantation monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/an-open-label-phase-i-dose-finding-study-of-apr-246-in-hematological-malignancies monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/long-lasting-humoral-immunity-existence-of-memory-b-cell-independent-long-lived-plasma-cells-in-humans monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/acute-myeloid-leukemia-investigating-the-clinical-significance-of-g-catenin monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/medical-information/a-personalized-approach-for-acute-myeloid-leukemia-biologic-prognostic-and-therapeutic-insights monthly 0.9 2020-11-06T13:12:00.000Z https://aml-hub.com/about-us/louise-niven monthly 0.6 2026-03-10T10:35:00.000Z https://aml-hub.com/about-us/helen-croxall-1 monthly 0.6 2026-03-10T10:35:00.000Z https://aml-hub.com/about-us/jen-wilkinson monthly 0.6 2026-03-10T10:35:00.000Z https://aml-hub.com/about-us/amelia-campbell-warner monthly 0.6 2026-03-10T10:35:00.000Z https://aml-hub.com/about-us/jennifer-higgins monthly 0.6 2026-02-25T14:51:00.000Z https://aml-hub.com/about-us/haimanti-mandal monthly 0.6 2026-02-25T14:51:00.000Z https://aml-hub.com/about-us/beth-campbell monthly 0.6 2026-03-10T10:35:00.000Z https://aml-hub.com/about-us/dylan-barrett monthly 0.6 2026-03-10T10:35:00.000Z https://aml-hub.com/about-us/sari-cumming monthly 0.6 2026-03-10T10:35:00.000Z https://aml-hub.com/about-us/devon-else monthly 0.6 2026-02-25T14:51:00.000Z https://aml-hub.com/about-us/nathan-fisher monthly 0.6 2026-02-25T14:51:00.000Z https://aml-hub.com/about-us/amy-hopkins monthly 0.6 2026-02-25T14:51:00.000Z https://aml-hub.com/about-us/becky-gribbell monthly 0.6 2026-03-20T13:09:00.000Z https://aml-hub.com/about-us/natasha-fort monthly 0.6 2026-02-25T14:51:00.000Z https://aml-hub.com/about-us/addy-dullaghan monthly 0.6 2026-02-25T14:51:00.000Z https://aml-hub.com/about-us/alison-roddam monthly 0.6 2026-02-25T14:51:00.000Z https://aml-hub.com/about-us/monty-morris monthly 0.6 2026-04-02T14:48:00.000Z https://aml-hub.com/about-us/abbie-mckillop monthly 0.6 2026-04-02T14:48:00.000Z https://aml-hub.com/about-us/nathalie-tipler monthly 0.6 2026-04-02T14:48:00.000Z https://aml-hub.com/about-us/suzanna-de-barra monthly 0.6 2026-04-02T14:48:00.000Z https://aml-hub.com/about-us/chris-barnes monthly 0.6 2026-04-02T14:48:00.000Z https://aml-hub.com/contributors/charles-craddock monthly 0.6 2025-11-06T15:15:00.000Z https://aml-hub.com/contributors/gail-j-roboz monthly 0.6 2025-04-24T09:35:00.000Z https://aml-hub.com/contributors/jorge-cortes monthly 0.6 2025-11-06T15:14:00.000Z https://aml-hub.com/contributors/andrew-wei monthly 0.6 2025-10-30T16:29:00.000Z https://aml-hub.com/contributors/courtney-dinardo monthly 0.6 2025-10-30T16:29:00.000Z https://aml-hub.com/contributors/gunnar-juliusson monthly 0.6 2025-04-24T09:16:00.000Z https://aml-hub.com/contributors/jeffrey-lancet monthly 0.6 2025-04-24T09:16:00.000Z https://aml-hub.com/contributors/jorge-sierra monthly 0.6 2025-10-30T16:29:00.000Z https://aml-hub.com/contributors/naval-daver monthly 0.6 2025-10-30T16:29:00.000Z https://aml-hub.com/contributors/roland-walter monthly 0.6 2025-10-30T16:29:00.000Z https://aml-hub.com/contributors/selina-luger monthly 0.6 2025-10-30T16:29:00.000Z https://aml-hub.com/contributors/yasushi-miyazaki monthly 0.6 2025-10-30T16:29:00.000Z https://aml-hub.com/contributors/agnieszka-wierzbowska monthly 0.6 2025-04-24T09:19:00.000Z https://aml-hub.com/contributors/brian-huntly monthly 0.6 2025-08-12T11:52:00.000Z https://aml-hub.com/contributors/hee-je-kim monthly 0.6 2025-08-12T11:52:00.000Z https://aml-hub.com/contributors/isolda-fernandez monthly 0.6 2025-08-12T11:52:00.000Z https://aml-hub.com/contributors/joshua-zeidner monthly 0.6 2025-08-12T11:52:00.000Z https://aml-hub.com/contributors/julie-bergeron monthly 0.6 2025-08-12T11:52:00.000Z https://aml-hub.com/contributors/lars-bullinger monthly 0.6 2025-08-12T11:52:00.000Z https://aml-hub.com/contributors/uwe-platzbecker monthly 0.6 2025-08-12T11:52:00.000Z https://aml-hub.com/contributors/hwei-fang-tien monthly 0.6 2025-03-25T11:08:00.000Z https://aml-hub.com/contributors/jessica-altman monthly 0.6 2025-08-12T11:52:00.000Z https://aml-hub.com/steering-committees monthly 0.7 2026-04-12T07:38:23.174Z https://aml-hub.com/about-us monthly 0.7 2026-04-12T07:38:23.174Z https://aml-hub.com/newsletter monthly 0.7 2026-04-12T07:38:23.174Z https://aml-hub.com/our-hubs monthly 0.7 2026-04-12T07:38:23.174Z https://aml-hub.com/contact monthly 0.7 2026-04-12T07:38:23.174Z